US Pat. No. 10,246,740

SELECTIVE AMPLIFICATION OF DESIRED NUCLEIC ACID REGIONS IN A TARGET SEQUENCE

1. A method for selective amplification of desired amplicons in a two-stage polymerase chain reaction, comprising the steps of:providing a target genetic material;
denaturing the target genetic material;
adding a set of target primers under conditions allowing annealing of primers to the target genetic material;
each primer in said set of target primers comprising
a target specific sequence,
a mismatch control sequence, and
a generic hybridization sequence;
said generic hybridization sequence being identical in each target primer;
said mismatch control sequence and generic hybridization sequence being in close proximity to each other; and
said set of target primers comprising at least two primer pairs adapted for amplification of at least two overlapping desired amplicons in the target genetic material, such that there is a possibility of obtaining at least one undesired amplicon in the region of overlap;
said set of target primers being further characterized in that any pair of primers that flank a desired amplicon sequence have non-matching mismatch control sequences, while any pair of primers that flank an undesired amplicon sequence have matching mismatch control sequences;
carrying out a first multiplex polymerase chain reaction resulting in overlapping amplicons corresponding to different possible pair-wise combinations of primers in the first set of primers, said overlapping amplicons being maintained under conditions such that they self-hybridize through base-pair coupling between the complementary sequences resulting from the generic hybridization sequence in each primer;
treating said overlapping amplicons under selection conditions that are such that desired amplicons denature because of non-complementary sequences resulting from the non-matching mismatch control sequences, while undesired amplicons stay self-hybridized because of additional complementary sequences resulting from the matching mismatch control sequences;
adding generic primers, each comprising a sequence which is complementary to the generic hybridization sequence;
carrying out a second polymerase chain reaction, resulting in the selective amplification of desired amplicons.

US Pat. No. 10,246,739

EXONUCLEASE CYCLING ASSAY

GEORGETOWN UNIVERSITY, W...

1. A method for detecting a target polynucleotide in a test sample, wherein the target polynucleotide has a target sequence and is protected against digestion by a 5? exonuclease, wherein the 5? exonuclease is lambda exonuclease, comprising(a) incubating the test sample with a probe having a sequence complementary with the target sequence and lacking a phosphorylated 5? end, wherein the probe has a quencher at its 5? end and a fluor, whereby a hybrid of the probe and the target polynucleotide is formed, wherein the hybrid comprises a hybridization region formed between the target sequence and the probe, wherein the fluor of the probe is quenched by the quencher before forming the hybrid, and wherein the fluor of the probe is quenched by the quencher in the hybrid;
(b) exposing the hybrid to the 5? exonuclease to digest the probe in the hybrid and forming a reaction mixture, whereby a digested probe comprising the fluor is generated, wherein the fluorescence of the fluor of the digested probe is not quenched;
(c) dissociating the target polynucleotide from the digested probe in the reaction mixture;
(d) repeating steps (a)-(c) by adding the probe and the 5? exonuclease to the reaction mixture after step (c), wherein step (b) of step (d) is performed for a first time period until no further increase in the fluorescence in the reaction mixture;
(e) determining a first fluorescence intensity of the fluor in the reaction mixture after step (d);
(f) repeating steps (a)-(d) with a control sample in place of the test sample, wherein step (b) in step (f) is performed for a second time period, wherein the second time period equals to the first time period, wherein the control sample is identical to the test sample except without the target polynucleotide; and
(g) determining a second fluorescence intensity of the fluor in the control sample after step (f), wherein the first fluorescence intensity greater than the second fluorescence intensity indicates the presence of the target polynucleotide in the test sample.

US Pat. No. 10,246,738

DNA-ANTIGEN EXCHANGE AND AMPLIFICATION

Ultivue, Inc., Cambridge...

1. A method comprising:(1) contacting a sample being tested for the presence of one or more targets with one or more target-specific binding partners, wherein each target-specific binding partner is linked to a first docking strand, and wherein target-specific binding partners of different specificity are linked to different docking strands,
(2) optionally removing unbound target-specific binding partners,
(3) contacting the sample with antigen-bound imager strands and antigen-specific binding partners,
wherein the antigen-bound imager strands have complementarity to the first docking strand, directly or indirectly, and
wherein each antigen-specific binding partner is linked to at least one second docking strand, and wherein the antigen specific binding partner binds to the antigen of the antigen-bound imager strand;
(4) optionally removing unbound antigen-bound imager strands and/or antigen specific binding partners,
(5) increasing the number of second docking strands by a DNA amplification reaction and labeling of the at least one second docking strand using an optical label,
(6) imaging the sample to detect bound labeled antigen-specific binding partners,
(7) optionally extinguishing the signal from the optical label, and
(8) optionally repeating steps (1)-(7), or any subset thereof.

US Pat. No. 10,246,735

METHODS FOR PREPARING SAMPLES FOR NUCLEIC ACID AMPLIFICATION

ROCHE MOLECULAR SYSTEMS, ...

1. A method for passing a liquid sample through a porous solid matrix, comprising the steps of sealing the liquid sample within a container which comprises a porous solid matrix as at least a part of the container and raising a temperature to increase pressure inside the container, thereby to cause the liquid sample to pass through the porous solid matrix, wherein the liquid sample includes a biological sample and a buffer.

US Pat. No. 10,246,730

SEMICONDUCTOR MANUFACTURED NANO-STRUCTURES FOR MICROBE OR VIRUS TRAPPING OR DESTRUCTION

INTERNATIONAL BUSINESS MA...

1. A method of damaging or destroying a microbe or a virion, the method comprising:forming an array of protrusions arranged on a semiconductor substrate by forming a diamond-shaped epitaxial growth on a surface of a semiconductor bar structure extending from a surface of the semiconductor substrate, the array of protrusions having nanoscale dimensions;
disposing a solution comprising a microbe or virion onto the array of protrusions; and
damaging or destroying the microbe or the virion;
wherein forming the array of protrusions comprises patterning a hard mask on the semiconductor substrate to form an array of cube-shaped hard mask structures on the semiconductor substrate, recessing the semiconductor substrate to form trenches in the semiconductor substrate, performing a crystallographic etch to convert the trenches into inverted pyramid-shaped trenches, and removing remaining portions of the hard mask to form sharp protrusions.

US Pat. No. 10,246,724

PRODUCTION OF HYDROGEN USING AN ANAEROBIC BIOLOGICAL PROCESS

Purdue Research Foundatio...

1. A modular renewable energy system comprising:a solar collector system for generating heat energy;
a bioreactor including a chamber for fermenting organic waste; and
one of a fuel cell and a heat engine in gaseous communication with the bioreactor;
wherein anaerobic fermentation of organic waste in the chamber generates hydrogen gas, the hydrogen gas being directed to the one of a fuel cell and a heat engine; and
wherein heat energy effective for sterilization is applied to the organic waste subsequent to fermentation, the heat energy being generated by the solar collector system.

US Pat. No. 10,246,711

RNAI INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS

Rakhee Gupte, Fishkill, ...

1. A method for treating a cardiovascular disorder and/or a pulmonary disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polynucleotide inhibitor of Glucose-6-phosphate dehydrogenase (G6PD) or a nucleic acid encoding G6PD, wherein the polynucleotide inhibitor comprises the nucleotide sequence set forth in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or combinations thereof.

US Pat. No. 10,246,709

TARGETING LIGANDS FOR THERAPEUTIC COMPOUNDS

Arrowhead Pharmaceuticals...

1. A targeting ligand comprising the structure of Formula B:
wherein n is an integer from 1 to 20; X is O, S, or NH; and Targeting Moiety is selected from the group consisting of: N-acetyl-galactosamine, galactose, galactosamine, N-formyl-galactosamine, N-propionyl-galactosamine, N-n-butanoylgalactosamine, and N-iso-butanoylgalactosamine.

US Pat. No. 10,246,704

DETECTION OF MICROORGANISMS IN FOOD SAMPLES AND FOOD PROCESSING FACILITIES

Clear Labs, Inc., Menlo ...

1. A method comprising:(a) adding a first barcode to a first plurality of nucleic acid sequences from a sample, wherein said sample is a food sample or an environmental sample from a food processing facility, wherein said plurality of nucleic acid sequences comprise a mixture of cDNA, RNA, and gDNA sequences, thereby providing a first plurality of barcoded nucleic acid sequences; and
(b) performing a first pore sequencing reaction on said first plurality of barcoded nucleic acid sequences, wherein said pore sequencing reaction is performed on a sequencing apparatus comprising a flow cell;
(c) adding a second barcode to a second plurality of nucleic acid sequences from a second sample, wherein said sample is a food sample or an environmental sample from a food processing facility, wherein said plurality of nucleic acid sequences comprise a mixture of cDNA, RNA, and gDNA sequences, thereby providing a second plurality of barcoded nucleic acid sequences; and
(d) performing a second pore sequencing reaction on said second plurality of barcoded nucleic acid sequences, wherein said second pore sequencing reaction is performed on said sequencing apparatus comprising said flow cell, thereby reusing said flow cell.

US Pat. No. 10,246,703

HIGH-THROUGHPUT SINGLE CELL BARCODING

President and Fellows of ...

14. A bead in an oil-water emulsion comprising(a) a first polynucleotide,
(b) a second polynucleotide,
(c) a barcode sequence, and
(d) a copy of the barcode sequence;
wherein the first polynucleotide comprises a sequencing primer sequence, the barcode sequence, and an annealing primer sequence which targets a nucleic acid of interest, and
wherein the second polynucleotide comprises a copy of the sequencing primer sequence, the copy of the barcode sequence, and a copy of the annealing primer sequence.

US Pat. No. 10,246,702

COMPOSITIONS AND METHODS FOR LABELING TARGET NUCLEIC ACID MOLECULES

New England Biolabs, Inc....

1. A method, comprising:(a) hybridizing a primer to a library of polynucleotide molecules comprising, in 3? to 5? order, a first adapter, a sequence derived from genomic DNA, cDNA or RNA, and a second adapter, wherein the primer hybridizes to the first adaptor;
(b) extending the 3? end of the hybridized primer to produce primer extension products;
(c) hybridizing the primer extension products with synthetic oligonucleotides, wherein:
(i) the synthetic oligonucleotides comprise, in 3? to 5? order, a non-extendable 3? end, a hybridization sequence, and a variable barcode sequence; and
(ii) the hybridization sequence hybridizes to a 3? terminal region of the sequence complementary to the second adapter; and
(d) incubating the hybridized primer extension products of step (b) with a polymerase such that the polymerase extends the 3? end of the primer extension products to form a further extended primer extension product.

US Pat. No. 10,246,701

MULTIPLEXED DIGITAL QUANTITATION OF REARRANGED LYMPHOID RECEPTORS IN A COMPLEX MIXTURE

ADAPTIVE BIOTECHNOLOGIES ...

1. A method for estimating an absolute abundance of individual T cell or B cell clones in a biological sample, comprising:A) distributing a biological sample from a human subject comprising T cells and/or B cells or DNA isolated from the T cells and/or B cells in the biological sample to a plurality of wells on a multi-well plate;
B) amplifying rearranged T cell receptor (TCR) or immunoglobulin (IG) complementarity determining region 3 (CDR3) regions of the T cells and/or B cells in each well in a multiplex polymerase chain reaction (PCR) to obtain a first set of amplicons, wherein the multiplex PCR is performed with a plurality of V region specific primers and a plurality of J region specific primers such that the plurality of V region and J region specific primers amplify substantially all combinations of the V and J segments of the CDR3 regions of the T cells and/or B cells, and wherein the V region specific primers and/or the plurality of J region specific primers comprise a unique amplicon specific barcode;
C) amplifying the first set of amplicons in a second PCR using tailing primers comprising a unique well-specific barcode for each well of the multi-well plate to obtain a second set of amplicons;
D) sequencing by high-throughput sequencing the second set of amplicons to obtain a plurality of barcoded sequencing reads;
E) identifying which well of the multi-well plate the barcoded reads are located in by identifying the unique well-specific barcodes on each of the sequencing reads; and
F) estimating the absolute abundance of individual T cell or B cell clones having a particular TCR or IG-CDR3 region in the biological sample by application of likelihood (L) model equation (1) for probability P that w number of W total wells will contain a T cell or a B cell clone, wherein the w represents the number of wells containing a well-specific barcode, W represents the total number of wells in the multi-well plate, and n represents the total number of cells inputted into the wells:
wherein the absolute abundance of individual T cell or B cell clones in the sample reflects the human subject's immune status.

US Pat. No. 10,246,699

MICROPARTICLE SEPARATION APPARATUS ASSEMBLY COMPRISING MULTIPLE SEPARABLE PANELS

INJE UNIVERSITY INDUSTRY-...

1. A microparticle separation apparatus assembly comprising:a first panel comprising a magnetic microstructure;
a second panel detachable from the first panel and including a microchannel structure through which the sample passes; and
a thin film portion between the second panel and the first panel, the thin film portion having a thickness of 50 um or less and made of PET, PI, PE, PP, PMMA or glass,
wherein the magnetic microstructures included in the first panel include a pattern formed in a direction perpendicular to the direction in which the sample is introduced.

US Pat. No. 10,246,698

COMPOSITES MATERIAL WITH SUSPENDED PARTICLES AND METHOD OF USING THE SAME

Purdue Research Foundatio...

1. A method of depositing biomolecules or chemical material on a surface, the method comprising:suspending particles in a hydrogel, the particles having a first charge, thereby generating a hydrogel-spore composite (first composite);
embedding biomolecule or chemical material (agent) having a second charge into the first composite thereby allowing absorption of the agent by the spores generating a second composite; and
micro-manipulating the second composite proximate to a surface resulting in deposition of the agent on the surface.

US Pat. No. 10,246,684

CANCER CELL-TRAPPING METAL FILTER, CANCER CELL-TRAPPING METAL FILTER SHEET, CANCER CELL-TRAPPING DEVICE, AND MANUFACTURING METHODS THEREFOR

HITACHI CHEMICAL COMPANY,...

1. A method of manufacturing a cancer cell-trapping metal filter, comprising:laminating a photoresist on metal foil;
overlapping a photomask including a wave-shaped light-transmitting portion on the photoresist and exposing the photoresist;
removing an uncured portion of the photoresist by development to form photoresist patterns;
performing metal plating between the photoresist patterns to form metal plating patterns having a height lower than a height of the photoresist patterns;
removing the metal foil by chemical dissolution to obtain a structure including the metal plating patterns and the photoresist patterns; and
removing the photoresist patterns from the structure to obtain the metal plating patterns having a through-hole corresponding to the light-transmitting portion.

US Pat. No. 10,246,676

CELL STIMULATION APPARATUS

INDUSTRY-ACADEMIC COOPERA...

7. A cell stimulation apparatus, comprising:a cell containment part in which a plurality of cell containment grooves containing cells are formed;
a protrusion part that is formed, in a concave and convex shape, on inner circumferential surfaces of the plurality of cell containment grooves; and
a pressure control part that supports the cell containment part and controls intensity of mechanical stimulation applied to cells by applying pressure to the cell containment part,
wherein a bottom of the cell containment part is made of a flexible material,
wherein the pressure control part comprises:
a stage which supports the cell containment part and includes air holes through which air enters and exits;
a pump that applies vacuum pressure to the cell containment part in a vertical direction; and
a control part that controls driving of the pump,
wherein a plurality of air suction pipes are provided to the stage,
wherein the plurality of air suction pipes are disposed at positions corresponding to the plurality of cell containment grooves, and
wherein air suction pipes among the plurality of air suction pipes disposed in a same row or a same column of plurality of rows and columns formed b the plurality of cell containment grooves are independently controlled from the other air suction pipes of the plurality of air suction pipes.

US Pat. No. 10,246,675

BIOCHEMICAL CARTRIDGE, AND BIOCHEMICAL CARTRIDGE AND CARTRIDGE HOLDER SET

Hitachi High-Technologies...

1. A cartridge for sending a liquid inside a sealed space, the cartridge comprising:a cartridge main body having a top surface and a bottom surface substantially in one plane;
a plurality of chambers internally provided in the cartridge main body that accept the liquid, including a first chamber having a first opening, a second chamber having a second opening and a third opening, and a third chamber having a fourth opening; and
an elastic body having substantially planar top and bottom surfaces wherein one of the surfaces of the elastic body is attached to only first portions of the bottom surface of the cartridge main body among the first portions and second portions of the bottom surface of the cartridge main body,
wherein the elastic body undergoes deformation with changes in externally applied pressure,
wherein the elastic body is configured to close the bottom surface side of the plurality of chambers,
wherein a part of the second portions of the bottom surface of the cartridge main body is between the first opening of the first chamber and the second opening of the second chamber and another part of the second portions of the bottom surface of the cartridge main body is between the third opening of the second chamber and the fourth opening of the third chamber,
wherein the elastic body only deforms away from the substantially planar bottom surface of the cartridge main body at the second portions of the bottom surface of the cartridge main body wherein a flow channel is formed after the elastic body is deformed,
wherein in a state without externally applied pressure causing deformation of the elastic body, substantially an entirety of the one surface of the elastic body contacts the bottom surface of the cartridge main body in the one plane,
wherein at least the first chamber and the second chamber initially hold a reagent, and
wherein a film is attached to the top surface of the cartridge main body covering each of the first chamber, the second chamber, and the third chamber.

US Pat. No. 10,246,674

LIGHT EMITTING DIODE PHOTOBIOREACTORS AND METHODS OF USE

Algal Research Center, LL...

1. A cultivation system, comprising:a firewall vessel configured to contain therein fluid, the firewall vessel being capable of communication with a source of sterilant configured to sterilize fluid originating from the firewall vessel;
a growth stage comprising one or more growth vessels that are capable of selective fluid communication with the firewall vessel,
the one or more growth vessels being configured to (1) receive fluid from the firewall vessel that has been sterilized with the sterilant, and (2) following removal of sufficient sterilant, support production of biomass by cultivation of photosynthetic microorganisms introduced to the one or more growth vessels;
a CO2 diffuser configured to deliver CO2 to the one or more growth vessels so as to affect pH levels in the one or more growth vessels;
at least one bubbler configured to provide airflow into the one or more growth vessels so as to circulate fluid disposed within the at least one growth vessel;
a light panel assembly immersed within a growth vessel of the growth stage; and
a fluidic pathway comprising one or more fluid channels and one or more valves, the fluidic pathway being switchable between
a first state that places fluid originating from the firewall vessel into communication with the one or more growth vessels, and
a second state that places the firewall vessel into fluid isolation from the one or more growth vessels.

US Pat. No. 10,246,671

COMPOSITIONS AND METHODS FOR USE IN SURFACE DECONTAMINATION

Kinnos Inc., Brooklyn, N...

1. A solid composition comprisingat least one water-soluble pigment in an amount of from 1.5-22% w/w, based on the total weight of the composition,
at least one surfactant in an amount of from 10-75% w/w, based on total weight of the composition, the surfactant selected from the group consisting of sodium dodecyl sulfate (SDS), sodium xylene sulfonate (SXS), an acetylenic diol, and mixtures thereof,
an alkaline builder in an amount of from 2-50% w/w, based on the total weight of the composition, the alkaline builder selected from NaOH and Ca(OH)2, and mixtures thereof, and
a rheology modifier in an amount of from 10-65% w/w, based on the total weight of the composition, wherein the rheology modifier is lambda carrageenan.

US Pat. No. 10,246,670

AZEOTROPE-LIKE COMPOSITION CONTAINING FLUORINATED OLEFIN AS COMPONENT

Central Glass Company, Li...

1. An azeotrope (or azeotrope-like) composition comprising: (Z)-1,2-dichloro-3,3,3-trifluoropropene (1223Z) and (E)-1,2-dichloro-3,3,3-trifluoropropene (1223E).

US Pat. No. 10,246,666

IN SITU CLEANING SYSTEM

Ecolab USA Inc., Saint P...

1. A method for cleaning using a cleaning compound from an in situ cleaning system comprising:(a) providing feed water to an in situ cleaning system said cleaning system comprising one or more of:
(i) a water treatment component, wherein the water treatment component comprises a treatment reservoir comprising one or more conversion agents selected from the group of metal oxides, metal hydroxides, and mixtures thereof;
(ii) an oxidizing agent generating component; and
(iii) an alkalinity generating component, wherein the alkalinity generating component further comprises a decomposition agent selected from the group consisting of a source of manganese, a source of silver, and combinations thereof, wherein the decomposition agent catalyzes the decomposition of an oxidizing agent to form a source of alkalinity when contacted with the oxidizing agent;
wherein the cleaning system provides a use solution; and
(b) contacting an article with the use solution and;
(c) washing the article in a washing system.

US Pat. No. 10,246,665

VISCOELASTIC AMPHOTERIC SURFACTANT BASED CLEANING COMPOSITIONS

Ecolab USA Inc., Saint P...

1. A method of cleaning an object comprising:contacting the object with a viscoelastic cleaning composition for a predetermined time,
wherein
the cleaning composition comprises:
(a) a source of alkalinity,
(b) a nonpolymer viscoelastic surfactant having the following formula:
wherein R1 represents a hydrophobic moiety of alkyl, alkylarylalkyl, alkoxyalkyl, alkylaminoalkyl and alkylamidoalkyl, wherein alkyl represents a group that contains from about 16 to about 22 carbon atoms which may be branched or straight chained and which may be saturated or unsaturated;R2 and R3 are independently an aliphatic chain having from about 1 to about 30 atoms in which the aliphatic group can be branched or straight chained, saturated or unsaturated, a hydroxyalkyl chain or a carboxyalkyl chain; and
R4 is a hydrocarbyl radical (e.g. alkylene) with chain length 1 to 4; and
(c) from about 0.2 wt. % to about 5 wt. % by weight of said composition of a pseudolinker, wherein the pseudo linker is magnesium sulfate, magnesium acetate, aluminum sulfate, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), sodium tripolyphosphate (STPP), neutralized aminotris(methylenephosphonic acid) (ATMP), neutralized 1-hydroxyethane 1,1-diphosphonic acid (HEDP), and/or neutralized 2-phosphonobutane-1,2,4-tricarboxylic acid (PBTC);
wherein said pseudo linker is present in a ratio greater than 1:1 of active percent
by weight of linker to active percent by weight of surfactant; and thereafter rinsing the cleaning composition from the object so that the cleaning composition and any soils or debris are washed away.

US Pat. No. 10,246,664

CLEANING SOLUTION

1. A cleaning solution comprising:deionized water;
about 0.01% wt. to 0.5% wt. thickener wherein said thickener is xanthan gum;
about 3% wt. to 8% wt. hydrogen peroxide (H2O2);
a surfactant, wherein said surfactant is a 1-octanesulfonic acid sodium salt at a percent weight range of 1-6% and a C8-C10 alkyl polyglucoside at a percent weight range of 1-8%; and
about 0.01% wt. to 0.99% wt pH adjuster wherein said pH adjuster is sodium metasilicate.

US Pat. No. 10,246,663

LIPID COMPOSITION AND METHOD FOR PRODUCING SAME

IHI CORPORATION, Tokyo (...

1. A lipid composition, wherein the EPA to DHA mass ratio (EPA/DHA) in fatty acids constituting the lipid is (EPA/DHA)=1.2 to (EPA/DHA)=7.2, the proportion of phospholipid in the total lipid is no lower than 3% by mass and no higher than 54% by mass, the cadmium concentration is 0.4 mg or lower per kilogram of lipid, the arsenic concentration is 3 mg or lower per kilogram of lipid, and the concentration of dioxins is 2 pg-TEQ or lower per gram of lipid.

US Pat. No. 10,246,662

PIGMENTED, FINE-STRUCTURED, TRIBOLOGICAL COMPOSITE MATERIAL

Leibniz-Institut fuer Neu...

1. A composition for producing a tribological composite material, comprising:a) at least one platelet-shaped, solid-state lubricant;
b) at least one type of inorganic, platelet-shaped pigment particles;
c) at least one surface-active compound possessing at least one hydrophilic group and at least one hydrophobic group; and
d) a curable binder system comprising at least one organic polymer or oligomer having one or more functional groups, or a precursor thereof,
wherein the pigment particles comprise transition metal oxides and form bonds to the at least one hydrophilic group of the at least one surface-active compound, resulting in a quasi-transfer film in interlayers between the solid-state lubricant and the pigment particles.

US Pat. No. 10,246,661

ALKOXYLATED AMIDES, ESTERS, AND ANTI-WEAR AGENTS IN LUBRICANT COMPOSITIONS AND RACING OIL COMPOSITIONS

BASF SE, Ludwigshafen (D...

1. An additive package for a lubricant composition, said additive package comprising:an alkoxylated amide having a general formula (I):

and an ester having a general formula (II):

wherein
each R1, R2, R3, and R4 is, independently, a linear or branched, saturated or unsaturated, hydrocarbyl group,
at least one of R2 and R3 comprises an alkoxy group, and
R4 comprises an amine group; and
an anti-wear agent comprising phosphorus.

US Pat. No. 10,246,660

NATURAL-GAS PURIFICATION APPARATUS

MITSUBISHI HEAVY INDUSTRI...

1. A natural-gas purification apparatus for purifying natural gas from ground by separating carbon dioxide from the natural gas, comprising:a pressure adjuster that adjusts a pressure of the natural gas from the ground;
a natural-gas-liquid separator that liquefies and separates a part of natural-gas liquid by cooling the natural gas after the pressure adjustment by the pressure adjuster;
a heater that heats the natural gas after the separation of the part of the natural-gas liquid by the natural-gas-liquid separator;
a carbon-dioxide separator that separates carbon dioxide from the natural gas heated by the heater through a carbon-dioxide separation membrane; and
a controller that adjusts and controls at least one of a pressure of the natural gas to be achieved by the pressure adjuster, a temperature to which the natural gas is to be cooled by the natural-gas-liquid separator, and a temperature to which the natural gas is to be heated by the heater to a value which has been set in advance according to composition of the natural gas from the ground, such that the natural-gas-liquid separator liquefies and separates the part of the natural-gas liquid in the natural gas and the carbon-dioxide separator maintains a remaining part of the natural-gas liquid in the natural gas in gaseous form.

US Pat. No. 10,246,657

FUEL BLENDS FOR HOMOGENEOUS CHARGE COMPRESSION IGNITION ENGINES

Phillips 66 Company, Hou...

1. A fuel for a homogeneous charge compression ignition engine, comprising:(a) a mixture of hydrocarbons, each hydrocarbon in the mixture containing from 4 to 14 carbon atoms;
(b) at least 20 wt. % n-paraffins;
(c) at least 30 wt. % naphthenes;
(d) 20 wt. % or less of aromatic hydrocarbons;
(e) 5 wt. % or less of olefins.

US Pat. No. 10,246,656

VERSATILE SYSTEMS FOR CONTINUOUS IN-LINE BLENDING OF BUTANE AND PETROLEUM

1. A system for blending a volatility modifying agent with a petroleum stream having a petroleum flow rate, comprising:a petroleum stream downstream of a refinery;
an injection device injecting the volatility modifying agent into the petroleum stream at a volatility modifying agent flow rate;
a volatility measurement device in communication with the petroleum stream, the volatility measurement device configured to output data representative of a volatility measurement; and
a processor in connection with the injection device and the volatility measurement device, the processor configured to:
receive the volatility measurement; receive a target volatility value;
determine an adjustment to the volatility modifying agent flow rate based on the volatility measurement and the target volatility value; and
output a signal representative of the adjustment to the injection device,
wherein the injection device is electronically configured to access or receive the signal representative of the adjustment and to adjust the volatility modifying agent flow rate.

US Pat. No. 10,246,655

HIGH DENSITY RENEWABLE FUELS FROM SANTALENES

The United States of Amer...

1. A method for manufacturing turbine and diesel fuels, comprising:providing a sesquiterpene mixture consisting of santalene, alpha-santalene, beta-santalene, alpha-bergamotene, farnesene, and combinations thereof, wherein the sesquiterpene mixture is generated by metabolically engineered organisms from substrates including glucose, sucrose, fructose, other reducing sugars, cellobiose, cellulose, hemicellulose, lignocellulose, lignin, methane, natural gas, and CO2, or by isolating from plant material by solvent extraction or steam distillation;
purifying said sesquiterpene mixture, thereby forming a purified sesquiterpene mixture;
isomerizing said purified sesquiterpene mixture with at least one heterogeneous or homogenous acid catalyst to produce isomers; and
hydrogenating said isomers with at least one hydrogenation catalyst under hydrogen pressure to generate hydrogenated isomers; and distilling said hydrogenated isomers to produce a first high density fuel and a higher molecular weight residue.

US Pat. No. 10,246,654

HIGH DENSITY RENEWABLE FUELS BASED ON BARBATENE AND THUJOPSENE

The United States of Amer...

1. A method for manufacturing turbine and diesel fuels, comprising:providing a sesquiterpene mixture consisting of barbatene, thujopsene, alpha-barbatene, beta-chamigrene, beta-acoradiene, cuparene, and combinations thereof, wherein the sesquiterpene mixture is generated by metabolically engineered organisms from substrates including glucose, sucrose, fructose, other reducing sugars, cellobiose, cellulose, hemicellulose, lignocellulose, lignin, methane, and CO2, or by isolating the sesquiterpene mixture from plant material by solvent extraction or steam distillation;
purifying said sesquiterpene mixture, thereby forming a purified sesquiterpene mixture;
isomerizing said purified sesquiterpene mixture with at least one heterogeneous or homogenous acid catalyst to produce isomers; and
hydrogenating said isomers with at least one hydrogenation catalyst under hydrogen pressure to generate hydrogenated isomers; and distilling said hydrogenated isomers to produce a first high density fuel and a higher molecular weight residue.

US Pat. No. 10,246,653

POWDER TRANSPORT DEVICE AND CHAR RECOVERY DEVICE

MITSUBISHI HITACHI POWER ...

1. A powder transport device, comprising:a powder transport line which can transport powder by way of gravity by having a prescribed angle of inclination;
a porous plate which is disposed along the powder transport line to divide a line cross section into a top section and a bottom section and form a powder line in the top section;
a supply line which is provided below the porous plate and supplies an inert gas for fluidization to the powder line through the porous plate;
a fixed amount supply state monitoring device which detects a wall surface temperature of the powder transport line and includes multiple temperature sensors for monitoring a fixed amount supply state of flowing powder in the powder line, the multiple temperature sensors being provided in an axial direction of the powder transport line; and
a controller which controls an amount of the inert gas for fluidization supplied to the supply line so as to fluidize the powder deposited in the powder line, if at least one detection value of the multiple temperature sensors indicates a state where a flow amount of powder decreases in association with a decrease in the wall surface temperature of the powder transport line.

US Pat. No. 10,246,652

PROCESS FOR THE DEAROMATIZATION OF PETROLEUM CUTS

Total Marketing Services,...

1. A process for continuous dearomatization of a petroleum cut, comprising:(a) producing a hydrocarbon-containing fluid with a very low sulphur content and very low aromatic compounds content, at least one stage of catalytic hydrogenation at a temperature comprised between 80 and 180° C. and at a pressure comprised between 50 and 160 bar, and the stage of catalytic hydrogenation is made up of several interchangeable reactors linked in series;
(b) isolating one of the reactors;
(c) feeding a first one of two non-isolated reactors with the petroleum cut and feeding a second non-isolated reactor with effluent from the first non-isolated reactor;
(d) regenerating the isolated reactor by replacement of the catalyst;
(e) interrupting the feeding the second non-isolated reactor with effluent from the first non-isolated reactor; and
(f) feeding the regenerated reactor with the effluent from the first non-isolated reactors of stage (c) and feeding the second non-isolated reactor of stage (c) with the effluent from the regenerated reactor.

US Pat. No. 10,246,651

INTEGRATED SOLVENT DEASPHALTING, HYDROTREATING AND STEAM PYROLYSIS SYSTEM FOR DIRECT PROCESSING OF A CRUDE OIL

Saudi Arabian Oil Company...

1. An integrated solvent deasphalting, hydrotreating and steam pyrolysis system for the direct processing of a crude oil to produce olefinic and aromatic petrochemicals, the system comprising:a solvent deasphalting zone having a deasphalted and demetalized oil stream outlet and a bottom asphalt outlet;
a catalytic hydroprocessing zone in fluid communication with the deasphalted and demetalized oil stream outlet of the solvent deasphalting zone, the catalytic hydroprocessing zone having inlet for receiving a mixture of the deasphalted and demetalized oil stream and hydrogen recycled from a steam pyrolysis product stream effluent, and make-up hydrogen as necessary, and an outlet for discharging a hydroprocessed effluent, the catalytic hydroprocessing zone including a reactor operating under conditions effective to produce a hydroprocessed effluent;
a thermal cracking zone including
a thermal cracking convection section with an inlet in fluid communication with the hydroprocessing zone outlet, and an outlet,
a vapor-liquid separator having an inlet in fluid communication with the thermal cracking convection section outlet, a vapor fraction outlet and a liquid fraction outlet,
wherein the vapor liquid separator includes:
a pre-rotational element having an entry portion and a transition portion, the entry portion having an inlet for receiving a flowing fluid mixture from the thermal cracking convection section outlet, and a curvilinear conduit;
a controlled cyclonic section having
an inlet adjoined to the pre-rotational element through convergence of the curvilinear conduit and the cyclonic section,
a riser section at an upper end of the cyclonic member through a vapor fraction outlet through which vapors passes to a thermal cracking pyrolysis section;
and
a liquid collector/settling section through which liquid passes as a discharged liquid fraction,
and
the thermal cracking pyrolysis section having an inlet in fluid communication with the vapor fraction outlet of the vapor-liquid separator, and a pyrolysis section outlet;
a quenching zone in fluid communication with the pyrolysis section outlet, the quenching zone having an outlet for discharging an intermediate quenched mixed product stream and an outlet for discharging quenching solution;
a product separation zone in fluid communication with the intermediate quenched mixed product stream outlet, and the product separation zone having a hydrogen outlet, one or more olefin product outlets and one or more pyrolysis fuel oil outlets; and
a hydrogen purification zone in fluid communication with the product separation zone hydrogen outlet, the hydrogen purification zone having an outlet in fluid communication with the hydroprocessing zone.

US Pat. No. 10,246,650

CATALYTIC CRACKING FRACTIONATION AND ABSORPTION STABILIZATION SYSTEM, AND ENERGY SAVING METHOD THEREOF

Tianjin University, Tian...

1. A catalytic cracking fractionation and absorption-stabilization system of an oil refinery, wherein heat is extracted from the top of a main fractionating tower (1) by a first waste heat refrigerator (3) to serve as a refrigerator driving heat source after heat extraction so as to cool naphtha; rich gas (28) at the top of the main fractionating tower enters into a compressor for compression, the compressed rich gas is mixed with rich gasoline (30) discharged from the bottom of an absorber and desorbed gas (31) discharged from the top of a desorber to form a mixture, and the mixture enters into a gas-liquid separation tank (8) to reduce the phase splitting temperature therein after being cooled in a second waste heat refrigerator (7); a diesel oil tower (2) is arranged on the siding of the main fractionating tower (1), after the diesel oil discharged from the bottom of the diesel oil tower (2) exchanges heat with a diesel oil heat exchanger (11), the residual waste heat is used for generating power by a waste heat generator; in an absorption-stabilization system, two absorber intermediate heat exchangers (21) serially connected are arranged on each side edge of an absorber (9) and are serially connected with a third waste heat refrigerator (14) that is driven by the waste heat of the stable gasoline by pipelines so as to extract the heat discharged by the absorber in time during absorption and control low temperature absorption of the absorber; a residual pressure generator is connected to the top of a reabsorber (10) to generate power by the medium and low residual pressure of dry gas (32) at the top; a liquid phase at the bottom of a stabilizer (18) preheats the feedstock by a feedstock heat exchanger and is entered into the third waste heat refrigerator, a part of the discharge is extracted as product gasoline (34), and the other part enters into the third waste heat refrigerator to be refrigerated and cooled and returns to the top of the absorber from the third waste heat refrigerator to serve as circulating gasoline (35); and the residual pressure generator and the third waste heat generator generate electricity which is respectively conveyed into a grid by electric wires, and the power supply used by the compressor is led out from the grid by an electric wire.

US Pat. No. 10,246,646

MOBILE TRANSPORT FUEL REFINERY SYSTEM AND METHOD, FUEL REFINERY AND DISPENSING SYSTEM AND METHOD, AND FUEL COMPOSITION

1. A fuel refinement apparatus comprising:a particulate filter;
a water filter;
a magnetic field;
a catalyst injector; and
a dispensing conduit.

US Pat. No. 10,246,645

METHODS FOR REDUCING FLUE GAS EMISSIONS FROM FLUID CATALYTIC CRACKING UNIT REGENERATORS

UOP LLC, Des Plaines, IL...

1. A method for reducing flue gas particulate emissions from a fluid catalytic cracking (FCC) unit regenerator comprising the steps of:combining biochar with a hydrocarbon feedstock to generate a biochar-containing feedstock, wherein said biochar is derived from rapid thermal processing of biomass;
contacting the biochar-containing feedstock with an FCC catalyst; and
regenerating said FCC catalyst to produce the flue gas.

US Pat. No. 10,246,643

PROCESS AND APPARATUS FOR PRODUCING HYDROCARBON FUEL FROM WASTE PLASTIC

Virens Energy, LLC., Den...

1. A pyrolysis reactor for continuously producing a hydrocarbon oil from a melted waste plastic and separating a hydrocarbon vapor from a solid byproduct comprising:a reactor body comprising:
a longitudinal side, a first end, a second end located on the opposite side of the reactor body from the first end;
a side having a cylindrical shape, connecting the first end and the second end;
an inside; and an outside;
a first inlet feed connected through the first end, wherein the first inlet feed is capable of transferring the melted waste plastic into the inside of the reactor body;
a first outlet chamber connected to the second end, the first outlet chamber further comprising:
an opening positioned along a longitudinal wall of the first outlet chamber,
wherein the opening is located between about 60 percent and about 90 percent of the length of the longitudinal wall, and
a grating positioned within the first outlet chamber and connected to the opening, and
wherein the grating is oriented on an inclined angle of at least 25 degrees;
a first screw device located on the inside of the reactor body,
wherein the first screw device is hollow and comprising a heating system;
a plurality of vapor ports positioned along the longitudinal side of the reactor;
wherein the vapor ports are capable of removing the hydrocarbon vapor from the inside to the outside of the reactor;
a second outlet chamber connected to the opening of the first outlet chamber and comprising a discharging end located on the bottom of the second outlet chamber; and
a second screw device connecting the discharging end with the first end of the reactor body at an inclining angle of at least 20 degrees; and
a solid heat transfer medium located inside the reactor body capable of transferring heat from the solid heat transfer medium to the melted waste plastic.

US Pat. No. 10,246,640

MIXTURES OF AT LEAST ONE DIALKYLPHOSPHINIC ACID WITH AT LEAST ONE OTHER DIALKYLPHOSPHINIC ACID THAT IS DIFFERENT THEREFROM, METHOD FOR PRODUCTION THEREOF, AND USE THEREOF

Clariant International Lt...

1. A flame-retardant thermoset composition or, film, comprising 0.5 to 45% by weight of a mixture of at least one dialkylphosphinic acid of the formula (I)
wherein
R1, R2 are the same or different and are C1-C18-alkyl, C2-C18-alkenyl, C6-C18-aryl or C7-C18-alkylaryl,
with at least one different dialkylphosphinic acid of the formula (II)

wherein
R3, R4 are the same or different and are C1-C18-alkyl, C2-C18-alkenyl, C6-C18-aryl or C7-C18-alkylaryl,with the proviso that at least one of the R3 and R4 radicals is different than R1 and R2, 0.5 to 99.5% by weight of thermoset polymer, 0 to 55% by weight of additives and 0 to 55% by weight of filler or a reinforcing material, where the sum of the components is 100% by weight.

US Pat. No. 10,246,639

FIRE RETARDANT COMPOSITIONS AND CABLE SEPARATORS FORMED THEREOF

General Cable Technologie...

1. A fire retardant composition comprising:polyvinyl chloride;
about 10 parts to about 40 parts, by weight, of a plasticizer comprising one or more of a trimellitate ester and a phosphate ester;
about 0.1 part to about 25 parts, by weight, of a brominated fire retardant additive;
about 25 parts to about 75 parts, by weight, of a fire retardant synergist comprising a metal hydroxide;
about 1 part to about 10 parts, by weight, of a mixed metal stabilizer; and
wherein the fire retardant composition is substantially free of a halogenated plasticizer.

US Pat. No. 10,246,638

QUANTUM DOT LIGHT EMITTING DIODE (LED) WITH SUPPRESSED PHOTOBRIGHTENING

eLux, Inc., Vancouver, W...

1. A treated quantum dot (QD) with suppressed photobrightening comprising:a QD nanocrystal having a surface with a maximum cross-sectional dimension of 10 nanometers (nm), capable of emissions in the visible spectrum of light;
elements attached to the surface of the QD nanocrystal consisting of cations; and,
wherein the treated QD emits a non-varying intensity of first wavelength of light in the visible spectrum when subjected to a continuous exposure of a second wavelength of light having an intensity of greater than 50 watts per square centimeter (W/cm2).

US Pat. No. 10,246,636

LED DEVICE

LEEDARSON LIGHTING CO. LT...

1. A LED device, comprising:a LED module mounted on a substrate for emitting a blue light;
a first fluorescent layer with a first side facing to the LED module for converting the blue light to a red light;
a second fluorescent layer having a first side attached to a second side of the first fluorescent layer for converting the blue light to a green light emitted from a second side of the second fluorescent layer; and
a package housing for holding the substrate and the first fluorescent layer, wherein the package housing has a ladder wall for engaging with a peripheral part of the second fluorescent layer.

US Pat. No. 10,246,635

METHOD FOR PRODUCING A CONVERSION ELEMENT

OSRAM OPTO SEMICONDUCTOR ...

1. A method for producing a conversion element for an optoelectronic component, the method comprising:providing an acidic medium having a pH value of less than 2;
adding a conversion material into the acidic medium thereby forming a mixture;
adding a silicate solution having a viscosity between 2 and 10 000 poise inclusive to the mixture such that the pH value during the addition of the silicate solution is smaller than 2;
obtaining a precipitate which contains the conversion material and silicon dioxide as a matrix material;
separating the precipitate;
washing the precipitate with a washing medium, wherein the washing medium has a pH value of less than 2; and
hardening the precipitate thereby forming the conversion element.

US Pat. No. 10,246,634

QUANTUM DOT HAVING POLYMERIC OUTER LAYER, PHOTOSENSITIVE COMPOSITIONS INCLUDING THE SAME, AND QUANTUM DOT POLYMER COMPOSITE PATTERN PRODUCED THEREFROM

SAMSUNG ELECTRONICS CO., ...

17. A quantum dot complex comprising:an organic ligand compound bonded to the surface of the quantum dot, and
a polymeric outer layer comprising a copolymer, which comprises;
a first repeating unit comprising a moiety capable of intermolecularly interacting with the organic ligand compound, the quantum dot surface, or a combination thereof, and
a second repeating unit comprising a reactive moiety selected from the group consisting of a C2 to C20 alkenyl group, a C2 to C20 alkynyl group, an epoxy group, a thiol group, an anhydride group represented by Chemical Formula 4, an imide group represented by Chemical Formula 5, a group represented by any of Chemical Formula 6 to Chemical Formula 12, and a combination thereof:

wherein, in the chemical formulae, R is H, a C1 to C10 alkyl group, or a C6 to C20 aryl group, and
* is a linking portion to an adjacent atom present in a backbone of the copolymer.

US Pat. No. 10,246,632

PROPPANT HAVING AMPHIPHOBIC COATINGS AND METHODS FOR MAKING AND USING SAME

CARBO CERAMICS INC., Hou...

1. An amphiphobic proppant particle, comprising:a proppant particle having an internal interconnected porosity from about 5% to about 75%, a size from about 8 mesh to about 140 mesh and a density of less than 4.0 g/cm3; and
a degradable coating comprising an amphiphobic material infused into at least a portion of the internal interconnected porosity and formed on an outer surface of the proppant particle,
wherein the degradable coating comprises a degradable polymer blended with the amphiphobic material.

US Pat. No. 10,246,631

METHOD OF STIMULATING A SUBTERRANEAN FORMATION USING AN ACID PRECURSOR COMPOSITION

Halliburton Energy Servic...

1. A method of stimulating a subterranean formation, comprising:placing a fracturing composition in a subterranean formation;
hydraulically fracturing the subterranean formation with the fracturing composition to form at least one fracture and a spent fracturing composition;
flushing the subterranean formation;
placing an acid precursor composition in the subterranean formation, wherein the precursor composition comprises greater than 7 to about 99 wt. %, based on the total weight of the precursor composition, of an acid precursor;
forming an acid from the acid precursor; and
acidizing the subterranean formation in the fracture with the formed acid.

US Pat. No. 10,246,630

WATER SOLUTION, CLEAN FRACTURING FLUID AND METHOD FOR FRACTURING RESERVOIR

CHINA UNIVERSITY OF PETRO...

1. A method for fracturing a reservoir, comprising:preparing an aqueous solution by:
mixing an organic acid amidopropyl dimethylamine, an additive, and water, while stirring at a temperature of 30° C. to 50° C. for a time of 5 min to 20 min,
wherein the additive is selected from the group consisting of salicylate, cis-butenedioic acid, o-phthalic acid, dodecyl sulfonate, p-toluene sulfonate, benzoate and combinations thereof,
wherein a weight ratio of the organic acid amidopropyl dimethylamine and the additive is 8:1-12:1;
introducing carbon dioxide at a rate of 0.1-0.5 L/min. into the aqueous solution for gelatinization, to form a clean fracturing fluid,
wherein the carbon dioxide is introduced for a time sufficient render the clean fracturing fluid clear;
injecting the clean fracturing fluid into a reservoir for fracturing; and
introducing air, nitrogen, or an inert gas into the reservoir after the fracturing for gel breaking.

US Pat. No. 10,246,629

MITIGATION OF CORROSION IN GEOTHERMAL SYSTEMS

ECOLAB USA INC., St. Pau...

1. A corrosion inhibitor blend comprising an ether compound, a quaternary ammonium compound, and a fatty acid amine condensate, wherein the quaternary ammonium compound is selected from the group consisting of benzyldimethyldodecylammonium chloride, benzyldimethylhexadecylam monium chloride, benzyldimethyloctadecyl ammonium chloride, and any combination thereof.

US Pat. No. 10,246,628

MULTIPLE HYDROPHILIC HEAD CORROSION INHIBITORS

MULTI-CHEM GROUP, LLC, H...

1. A method of inhibiting corrosion, the method comprising:introducing a composition comprising a hydrophilic solvent and a corrosion-inhibiting compound into a wellbore penetrating at least a portion of a subterranean formation; and
contacting a metal surface in the wellbore with the corrosion-inhibiting compound;
wherein the corrosion-inhibiting compound has the structural formula:

wherein each of R1 and R2 is CH3 and R3 is benzyl;
wherein each of M, M?, and M? is nitrogen;
wherein R is a C1 to C30 hydrocarbon chain;
wherein J is selected from the group consisting of hydrogen, a C1 to C6 hydrocarbon chain, and combinations thereof; and
wherein each of X, X?, and X? is an anion selected from the group consisting of halide, carboxylate, sulfate, organic sulfonate, hydroxide, and combinations thereof.

US Pat. No. 10,246,627

METHODS OF USING INVERT EMULSION FLUIDS WITH HIGH INTERNAL PHASE CONCENTRATION

M-I L.L.C., Houston, TX ...

1. A method of completing a wellbore penetrating a subterranean formation, the wellbore comprising a cased section and an uncased section, the method comprising:introducing invert emulsion fluid into the uncased section of the wellbore, the invert emulsion fluid comprising:
an oleaginous external phase;
a non-oleaginous internal phase, wherein a ratio of the oleaginous external phase and non-oleaginous internal phase is less than 50:50; and
an emulsifier stabilizing the oleaginous external phase and the non-oleaginous internal phase; and
running a liner, sand control screen assembly, swell packer assembly, or inflow control device to a selected depth within the uncased section of the wellbore in which the invert emulsion fluid is located;
wherein the emulsifier is an alkoxylated ether acid.

US Pat. No. 10,246,626

LOSS CIRCULATION COMPOSITIONS (LCM) HAVING PORTLAND CEMENT CLINKER

Saudi Arabian Oil Company...

1. A lost circulation material (LCM) composition, comprising:Portland cement clinker, wherein the Portland cement clinker consists of non-hydraulic, non-cementiceous unground Portland cement clinker particles;
cement;
a carrier fluid, wherein the carrier fluid comprises an aqueous carrier fluid that includes at least one of diutan gum, xanthan gum, and welan gum; and
an inorganic consolidation activator selected to consolidate the clinker in the composition to form a plug when introduced into a lost circulation zone.

US Pat. No. 10,246,624

MODIFIED DEFORMED REINFORCEMENT FIBERS, METHODS OF MAKING, AND USES

FORTA CORPORATION, Grove...

1. A modified reinforcement fiber-containing drilling liquid, comprising:a drilling liquid; and
a reinforcement fiber component in a form selected from individual fibers, a clip of fibers and a bundle of fibers, at least a portion of the reinforcement fiber component comprises a plurality of modified reinforcement fibers each having a length from about 3 to 25 millimeters and a deformation formed in the length, wherein the deformation includes at least one crimp,
wherein, the reinforcement fiber component and the drilling liquid form a blend or mixture, and
wherein, the modified reinforcement fiber-containing drilling liquid is effective to increase suspension and debris removal from a wellbore as compared to a drilling liquid absent of the plurality of modified reinforcement fibers.

US Pat. No. 10,246,623

RESIN COMPOSITION, ARTICLE PREPARED BY USING THE SAME, AND METHOD OF PREPARING THE SAME

Naieel Technology, (KR)

1. A resin composition comprising:thermally conductive particles;
boron nitride nanotubes, wherein the boron nitride nanotubes are at an amount in a range of about 1.5 wt % to not more than 4.5 wt % based on a total weight of the thermally conductive particles; and
a matrix resin.

US Pat. No. 10,246,621

HEAT TRANSFER METHODS, SYSTEMS AND COMPOSITIONS

HONEYWELL INTERNATIONAL I...

1. A refrigerant blend consisting of:about 50% by weight difluoromethane (HFC-32),
about 11.5% by weight pentafluoroethane (HFC-125), and
about 38.5% by weight trifluoroiodomethane (CF3I),
wherein the percentages are based on the total weight of the three compounds in the blend.

US Pat. No. 10,246,620

CMP POLISHING AGENT, METHOD FOR MANUFACTURING THEREOF, AND METHOD FOR POLISHING SUBSTRATE

SHIN-ETSU CHEMICAL CO., L...

1. A CMP polishing agent, comprising polishing particles, a protective film-forming agent, and water, whereinthe protective film-forming agent is a copolymer of styrene and acrylonitrile,
an average molecular weight of the copolymer of styrene and acrylonitrile is 500 or more and 20000 or less, and
the copolymer of styrene and acrylonitrile is present in an amount of 0.1 part by mass or more and 5 parts by mass or less on the basis of 100 parts by mass of the polishing particles.

US Pat. No. 10,246,619

METHOD FOR INCREASING THE REACTIVITY OF LIGNIN

UPM-KYMMENE CORPORATION, ...

1. A method for producing a binder composition, the method comprising:(a) forming, under heating at a temperature of 30-70° C., an aqueous dispersion consisting of alkali, lignin, and water, wherein the alkali comprises a hydroxide of an alkali metal, and wherein the concentration of the lignin is 10-50 weight-% based on the total weight of the aqueous dispersion;
(b) heating the aqueous dispersion formed in step (a) at a temperature of 50-95° C., thereby producing alkalated lignin, wherein the alkalated lignin has an increased reactivity relative to the lignin; and
(c) cooking an aqueous composition comprising reactant components including the alkalated lignin, a polymerizable substance, and a crosslinking agent in the presence of a catalyst at a temperature of 60-95° C. for polymerizing the reactant components until a binder composition is formed.

US Pat. No. 10,246,616

ADHESIVE COMPOSITIONS AND ARTICLES, AND METHODS OF MAKING AND USING THE SAME

3M Innovative Properties ...

1. An adhesive composition comprising a polymerized reaction product of components comprising:a) first components of a first acrylic polymer comprising:
i) at least one alkyl (meth)acrylate having from 4 to 22 carbon atoms;
ii) at least one of acrylic acid and methacrylic acid;
b) at least one second acrylic polymer prepared by polymerization of second components comprising:
iii) at least one alkyl (meth)acrylate having from 4 to 22 carbon atoms;
iv) at least one (meth)acrylamide represented by the formula

wherein R1 is H or methyl; and
R2 and R3 independently represents H or an alkyl group having from 1 to 8 carbon atoms, or taken together R2 and R3 may form a divalent alkylene group having from 4 to 6 carbon atoms; and
v) at least one high Tg macromer having a terminal free-radically polymerizable unsaturated group, wherein the high Tg macromer has a Tg of at least 45° C.; andwherein, based on the combined total weight of the components a) and b), second acrylic polymer b) is present at a level of from 5 to 40 percent by weight.

US Pat. No. 10,246,615

ULTRAVIOLET-LIGHT-EMITTING DEVICE WITH ADHESIVE HAVING LOW GLASS TRANSITION TEMPERATURE

AGC, Inc., Chiyoda-ku (J...

1. An adhesive for forming an adhesive joint in an ultraviolet-light-emitting device, which is either the following adhesive (A) or the following adhesive (B) comprising a fluoropolymer having a fluorine-containing alicyclic structure:wherein:
the ultraviolet-light-emitting device comprises a light-emitting element generating ultraviolet light having a wavelength of from 200 to 400 nm, an optical member which transmits the ultraviolet light generated by the light-emitting element and the adhesive joint formed from the adhesive between the light-emitting element and the optical member, wherein the optical member is made of a fluoropolymer having a fluorine-containing alicyclic structure;
the adhesive (A) is an adhesive in which the glass transition temperature of the fluoropolymer is from 30 to 100° C., and which does not comprise an ultraviolet-shielding agent; and
the adhesive (B) is an adhesive comprising the fluoropolymer and an ultraviolet-shielding agent.

US Pat. No. 10,246,613

LIGHT-REFLECTIVE ANISOTROPIC CONDUCTIVE ADHESIVE AND LIGHT-EMITTING DEVICE

DEXERIALS CORPORATION, T...

1. A light-reflective anisotropic conductive adhesive used for an electrically anisotropic conductive connection of a light-emitting element to a wiring substrate, the light-reflective anisotropic conductive adhesive comprisinga thermosetting resin composition,
conductive particles,
a curing agent for an epoxy resin, and
light-reflective insulating particles, wherein
the curing agent for an epoxy resin is an acid anhydride-based curing agent, and
the thermosetting resin composition includes a diglycidyl isocyanuryl modified polysiloxane represented by the formula (1)
wherein in the formula, R represents an alkyl group or an aryl group, and n represents an integer of 1 to 40.

US Pat. No. 10,246,611

TRANSPARENT FILM

SUMITOMO CHEMICAL COMPANY...

1. A transparent film having a polysiloxane backbone,wherein the transparent film has a structure (a) in which a fluorine-containing group having a perfluoroalkyl group or a perfluoropolyether group on the free end side thereof is bonded to a silicon atom of the polysiloxane backbone,
the fluorine-containing group having the perfluoroalkyl group on the free end side thereof is a group represented by the following formula (3-1) or (4-1),

in the formula (3-1),
Rf represents a fluorine atom or an alkyl group which has 1 to 20 carbon atoms and is substituted with one or more fluorine atoms,
Rf2 each independently represents a fluorine atom or an alkyl group which has 1 to 20 carbon atoms and is substituted with one or more fluorine atoms, R3 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms,
D each independently represents —O—, —COO—, —OCO—, —NR—, —NRCO—, or —CONR—, wherein R represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or a fluorine-containing alkyl group having 1 to 4 carbon atoms,
a2, c2, d2, and e2 are each independently an integer of not less than 0 and not more than 600, and the sum total of a2, b2, c2, d2, and e2 is 13 or more,
b2 is not less than 20 and not more than 600,
in the formula (4-1),
Rf represents a fluorine atom or an alkyl group which has 1 to 20 carbon atoms and is substituted with one or more fluorine atoms,
Rf3 each independently represents a fluorine atom or an alkyl group which has 1 to 20 carbon atoms and is substituted with one or more fluorine atoms, R5 each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms,
G each independently represents —O—, —COO—, —OCO—, —NR—, —NRCO—, or —CONR—, wherein R represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or a fluorine-containing alkyl group having 1 to 4 carbon atoms,
Y each independently represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms,
Z represents a hydrogen atom or a halogen atom,
a3, c3, d3, and e3 are each independently an integer of not less than 0 and not more than 600, and the sum total of a3, b3, c3, d3, and e3 is 13 or more,
b3 is not less than 20 and not more than 600,
h3 is an integer of not less than 0 and not more than 2,
q is an integer of not less than 1 and not more than 10,
the fluorine-containing groups are bonded to some silicon atoms of the polysiloxane backbone in the structure (a),
the transparent film has a structure (b) in which carbon fluoride-containing groups or hydrolysable silane oligomer residue are bonded to some of the remaining silicon atoms of the polysiloxane backbone,
the molecular length of the structure (b) is shorter than the molecular length of the structure (a), and
the transparent film has a slip rate of 0.2 mm/s or more for a 120 ?l waterdrop on an 8° incline.

US Pat. No. 10,246,605

RESIN COMPOSITION FOR UNDERLAYER FILM FORMATION, LAYERED PRODUCT, METHOD FOR FORMING PATTERN, IMPRINT FORMING KIT, AND PROCESS FOR PRODUCING DEVICE

FUJIFILM Corporation, To...

1. A resin composition for underlayer film formation which is used to form an underlayer film by being applied onto a base material, comprising:a first resin having a radical reactive group in a side chain;
a second resin containing at least one selected from a fluorine atom and a silicon atom; and
a solvent,
wherein the second resin contains a repeating unit having a fluorine atom and a repeating unit represented by General Formula (CIII):

wherein Rc31 represents a hydrogen atom, an alkyl group, a cyano group, or a CH2—O-Rac2 group; Rac2 represents a hydrogen atom, an alkyl group, or an acyl group; Rc32 represents a group having an alkyl group, a cycloalkyl group, an alkenyl group, a cycloalkenyl group, or an aryl group; and Lc3 represents a single bond or a divalent linking group; and
the repeating unit having a fluorine atom contains at least one unit selected from the group consisting Formulae (C-Ia) to (C-Id):

wherein R10 and R11 each independently represents a hydrogen atom, a fluorine atom, or an alkyl group; and W3 to W6 each independently represents an organic group containing at least one or more fluorine atoms.

US Pat. No. 10,246,604

METHOD FOR PRODUCING VINYL POLYMER-CONTAINING AQUEOUS LIQUID AND METHOD FOR PRODUCING WATER/OIL RESISTANT AGENT

AGC Inc., Chiyoda-ku (JP...

1. A production method of a vinyl polymer aqueous liquid, the production method comprising:filling a closed container having a gas outlet with a mixed liquid containing water and a hydrophilic organic solvent with a boiling point of lower than 10020 C., wherein a vinyl polymer having hydrophobic groups and hydrophilic groups is dissolved or dispersed, to form a liquid phase and a gas phase;
forming a part of the liquid of the liquid phase into small droplets;
bringing the small droplets into contact with the gas phase to vaporize the hydrophilic organic solvent in the small droplets; and
removing the gas of the gas phase containing the vaporized hydrophilic organic solvent from the gas outlet of the closed container, whereby the amount of the hydrophilic organic solvent in the liquid phase is reduced to at most 1 mass % per the total amount of the hydrophilic organic solvent and water.

US Pat. No. 10,246,603

COATING MATERIAL COMPOSITION, SOLVENT-BASED COATING MATERIAL, AQUEOUS COATING MATERIAL, POWDER COATING MATERIAL AND COATED ARTICLE

AGC Inc., Chiyoda-ku (JP...

1. A coating material composition, comprising:a fluorinated copolymer (A); and
a pigment (B),
wherein
the fluorinated copolymer (A) has units represented by the following formula (1) and units represented by the following formula (2),
a number average molecular weight of the fluorinated copolymer (A) is from 10,000 to 100,000,
a hydroxy value of the fluorinated copolymer (A) is at least 100 mgKOH/g, and
a content of the pigment (B) is from 20 to 200 parts by mass, per 100 parts by mass of the fluorinated copolymer (A):

where in the formula (1), X and Y are each independently H, F, CF3 or Cl.

US Pat. No. 10,246,601

COLORED MICROPARTICLE DISPERSION

KAO CORPORATION, Tokyo (...

1. A water-based ink for ink-jet printing, comprising a colored fine particle dispersion, in which:a content of water is not less than 20% by mass and not more than 60% by mass;
the colored fine particle dispersion comprises emulsified particles comprising a pigment and a polymer comprising a constitutional unit derived from a compound (A) represented by the following general formula (I) and a constitutional unit derived from a polymerizable monomer component comprising a hydrophobic vinyl-based monomer;

wherein BO is a butyleneoxy group, which is at least one group selected from the group consisting of a butane-1,2-diyloxy group, a butane-1,3-diyloxy group and a tetramethyleneoxy group; EO is an ethyleneoxy group; M is a cation; m represents an average molar number of addition of BO and is a number of not less than 1 and not more than 10; and n represents an average molar number of addition of E O and is a number of not less than 4 and not more than 25 , wherein a content of the constitutional unit derived from said compound (A) is in the range 3 to 20 parts by mass in terms of the monomer based on 100 parts by mass of the constitutional unit derived from said polymerizable monomer component;
the polymerizable monomer component comprises an ionic monomer; and
a content of the ionic monomer in the polymerizable monomer component is not less than 2% by mass and not more than 20% by mass.

US Pat. No. 10,246,600

PREPARATION OF HIGH SOLID YELLOW PIGMENT SLURRY

BEHR PROCESS CORPORATION,...

1. A method comprising:a) combining a dispersant having pigment affinic groups with water to form an aqueous dispersant mixture, the dispersant having pigment affinic groups including a polyacrylate backbone and polyetheramine side chains attached to the polyacrylate backbone, further including an additional dispersant that is ammonium salt of a polycarboxylated polymer or copolymer;
b) adding at least one pigment to the aqueous dispersant mixture to form an aqueous pigment composition; and
c) grinding the aqueous pigment composition until the average particle size is less than 30 microns to form a pigmented aqueous slurry, the aqueous pigment composition including about 30 to 60 weight percent pigment wherein the pigment has a color with a CIE 1931 color space dominant wavelength from 570 to 590 nm.

US Pat. No. 10,246,599

INK COMPOSITION AND METHOD OF DETERMINING A DEGREE OF CURING OF THE INK COMPOSITION

XEROX CORPORATION, Norwa...

1. An uncured silver paste ink composition, comprising:a plurality of first particles comprising silver, the first particles being flakes and having a largest dimension with an average length ranging from about 2 microns to about 10 microns, the first particles being present in the silver paste ink composition in an amount ranging from 70% by weight to about 95% by weight, based on the total weight of the silver paste ink composition;
a polymer binder comprising a thermoplastic material selected from the group consisting of a polyvinylbutyral terpolymer of a formula I and a mixture of the polyvinylbutyral terpolymer of formula I and polyvinylpyrrolidone,
where R1 is a chemical bond or a divalent hydrocarbon linkage having from about 1 to about 20 carbons; R2 and R3 are independently an alkyl group, an aromatic group or a substituted aromatic group having from about 1 to about 20 carbon atoms; x, y and z represent the proportion of the corresponding repeat units respectively expressed as a weight percent, and the sum of x, y and z is about 100 weight percent; x is independently from about 3 weight percent to about 50 weight percent; y is independently from about 50 weight percent to about 95 weight percent; and z is independently from about 0.1 weight percent to about 15 weight percent, the polymer binder being in an amount ranging from 0.5 to 5 weight percent, based on the total weight of the silver paste ink composition;a carrier solvent; and
a plurality of second particles comprising silver and having an average diameter ranging from about 3 nanometers to about 10 nanometers, the second particles being nanoparticles that are different than the first silver particles, the second particles in the ink composition being in an amount effective to impart a first color to the uncured silver paste ink composition, the first color being different than the color of the same ink composition without the nanoparticles, wherein the silver nanoparticles have a property of causing a change in the color of the ink composition when the ink composition is cured, the amount of second particles ranging from 3% by weight to about 20% by weight, relative to the total weight of the silver paste ink composition, wherein the plurality of second particles comprising silver are coated with an organic molecule stabilizer selected from the group consisting of octylamine, decylamine, dodecylamine, stearyl amine, octanoic acid, decanoic acid and stearic acid.

US Pat. No. 10,246,598

MANUFACTURE METHOD OF QUANTUM DOTS PRINTING INK AND QUANTUM DOTS PRINTING INK MANUFACTURED WITH THE MANUFACTURE METHOD

SHENZHEN CHINA STAR OPTOE...

1. A manufacture method of quantum dots printing ink, comprising steps of:step 1, providing quantum dots material and first solvent, and mixing the quantum dots material and the first solvent, together in uniform dispersion to obtain first mixed solution;
step 2, providing second solvent, which is mutually dissolvable with the first solvent, and adding the second solvent in the first mixed solution according to a volume ratio that the first solvent and the second solvent is 1:2-2:1 in uniform mixture to obtain a second mixed solution, of which a viscosity is 1-10 cps;
step 3, providing third solvent, which is mutually dissolvable with the first solvent and the second solvent, and adding the third solvent in the second mixed solution according to a volume ratio that a sum of the first solvent and the second solvent, and the third solvent is 1:2-2:1 in uniform mixture to obtain the quantum dots printing ink, of which a viscosity is 1-10 cps, and a surface tension is 30-40 dyne/cm; and
step 4, providing fourth solvent, which is mutually dissolvable with the first solvent, the second solvent and the third solvent, and adding the fourth solvent in the quantum dots printing ink according to a volume ratio that the fourth solvent and a sum of the first solvent, the second solvent and the third solvent is smaller than 1/9 in uniform mixture, so as to adjust a room temperature vapor pressure of the quantum dots printing ink under 100 mmHg as maintaining the viscosity of the quantum dots printing ink to be 1 -10 cps, and the surface tension to be 30-40 dyne/cm;
wherein the first solvent is monoethylene glycol; the second solvent is 1-butanol; the third solvent is pyrrolidinone; the fourth solvent is propylene glycol propyl ether.

US Pat. No. 10,246,595

COMBINATORIAL MATERIALS ARCHITECTURE AND PROCESS FOR TEXTILES AND RELATED APPLICATIONS

NanoMech, Inc., Springda...

1. A treated, flame-retardant substrate material complex, the complex consisting essentially of:a. a plurality of inorganic crystallites, each having a surface, wherein the plurality of inorganic crystallites comprises at least one of (a) a plurality of phosphorous-containing crystallites and (b) a plurality of nitrogen-containing crystallites; and
b. a plurality of functional particles deposited on the surface of at least a portion of the plurality of inorganic crystallites, wherein the functional particles comprise a plurality of metallic deposits,
wherein a portion of the surface of the inorganic crystallites remains uncovered and further wherein a portion of the surface of the inorganic crystallites is in direct contact with another of the inorganic crystallites.

US Pat. No. 10,246,591

SECOND COMPONENT FOR A TWO-COMPONENT SPRAYABLE METHYL-METHACRYLATE BASED PAINT AND METHOD OF PRODUCING THEREOF

1. A second component for a two-component sprayable paint, the first component comprising methyl-methacrylate, the second component comprising a mix of:a catalyst for the methyl-methacrylate; and
an acetone-based paint comprising an acrylic copolymer binder, wherein the second component comprises between 90% and 20% of catalyst by volume.

US Pat. No. 10,246,590

USE OF INDIGO DERIVATIVES FOR DYEING SYNTHETIC TEXTILES, NOVEL INDIGO DERIVATIVES AND PROCESS FOR DYEING SYNTHETIC TEXTILES

Sanko Tekstil Isletmeleri...

1. A method for dyeing synthetic textiles which comprises the use of indigo derivatives of Formula (I)
wherein:
R1 and R2 are, each independently, selected from hydrogen, a tert-butoxycarbonyl (t-Boc) and a fluorenylmethyloxycarbonyl (Fmoc) group, provided that R1 and R2 are not both hydrogen;
R3 and R4 are, each independently, selected from hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, NO2, CHO, and substituted phenyl, provided that R3 and R4 are not both hydrogen.

US Pat. No. 10,246,588

SOLVENT-FREE RESIN COMPOSITION AND USES OF THE SAME

TAIWAN UNION TECHNOLOGY C...

19. The resin composition of claim 18, wherein the flame retardant is selected from the group consisting of phosphorous-containing flame retardants, bromine-containing flame retardants, and combinations thereof.

US Pat. No. 10,246,583

CELLULOSE NANOCRYSTAL POLYMER COMPOSITE

1. A reinforced polymer composite, the reinforced polymer composite comprising:a polymer matrix, and
a strengthening agent, the strengthening agent including cellulose nanocrystals (CNC) and a stabilizing agent, wherein the stabilizing agent includes Boehmite nanoclay (Boe); and
wherein the strengthening agent is homogenously dispersed in the polymer matrix.

US Pat. No. 10,246,575

METAL-PLASTIC HYBRID COMPONENT

Evonik Degussa GmbH, Ess...

1. A polymer composition, comprising:a) from 50 to 99.7% by weight of at least one polymer having a molecular weight of 15,000 to 70,000 selected from the group consisting of polyamides, polyaryl ether ketones, and mixtures thereof, and
b) from 0.3 to 20% by weight of one or more additives of the formula (I):
MaM?bDcD?d  (I)
wherein
M=[R3SiO1/2]
M?=[R?R2SiO1/2]
D=[R2SiO2/2],
D?=[R?RSiO2/2]
wherein each R is independently selected from the group consisting of H, alkyl moieties having from 1 to 12 C atoms and a phenyl moiety, and each R? is independently a moiety having a structure of formula (II), formula (III) or formula (IV),
wherein formula (II) is an alkylamino moiety

wherein x=from 1 to 20 and R? is selected from the group consisting of H and an alkyl moiety having from 1 to 12 C atoms,
formula (III) is a (trialkoxysilyl)methylene moiety

wherein R?? is an alkyl moiety having from 1 to 4 C atoms,
and formula (IV) is an epoxycyclohexylalkyl moiety

wherein y=from 1 to 4,
wherein the indices are
a=from 0 to 2
b=from 0 to 2
c=from 10 to 500
d=from 0 to 50
a+b=2 and
b+d?2, and
wherein the proportions of all constituents of the composition give a total of 100% by weight.

US Pat. No. 10,246,573

ANTI-STATIC COMPOSITIONS

HONEYWELL INTERNATIONAL I...

1. A doped polyaniline comprising a dopant that is:a polymer comprising
a compound having the structure:

 or a salt thereof,
wherein
R2 is chosen from substituted or unsubstituted (C1-C10)hydrocarbyl- and substituted or unsubstituted (C1-C10)hydrocarbyl-O—,
L1 is substituted or unsubstituted (C1-C10)hydrocarbylene,
L2 is chosen from a bond, —O—, —O—C(O)—, and —NH—C(O)—, and
n is about 1 to about 100,000;
p-sulfonatocalix[n]arene or a salt thereof, wherein n is an even integer that is from 10 to about 100;
or
a combination thereof.

US Pat. No. 10,246,571

POLYFUNCTIONAL AMINES WITH HYDROPHOBIC MODIFICATION FOR CONTROLLED CROSSLINKING OF LATEX POLYMERS

Ennis Paint, Inc., Thoma...

1. A polyfunctional amine comprising recurring units derived from the reaction of one bi- or tri-glycidyl moiety and a single, di-, or tri-functional amino monomer(s), or combination of, mono/tri, mono/tetra, bi/bi, bi/tri, bi/tetra, tri/tri, tri/tetra, and tetra/tetra functional amino monomers resulting in one or more polyfunctional amines
wherein I-x-2-b? is a hydrophobic crosslinking agent and comprises at least three pH responsive amino group sites configured to accept or release proton(s) in response to a change in pH, and comprises at least one NH and/or one —NH2 site providing reactive sites for hydrophobic compounds that introduce at least one hydrophobic moiety into hydrophobic modifications of I-x-b-2? structures represented by formulae I-x-b-2? a, I-x-b-2?b, I-x-b-2?c and I-x-b-2?d:

wherein said structures of formulae I-x-b-2?a, I-x-b-2?b, I-x-b-2?c and I-x-b-2?d have at least one hydrophobic moiety introduced into said structures from the group consisting of: hydrophobic epoxides, hydrophobic glycidyl ethers and hydrophobic (meth)acrylates.

US Pat. No. 10,246,568

PRODUCTION OF POROUS MATERIALS BY THE EXPANSION OF POLYMER GELS

SUMTEQ GmbH, Cologne (DE...

1. A method of producing a micro- or nano-porous polymer material,swelling a polymer starting material using a plasticizer at a predetermined temperature to make the polymer starting material visco-elastic deformable, wherein the polymer starting material is at least partially crosslinked and the crosslinker content in the polymer starting material is in a range from 0.01 to 10 mol %, wherein the predetermined temperature is in a range from 0 to 100° C.;
subsequently, contacting the swollen polymer starting material with a foaming agent under a first pressure; and
subsequently, depressurizing from the first pressure to a second pressure such that the swollen polymer starting material further expands and solidifies to obtain a micro- or nanoporous material.

US Pat. No. 10,246,565

RAPIDLY CURING ADHESIVES USING ENCAPSULATED CATALYST AND FOCUSED ULTRASOUND

The Boeing Company, Chic...

1. A method for making an on-demand adhesive comprising the steps of:mixing a resin-based compound with a non-gas-filled encapsulated catalyst to form an uncured resin-based adhesive,
depositing said uncured resin-based adhesive onto component, said catalyst encapsulated within a shell, said shell having an average shell diameter of from about 1 to about 1000 microns, and said shell having an average shell wall thickness of from about 1 to about 10% of the shell diameter;
directing non-thermal ultrasonic energy from an ultrasonic energy source through the component, said ultrasonic energy source emitting ultrasonic energy from a curved piezoelectric ceramic probe head with the emitted ultrasonic energy tuned to an ultrasonic energy in the range of from about 0.5 to about 50 MHz;
focusing the non-thermal ultrasonic energy through the component to a region or point located in the deposited adhesive;
targeting non-thermal ultrasonic energy frequencies corresponding to a natural resonant frequency of the shell;
rupturing the non-gas-filled encapsulated catalyst; and
curing on-demand the uncured resin-based adhesive.

US Pat. No. 10,246,564

END-MODIFIED CONJUGATED DIENE POLYMER AND METHOD FOR PREPARING THE SAME

Korea Kumho Petrochemical...

1. A method for preparing an end-modified conjugated diene polymer, comprising:(a) polymerizing one or two of a conjugated diene monomer and an aromatic vinyl monomer to form a living polymer in the presence of a solvent, a lewis base, and an organometallic compound; and
(b) reacting the living polymer with a compound represented by Formula 2 below:

to modify an end of the living polymer,
wherein R1 to R8 are each C1-C20 saturated or unsaturated hydrocarbon chains; X is carbon (C), silicon (Si), or nitrogen (N); a is 1; b, c and d are each integers of 0 to 3 satisfying an equation of b+c+d=3; and n is an integer of 1 to 200.

US Pat. No. 10,246,563

PHOTOSTABILIZER MASTER BATCH AND METHOD FOR MANUFACTURING SAME

ADEKA CORPORATION, Tokyo...

1. A photostabilizer masterbatch obtained by adding and mixing 80 to 300 parts by mass of (B) a hindered amine compound represented by the following Formula (1) with respect to 100 parts by mass of (A) a silica produced by a wet process and subsequently further adding and mixing 5 to 50 parts by mass of (C) a silica produced by a dry process:
(wherein, R1 represents a hydrogen atom, a hydroxy group, an alkyl, hydroxyalkyl, alkoxy or hydroxyalkoxy group having 1 to 30 carbon atoms, or an oxy radical; and R2 represents an alkyl group having 1 to 30 carbon atoms, an alkenyl group having 2 to 30 carbon atoms, or a group represented by the following Formula (2))

(wherein, R3 represents the same as R1 in said Formula (1)).

US Pat. No. 10,246,561

METHOD OF MAKING SILVER-CONTAINING DISPERSIONS WITH NITROGENOUS BASES

EASTMAN KODAK COMPANY, R...

1. A method comprising, in sequence:A) mixing:
(a) one or more polymers selected from one or more of cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and carboxymethyl cellulose;
(b) reducible silver ions present in an amount of a weight ratio of (b) reducible silver ions to the one or more (a) polymers of at least 5:1 and up to and including 50:1; and
(c) one or more organic solvents, each of which has a boiling point at atmospheric pressure of at least 100° C. and up to but less than 500° C., wherein the Hansen parameter (?TPolymer) of each of the one or more polymers is less than or equal to the Hansen parameter (?TSolvent) of each of the one or more organic solvents,
to form a premix solution;
B) heating the premix solution to a temperature of at least 75° C.;
C) while keeping the premix solution at the temperature of at least 75° C., adding a (d) nitrogenous base having a pKa in acetonitrile of at least 15 and up to and including 25 at 25° C., to provide a concentration of the (d) nitrogenous base in an equimolar amount or in molar excess in relation to the amount of (b) reducible silver ions,
to form a silver nanoparticle composite;
D) after cooling, isolating the silver nanoparticle composite; and
E) re-dispersing the silver nanoparticle composite in the same or different one or more (c) organic solvents used in A), to provide a non-aqueous silver-containing dispersion comprising the silver nanoparticle composite.

US Pat. No. 10,246,558

COMPOSITIONS COMPRISING SILOXANE COMPOUNDS AND METHODS FOR USING THE SAME

1. A composition comprising:(a) a first siloxane compound of Formula (X)
wherein the variable n is selected from the group consisting of integers equal to or greater than 1; R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, and R19 are independently selected from the group consisting of alkyl groups, substituted alkyl groups, cycloalkyl groups, substituted cycloalkyl groups, alkenyl groups, substituted alkenyl groups, cycloalkenyl groups, substituted cycloalkenyl groups, heterocyclyl groups, substituted heterocyclyl groups, aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, and siloxy groups; at least one of R7 and R8 is different from each of R2, R3, R4, R5, and R6, and at least one of R16 and R17 is different from each of R13, R14, R15, R18, and R19; and(b) a first salt, the first salt comprising a conjugate base of a volatile organic acid, wherein the first salt is selected from the group consisting of tetramethylammonium formate, tetramethylammonium acetate, tetramethylammonium malonate, tetramethylammonium succinate, tetrabutylammonium formate, tetrabutylammonium acetate, tetrabutylammonium malonate, tetrabutylammonium succinate, tetrabutylphosphonium formate, tetrabutylphosphonium acetate, tetrabutylphosphonium malonate, tetrabutylphosphonium succinate, tetrabutylphosphonium bicarbonate, and mixtures thereof.

US Pat. No. 10,246,557

PH SENSITIVE QUANTUM DOTS FOR USE AS CURE INDICATORS

THE BOEING COMPANY, Chic...

1. A curable sealant composition comprising:(i) a curable composition comprising at least one thiol-terminated prepolymer, wherein the thiol-terminated prepolymer is selected from the group consisting of a polythioether and a polysulfide and
a curing agent, wherein the curing agent comprises an “ene” crosslinker; and
(ii) a pH indicator molecule comprising a quantum dot functionalized with a pH-responsive ligand comprising a pH-responsive moiety,
wherein energy transfer between the pH-responsive moiety and the quantum dot occurs when the pH-responsive moiety is protonated or deprotonated.

US Pat. No. 10,246,556

POLYIMIDE POLYMER AND POLYIMIDE FILM

TAIFLEX Scientific Co., L...

1. A polyimide polymer, comprising a repeating unit represented by formula 1:
wherein Ar is a tetravalent organic group derived from a tetracarboxylic dianhydride containing an aliphatic structure; and
A comprises
and at least one divalent organic group derived from an aromatic group-containing diamine other than

US Pat. No. 10,246,555

POLYIMIDE COPOLYMER OLIGOMER, POLYIMIDE COPOLYMER, AND METHOD FOR PRODUCING EACH OF SAME

Somar Corporation, Tokyo...

1. A polyimide copolymer obtained by copolymerizing (A) 3,3?,4,4?-biphenyltetracarboxylic dianhydride with (B) at least one diamine and/or diisocyanate represented by the following Formulae (1) or (2):
(wherein, X represents an amino group or an isocyanate group; R1 to R4 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; and at least one of said R1 to R4 is not a hydrogen atom), and in which (C) a second acid dianhydride and/or (D) a second diamine and/or diisocyanate is/are further copolymerized, wherein (D) the second diamine and/or diisocyanate is different from the diamine and/or diisocyanate (B) and is selected from the following formulae (5) to (14)

wherein, X represents an amino group or an isocyanate group; R11 to R14 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a carboxy group or a trifluoromethyl group; R21 to R24 each independently represent an alkyl group having 1 to 4 carbon atoms or a phenyl group; Y represents in formula (8) and Y and Z each represent in formulae (9),

wherein R31 and R32 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a carboxy group or a trifluoromethyl group); and Y represents, in formula (7)

wherein R31 and R32 each independently represent an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a hydroxyl group, a carboxy group or a trifluoromethyl group), and
wherein (C), the second acid dianhydride is pyromellitic dianhydride, 4,4?-oxydiphthalic dianhydride, 2,2?-bis[(dicarboxyphenoxy)phenyl]propane dianhydride or ethylene glycol-bis-trimellitic anhydride ester,
wherein the polyimide copolymer is not obtained by copolymerizing with 3,3?,4,4?-benzophenonetetracarboxylic dianhydride, and
wherein two of said R1 to R4 are ethyl groups and the other two are a methyl group and a hydrogen atom.

US Pat. No. 10,246,554

AEROGEL INSULATION PANELS AND MANUFACTURING THEREOF

Aspen Aerogels, Inc., No...

1. A laminate panel, comprising:a first layer including a fiber-reinforced aerogel composite, wherein the fiber-reinforced aerogel composite has
a density between 0.01 g/cc and 0.30 g/cc;
a thermal conductivity at ambient temperature and ambient pressure of between 15 mW/m-K and 30 mW/m-K, and
a flexural strength between 105 psi and about 275 psi; and
a second layer including a facesheet disposed on a major face of the first layer.

US Pat. No. 10,246,553

ORGANIC FLUORINE COMPOUND AND LUBRICANT

SHOWA DENKO K.K., Tokyo ...

1. An organic fluorine compound comprising one organic fluorine compound selected from the group of compounds represented by the following chemical formulas (1-5) to (1-11),
where each of “p” and “q” is a degree of polymerization.

US Pat. No. 10,246,552

PHOTOSTABILIZING POLYMER

SurfTech Corporation, La...

1. A photostabilizing polymer prepared by the esterification reaction of:1. a photo-absorbing group having the following structure:

wherein;
x is an integer ranging from 1 to 10;
2. a diacid independently selected from the group consisting of:
a. a fatty acid having to the following structure:
HOOC—R3—COOH
wherein;
R3 is alkyl containing 2 to 12 carbon atoms;
b. dimer Acid;
c. hydrogenated dimer acid;
d. mixtures thereof;
and
3. a diol having the following structure:
HO—R4—OH
wherein;
R4 is alkyl ranging from 3 to 12 carbons; and
4. a monofunctional alcohol independently selected from the group consisting of:
a. a branched alkyl having the structure:

wherein;
a is an integer ranging from 3-15;
b is an integer ranging from 5-17;
and mixtures thereof;
b. a fatty alcohol having the structure:
R2—OH
wherein;
R2 is alkyl having 8 to 26 carbon atoms,
and mixtures thereof.

US Pat. No. 10,246,551

FLAME-RETARDANT POLYMERS DERIVED FROM POLYOLS AND POLYACIDS

International Business Ma...

1. A flame-retardant polymer formed by a process that includes:reacting a triol with an organophosphorus mono-chloride to produce an intermediate compound; and
reacting the intermediate compound with a polycarboxylic acid to form the flame-retardant polymer, wherein phosphorus is chemically bound to a polymer chain of the flame-retardant polymer.

US Pat. No. 10,246,550

RESIN COMPOSITION

NAMICS CORPORATION, Niig...

1. A resin composition comprising:(A) a compound represented by formula (1) below;

(B) an oligomer having as its basic skeleton a structure represented by formula (2) below;

(C) an epoxy resin; and
(D) a curing accelerator, wherein
the mass ratio ((B)/(A)×100) between the compound of the (A) component and the oligomer of the (B) component is 5 to 25%,
the total content of the compound of the (A) component and the oligomer of the (B) component is 0.5 equivalents to 2.5 equivalents in terms of the ratio of the thiol equivalent of the compound of the (A) component and the oligomer of the (B) component with respect to the epoxy equivalent of the epoxy resin of the (C) component, and
a chloride ion concentration in the resin composition is 230 ppm or less.

US Pat. No. 10,246,548

COMPOSITIONS COMPRISING A POLYMERIC NETWORK

UNIVERSITEIT GENT, (BE)

1. A composition comprising a polymeric network having at least one unit of formula (I), (II), and/or (III);
wherein said composition is obtained by contacting at least one compound A comprising at least two functions selected from the group of function of formula —X—C(?O)—CHR1—C(?O)—R2, —C(?O)—C?C—R2; or —C(?O)—CR1?CR2—NR4R5; wherein at least 25% by weight of compounds A have a functionality ?5, with % by weight relative to the total weight of compounds A;
with at least one compound B comprising at least one —NH2, or —NH3+ groups, or at least one functional group that generates —NH2 or —NH3+ in situ;
wherein the ratio R=(sum(functionality of compound A×number of moles of compound A))/(sum(functionality of compound B×number of moles of all compound B)) is <1;

wherein faNa denotes the number of moles of —X—C(?O)—CHR1—C(?O)—R2, —C(?O)—C?C—R2; or —C(?O)—CR1?CR2—NR4R5 functions of the at least one compound A, and fbNb denotes the number of moles of —NH2, and/or —NH3+ groups or the number of moles of functional groups which could generate —NH2 or NH3+ in situ, of the at least one compound B;
R1 is hydrogen or is selected from the group consisting of C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl; wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-8cycloalkylC1-20alkyl; C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; and heteroarylC1-20alkyl, optionally comprises one or more heteroatoms in the alkyl, alkenyl, alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be unsubstituted or substituted with one or more Z1; each Z1 is independently selected from the group consisting of halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9; and
R4 is selected from the group consisting of C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-8cycloalkylC1-20alkyl; C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; and heteroarylC1-20alkyl, optionally comprises one or more heteroatoms in the alkyl, alkenyl, alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be unsubstituted or substituted with one or more Z4; each Z4 is independently selected from the group consisting of NR11R12; halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
or wherein the ratio R=(sum(functionality of compound A×number of moles of compound A ))/(sum(functionality of compound A×number of moles of compound A)+sum(functionality of compound B×number of moles of all compound B)) is <1;

when R1 and R4 together with the atom to which they are attached form a 5-, 6-, or 7-membered heterocyclyl or heteroaryl; wherein each of said heterocyclyl; or heteroaryl; can be unsubstituted or substituted with one or more Z5; each Z5 is independently selected from the group consisting of C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; halogen; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; C(O)NR11R12; and —C(O)R9;
wherein faNa denotes the number of moles of —X—C(?O)—CHR1—C(?O)—R2, —C(?O)—C?C—R2;
or —C(?O)—CR1?CR2—NR4R5 functions of the at least one compound A, and fbNb denotes the number of moles of —NH2, and/or —NH3+ groups or the number of moles of functional groups which could generate —NH2 or NH3+ in situ of the at least one compound B;
and wherein
X is selected from O, NR13, or CR14R15; or
X and R3 together form a group R6, wherein R6 is selected from the group consisting of C6-12aryl, heteroaryl or heterocyclyl; wherein said C6-12aryl, heteroaryl or heterocyclyl can be unsubstituted or substituted with one or more Z31; and Z31 is independently selected from the group consisting of —C(?O)—C?C—R2; —X—C(?O)—CHR1—C(?O)—R2, or —C(?O)—CR1?CR2—NR4R5; halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9; or
R3 is selected from the group consisting of C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; C1-20alkylC3-8cycloalkylC1-20alkyl; C3-8cycloalkylC1-20alkylC3-8cyclo alkyl; C1-20alkylC6-12arylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; C1-20alkylheterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-8cycloalkylC1-20alkyl; C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; C1-20alkylC3-8cycloalkylC1-20alkyl; C3-8cycloalkylC1-20alkylC3-8cycloalkyl; C1-20alkylC6-12arylC1-20alkyl; C1-20alkylheterocyclylC1-20alkyl; and heteroarylC1-20alkyl, optionally comprises one or more heteroatoms in the alkyl, alkenyl, alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; C1-20alkylC3-8cyclo alkylC1-20alkyl; C3-8cycloalkylC1-20alkylC3-8cycloalkyl; C1-20alkylC6-12arylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; C1-20alkylheterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; C1-20alkylC3-8cycloalkylC1-20alkyl; C3-8cycloalkylC1-20alkylC3-8cycloalkyl; C1-20alkylC6-12arylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; C1-20alkylheterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl; can be unsubstituted or substituted with one or more Z3; each Z3 is independently selected from the group consisting of —X—C(?O)—CHR1—C(?O)—R2, —C(?O)—C?C—R2; or —C(?O)—CR1?CR2—NR4R5; halogen; C1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
L1 is selected from the group consisting of C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene;
wherein said C1-20alkylene, C2-20alkenylene, C2-20alkynylene, C3-8cycloalkyleneC1-20alkylene; C6-12arylC1-20alkylene, heterocyclyleneC1-20alkylene; and heteroaryleneC1-20alkylene, optionally comprises one or more heteroatoms in the alkylene, alkenylene, alkynylene moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene; can be unsubstituted or substituted with one or more Z21; each Z21 is independently selected from the group consisting of halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
R2 is selected from the group consisting of C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-8cycloalkylC1-20alkyl; C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; and heteroarylC1-20alkyl, optionally comprises one or more heteroatoms in the alkyl, alkenyl, alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be unsubstituted or substituted with one or more Z2; each Z2 is independently selected from the group consisting of halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
L2 is selected from the group consisting of C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene;
wherein said C1-20alkylene, C2-20alkenylene, C2-20alkynylene, C3-8cycloalkyleneC1-20alkylene; C6-12arylC1-20alkylene, heterocyclyleneC1-20alkylene; and heteroaryleneC1-20alkylene, optionally comprises one or more heteroatoms in the alkylene, alkenylene, alkynylene moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkylene, C2-20alkenylene; C2-20alkynylene; C6-12arylene, C3-8cycloalkylene; C6-12aryleneC1-20alkylene; C3-8cycloalkyleneC1-20alkylene; heteroC1-20alkylene; heterocyclylene; heterocyclyleneC1-20alkylene; heteroarylene; and heteroaryleneC1-20alkylene; can be unsubstituted or substituted with one or more Z22; each Z22 is independently selected from the group consisting of halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
or wherein R2 and R4 together with the atom to which they are attached form a 5-, 6-, or 7-membered heterocyclyl or heteroaryl; wherein each of said heterocyclyl; or heteroaryl; can be unsubstituted or substituted with one or more Z6; each Z6 is independently selected from the group consisting of C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; halogen; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
R5 is hydrogen or is selected from the group consisting of C1-20alkyl, C2-20alkenyl; C2-20alkynyl; C6-12aryl, C3-8cycloalkyl; C6-12arylC1-20alkyl; C3-8cycloalkylC1-20alkyl; heteroC1-20alkyl; heterocyclyl; heterocyclylC1-20alkyl; heteroaryl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C3-8cycloalkylC1-20alkyl; C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; and heteroarylC1-20alkyl, optionally comprises one or more heteroatoms in the alkyl, alkenyl, alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be unsubstituted or substituted with one or more Z7; each Z7 is independently selected from the group consisting of NR11R12; halogen; C1-20alkyl; C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; C3-8cycloalkylC1-20alkyl; heterocyclylC1-20alkyl; heteroarylC1-20alkyl; haloC1-20alkyl; haloC1-20alkyloxy; —OR10; —SR10; —S(O)R9; —S(O)2R9; —SO2NR11R12; nitro; —NR10C(O)R9; —NR10S(O)2R9; —NR10C(O)NR11R12; cyano; —CO2R10; —C(O)NR11R12; and —C(O)R9;
each R9 is independently selected from hydroxyl; C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
each R10 is independently selected from the group consisting of hydrogen, C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
and wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
each R11 and R12 is independently selected from the group consisting of hydrogen; C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
and wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
or wherein R11 and R12 together with the atom to which they are attached form a 5-, 6-, or 7-membered heterocyclyl;
R13 is hydrogen or is selected from the group consisting of C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
and wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
R14 is hydrogen or is selected from the group consisting of C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
and wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2;
R15 is hydrogen or is selected from the group consisting of C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl;
wherein said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12arylC1-20alkyl, heterocyclylC1-20alkyl; heteroarylC1-20alkyl, optionally comprise one or more heteroatoms in the alkyl, alkenyl or alkynyl moiety, said heteroatoms being each independently selected from O, S and N;
and wherein at least one carbon atom or heteroatom of said C1-20alkyl, C2-20alkenyl, C2-20alkynyl, C6-12aryl, C3-8cycloalkyl, C6-12arylC1-20alkyl, heteroC1-20alkyl; heterocyclyl; heteroaryl; heterocyclylC1-20alkyl; and heteroarylC1-20alkyl; can be oxidized to form at least one C?O, C?S, N?O, N?S, S?O or S(O)2.

US Pat. No. 10,246,547

PROCESSES FOR OBTAINING A POLYOL FROM PALM OIL, POLYOLS OBTAINED FROM THE PROCESSES, PRODUCTS DERIVED FROM SUCH POLYOL AND THEIR METHOD OF PREPARATION

INDUSTRIAL AGRARIA LA PAL...

1. A method for the production of polyol from palm oil, characterized by comprising the following steps:a. mixing a source of palm oil with formic acid in the presence of heat;
b. adding hydrogen peroxide to the mixture of step a) and shake to obtain a reaction product of step b);
c. washing the reaction product of step b) with water at a temperature between 55° C. and 65° C. to obtain a product of step c);
d. washing the product obtained in the step c) with 5% sodium bicarbonate to obtain a product of reaction of step d);
e. washing the product of reaction of step d) with water at a temperature between 55° C. and 65° C. to obtain a product of step e);
f. washing the product obtained in step e) with 5% sodium chloride to obtain an aqueous phase and an organic phase;
g. discarding the aqueous phase obtained in step f) to obtain an epoxidized oil;
h. mixing the epoxidized oil obtained in step g) with glycerol and a catalyst, in the presence of heat and agitation, wherein the catalyst is sodium hydroxide;
i. neutralizing the sodium hydroxide catalyst with drops of phosphoric acid to avoid the formation of soap; and
j. obtaining the polyol resulting in a hydroxyl number between 400 and 440 mg KOH/g sample,
wherein step h) has a reaction temperature that varies between 170° C. and 190° C. and has a time of reaction that varies between 40 and 50 minutes.

US Pat. No. 10,246,546

POLYMER CONTAINING SILANE GROUPS

SIKA TECHNOLOGY AG, Baar...

1. A polymer having end groups of the formula (I)
where
either R? is a radical of the formula (II) and R? is a hydrogen radical
or R? is a hydrogen radical and R? is a radical of the formula (II);

R1 is a hydrocarbyl radical which has 1 to 18 carbon atoms and optionally has heteroatoms in the form of ether oxygen, ester oxygen, thioether sulfur or tertiary amine nitrogen;
R2 is a linear or branched alkylene or cycloalkylene radical having 1 to 20 carbon atoms, optionally having aromatic components, and optionally having one or more heteroatoms;
R3 is an alkyl radical having 1 to 8 carbon atoms;
R4 is an aliphatic or cycloaliphatic or arylaliphatic hydrocarbyl radical which has 1 to 12 carbon atoms and optionally has one or two ether oxygens;
X is O or S; and
n is 0 or 1 or 2.

US Pat. No. 10,246,545

BISMUTH-CONTAINING CATALYST FOR POLYURETHANE COMPOSITIONS

SIKA TECHNOLOGY AG, Baar...

1. A bismuth-containing catalyst, obtained by reacting at least one bismuth(III) salt or bismuth(III) complex with at least one 1,3-ketoamide with the formula (I),
where R1 and R2 independently of one another are a hydrogen group, a monovalent saturated or unsaturated hydrocarbon group having 1 to 10 carbon atoms, or together are a bivalent alkylene group having 3 to 6 carbon atoms, and
R3 and R4 independently of one another are a hydrogen group, a monovalent saturated hydrocarbon group, which optionally includes heteroatoms, having 1 to 12 carbon atoms, or together are a bivalent alkylene group, which optionally includes heteroatoms, having 3 to 6 carbon atoms.

US Pat. No. 10,246,541

OPHTHALMIC LENS AND METHOD FOR MAKING THE SAME

1. A method for making an ophthalmic lens comprising:mixing poly[bis(methacrylate)phosphazene], hydrophilic monomers, and a photoinitiator to form a mixture, wherein the poly[bis(methacrylate)phosphazene] has a mass percentage of 3.2% to 3.5% of a total mass of the mixture, the hydrophilic monomers have a mass percentage of 96% of the total mass of the mixture, the photoinitiator has a mass percentage of 0.5% to 0.8% of the total mass of the mixture;
feeding the mixture into a mold, and heating or exposing the mixture to ultraviolet radiation, thereby causing the poly[bis(methacrylate)phosphazene] to function as a cross-linking agent which undergoes a polymerization reaction with the hydrophilic monomers and the photoinitiator to form a polyphosphazenes hydrogel; and
separating the polyphosphazenes hydrogel from the mold, thereby the polyphosphazenes hydrogel forming the ophthalmic lens.

US Pat. No. 10,246,540

RAPID AZEOTROPIC PHOTO-COPOLYMERIZATION OF STYRENE AND METHACRYLATE DERIVATIVES AND USES THEREOF

ADA FOUNDATION, Chicago,...

1. A composition of matter, comprising:two or more vinyl-containing monomers consisting of at least two different types of vinyl functional monomers, wherein the two or more vinyl-containing monomers are triethyleneglycol divinylbenzyl ether (TEG-DVBE) and methacrylate derivatives; and
one or more initiators;
wherein the two or more vinyl-containing monomers undergo vinyl conversion to form a composition-controlled cross-linked resin.

US Pat. No. 10,246,536

FUNCTIONALIZED HIGHLY SYNDIOTACTIC POLYSTYRENE AND PREPARATION METHOD THEREOF

Changchun Institute of Ap...

1. A preparation method of a functionalized syndiotactic polystyrene, comprising:performing a polymerization of a functionalized styrene or a polymerization of styrene and a functionalized styrene in the presence of a catalyst to obtain the functionalized syndiotactic polystyrene, wherein the functionalized syndiotactic polystyrene comprises a repeating unit having a structure represented by formula (I), or comprises a repeating unit having a structure represented by formula (I) and a repeating unit having a structure represented formula (II):

wherein the functionalized styrene has a structure represented by formula (III):

wherein in formula (I) and formula (III),
R is independently selected from a C1-20 alkoxy group, a C6-20 aryloxy group, a C1-20 alkylthio group, a C6-20 arylthio group, or a C6-20 aryl group;
m is the number of substituent R and is independently selected from an integer from 1 to 5; and
the catalyst comprises a rare earth complex, an organoboron compound, and an organoaluminum compound.

US Pat. No. 10,246,535

METHODS OF CATALYST ACTIVATION

FINA TECHNOLOGY, INC., H...

1. A method comprising:preparing a multi-component catalyst system comprising a catalyst and a cocatalyst; and
adjusting a level of at least one component of the multi-component catalyst system to maintain a user-desired level of catalyst activity throughout a polymerization process;
wherein the at least one component comprises a catalyst activator, and wherein the catalyst activator comprises the catalyst.

US Pat. No. 10,246,534

APPARATUS FOR PREPARING POLYBUTADIENE

LG Chem, Ltd., (KR)

1. An apparatus for preparing polybutadiene, the apparatus comprising:two first polymerization reactors arranged in parallel to reduce a plugging phenomenon, wherein butadiene monomer, a polymerization catalyst, and a solvent are supplied and the butadiene monomer is polymerized;
at least one second polymerization reactor arranged in series with the parallel-arranged two first polymerization reactors, wherein a first polymerization solution containing a butadiene polymer discharged from the parallel-arranged two first polymerization reactors is supplied and a butadiene polymerization reaction is performed; and
one or more condensers which condense gases discharged from the parallel-arranged two first polymerization reactors and the second polymerization reactor and supply a condensate to the parallel-arranged two first polymerization reactors and/or the second polymerization reactor,
wherein the gases discharged from the parallel-arranged two first polymerization reactors and the second polymerization reactor are condensed in different condensers connected to each reactor.

US Pat. No. 10,246,532

CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS

Basell Poliolefine Italia...

1. A solid catalyst component for the polymerization of olefins comprising:(i) Mg,
(ii) Ti,
(iii) halogen, and
(iv) an electron donor of formula (I)

wherein
R and R1 are selected from the group consisting of C1-C20 hydrocarbon groups, and C6-C14 aryl or alkylaryl groups, wherein R and R1 optionally contain a heteroatom selected from the group consisting of halogen, P, S, N, and O; and
R2 to R11 groups, equal to or different from each other, are selected from the group consisting of hydrogen, halogen and C1-C15 hydrocarbon groups which are optionally fused together to form one or more cycles with the proviso that R6 and R11 cannot join together to form a phenyl ring.

US Pat. No. 10,246,531

PRODUCTION METHOD FOR OLEFIN-BASED POLYMER, OLEFIN POLYMERIZATION CATALYST, AND OLEFIN-BASED POLYMER

IDEMITSU KOSAN CO., LTD.,...

1. A production method for polypropylene, the production method comprising polymerizing propylene in the presence of the following components (A) to (D):(A) a transition metal compound;
(B) a boron compound capable of forming an ion pair with the component (A);
(C) an organoaluminum compound; and
(D) water,
wherein:
a molar ratio [(D)/(A)] of a molar quantity of the component (D) to a molar quantity of a transition metal in the component (A) is 5 or more and 10,000 or less;
a molar ratio [(D)/(C)] of the molar quantity of the component (D) to a molar quantity of an aluminum atom in the component C) is more than 0 and 0.9 or less;
the transition metal compound (A) is a double crosslinked metallocene complex represented by a formula (I):

M represents a metal element of Groups 3 to 10 of the periodic table or the lanthanoid series;
E1 and E2 each represent a ligand selected from a substituted cyclopentadienyl group, an indenyl group, a substituted indenyl group, a heterocyclopentadienyl group, a substituted heterocyclopentadienyl group, an amide group, a phosphide group, a hydrocarbon group, and a silicon-containing group, form a crosslinked structure via A1 and A2, and may be identical to or different from each other;
X represents a ?-bonding ligand, and when a plurality of X's are present, the plurality of X's may be identical to or different from each other, and X may be crosslinked with any other X, E1, E2, or Y;
Y represents a Lewis base, and when a plurality of Y's are present, the plurality of Y's may be identical to or different from each other, and Y may be crosslinked with any other Y, E1, E2, or X;
A1 and A2 each represent a divalent crosslinking group for bonding two ligands, and each represent a hydrocarbon group having 1 to 20 carbon atoms, a halogen-containing hydrocarbon group having 1 to 20 carbon atoms, a silicon-containing group, a germanium-containing group, a tin-containing group, —O—, —CO—, —S—, —SO2—, —Se—, —NR1—, —PR1—, —P(O)R1—, —BR1—, or —AlR1—, wherein R1 represents a hydrogen atom, a halogen atom, a hydrocarbon group having 1 to 20 carbon atoms, or a halogen-containing hydrocarbon group having 1 to 20 carbon atoms, and may be identical to or different from each other;
q represents an integer of from 1 to 5 representing [(valence of M)-2]; and
r represents an integer of from 0 to 3.

US Pat. No. 10,246,529

PROCATALYST FOR POLYMERIZATION OF OLEFINS

SABIC GLOBAL TECHNOLOGIES...

1. A process for preparing a procatalyst for preparing a catalyst composition for olefin polymerization, said process comprising the steps of:ia) contacting a Grignard reagent comprising R4zMgX42-z and an alkyl magnesium compound MgR4?2 with an alkoxy- or aryloxy-containing silane compound to give a first intermediate reaction product, being a solid Mg(OR1)xX12-x, wherein:
R4 and R4? are the same as R1 being a linear, branched or cyclic hydrocarbyl group independently selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, alkoxycarbonyl, alkylaryl groups, and one or more combinations thereof; wherein said hydrocarbyl group is substituted or unsubstituted, and optionally contains one or more heteroatoms;
X4 and X1 are each independently selected from the group consisting of fluoride (F—), chloride (Cl—), bromide (Br—) or iodide (I—);
x is in a range of larger than 0 and smaller than 2, being 0 z is in a range of larger than 0 and smaller than 2, being 0 ib) precipitating the solid Mg(OR1)xX12-x obtained in step ia) by contacting it with an tetrahalogensilane, SiX4?4, wherein X4? is each independently selected from the group consisting of fluoride (F—), chloride (Cl—), bromide (Br—) or iodide (I—), to obtain a solid support;
ii) optionally contacting the solid support obtained in step ib) with at least one activating compound selected from the group consisting of activating electron donors and metal alkoxide compounds of formula M1(OR2)v-w(OR3)w and M2(OR2)v-w(R3)w, to obtain a second intermediate reaction product; wherein:
M1 is a metal selected from the group consisting of Ti, Zr, Hf, Al or Si;
M2 is a metal being Si;
v is the valency of M1 or M2;
w is smaller than v;
R2 and R3 are each a linear, branched or cyclic hydrocarbyl group independently selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, alkoxycarbonyl, alkylaryl groups, and one or more combinations thereof; wherein said hydrocarbyl group is substituted or unsubstituted, and optionally contains one or more heteroatoms;
iii) contacting the first or second intermediate reaction product obtained in step ib) or ii) respectively, with a halogen-containing titanium compound and either an activator or an internal electron donor to obtain a third intermediate reaction product;
iv) optionally modifying the third intermediate reaction product obtained in step iii) with a modifier having the formula MX3, wherein M is a metal selected from the Group 13 metals and transition metals of the IUPAC periodic table of elements, and wherein X is a halide, to yield a modified intermediate reaction product; and
v) contacting said third intermediate reaction product obtained in step iii) or said modified intermediate reaction product obtained in step iv) with a halogen-containing titanium compound and in the case that in step iii) an activator was used an internal donor to obtain the procatalyst.

US Pat. No. 10,246,526

VULCANIZED RUBBER COMPOSITION AND PRODUCTION METHOD THEREOF

MITSUBISHI GAS CHEMICAL C...

1. A method for producing a vulcanized rubber composition, comprising:a first kneading step of obtaining a kneaded mixture comprising: a rubber component comprising at least one selected from the group consisting of natural rubbers and synthetic rubbers, a filler comprising an inorganic filler, and a sulfur-containing silane coupling agent;
a second kneading step of adding sulfur and a vulcanization accelerator to the kneaded mixture, followed by kneading, to thereby obtain an unvulcanized rubber composition; and
a vulcanization step of vulcanizing the unvulcanized rubber composition to thereby obtain a vulcanized rubber composition having a glass transition temperature of ?30° C. or more and 0° C. or less, wherein
at least one selected from the group consisting of compounds represented by formulae (1), (2), and (3) below is added, followed by kneading, in the first kneading step:
wherein X is an acid that forms a salt together with a guanidine moiety;wherein X is an acid that forms a salt together with a guanidine moiety, R1 and R2 are each independently any one selected from the group consisting of a hydrogen atom and an alkyl group, a cycloalkyl group, an aryl group, an alkyl aryl group, and an alkenyl group which have 1 to 18 carbon atoms, these groups each optionally having one or more substituents containing at least one selected from the group consisting of a sulfur atom, a nitrogen atom, and an oxygen atom; andwherein X is an acid that forms a salt together with a guanidine moiety.

US Pat. No. 10,246,522

CELLULOSE PARTICULATE MATERIAL

CELLUCOMP LIMITED, Burnt...

1. A process for preparing cellulose-containing particulate material which has a viscosity at a concentration of 1 dry wt % in water of less than 2500 cps, the process comprising the steps of:contacting herbaceous plant material with a peroxide reagent and water;
(ii) heating the mixture from (i) to a temperature of from 30 to 110° C. and maintaining said mixture at a temperature of from 30 to 110° C. until the pH of the mixture has dropped by at least 2 pH units;
(iii) isolating the cellulose-containing particles; and
(iv) reducing the water content of the product of step (iii).

US Pat. No. 10,246,499

COMPOSITION AND METHOD FOR DELIVERY OF BMP-2 AMPLIFIER/CO-ACTIVATOR FOR ENHANCEMENT OF OSTEOGENESIS

Ferring B.V., (NL) Brook...

1. A composition comprising:a synthetic growth factor analogue having the structure
wherein Hx is 6-aminohexanoic acid, andan osteoconductive material comprising 60-20 wt % hydroxyapatite and 80-40 wt % tricalcium phosphate;
wherein the synthetic growth factor analogue is bound to and can be released from the osteoconductive material.

US Pat. No. 10,246,491

PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA

AILERON THERAPEUTICS, INC...

1. A peptidomimetic macrocycle having the formulaor a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,487

AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS

viDA Therapeutics Inc., ...

1. A compound having Formula (I):
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein:
R1 is a heteroaryl group selected from
(a) 1,2,3-triazolyl, and
(b) 1,2,3,4-tetrazolyl;
n is 1 or 2;
R2a and R2b are independently selected from hydrogen and C1-C6 alkyl;
R2c at each occurrence is independently selected from
(a) hydrogen,
(b) halogen,
(c) C1-C6 alkyl,
(d) —XR11, wherein X is selected from O, C(?O), S, S?O, or S(?O)2,
(e) —C(?O)N(R12)(R13),
(f) —N(R11)(R12)(R13),
(g) —N—C(?O)—R11, and
(h) —N—C(?O)O—R11,
wherein R11, R12, and R13 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C6-C10 aryl, aralkyl, and C3-C10 heteroaryl;
m is 1, 2, or 3;
R3 is selected from
(a) hydrogen,
(b) C1-C4 alkyl optionally substituted with a carboxylic acid, carboxylate, or carboxylate C1-C8 ester group, an amide optionally substituted with an alkylheteroaryl group, or a heteroaryl group;
Z is an acyl group selected from the group

 wherein
Y is hydrogen, heterocycle, —NH2, or C1-C4 alkyl;
R4 is selected from
(i) C1-C12 alkyl,
(ii) C1-C6 heteroalkyl optionally substituted with C1-C6 alkyl,
(iii) C3-C6 cycloalkyl,
(iv) C6-C10 aryl,
(v) heterocyclyl,
(vi) C3-C10 heteroaryl,
(vii) aralkyl, and
(viii) heteroalkylaryl;
R5 is heteroaryl or C(?O)—R10,
wherein R10 is selected from
(i) C1-C12 alkyl optionally substituted with C6-C10 aryl, C1-C10 heteroaryl, amino, or carboxylic acid,
(ii) C1-C10 heteroalkyl optionally substituted with C1-C6 alkyl or carboxylic acid,
(iii) C3-C6 cycloalkyl optionally substituted with C1-C6 alkyl, optionally substituted C6-C10 aryl, optionally substituted C3-C10 heteroaryl, amino, or carboxylic acid,
(iv) C6-C10 aryl optionally substituted with C1-C6 alkyl, optionally substituted C6-C10 aryl, optionally substituted C3-C10 heteroaryl, amino, or carboxylic acid,
(v) heterocyclyl,
(vi) C3-C10 heteroaryl,
(vii) aralkyl, and
(viii) heteroalkylaryl.

US Pat. No. 10,246,486

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Gilead Sciences, Inc., F...

1. A compound of Formula I:or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester or prodrug thereof, wherein:A1 is (C2-C5)alkylene, (C2-C5)alkenylene, (C2-C5)alkynylene, —O—(C2-C4)alkylene, —O—(C2-C4)alkenylene, arylene, aryl(C1-C2)alkylene, heterocycloalkylene, pyrazolylene, pyridylene, pyrimidinylene or heterocycloalkyl(C1-C2)alkylene, wherein a sp3 carbon atom of A1 is optionally substituted with one or more (C1-C4)alkyl;
A2 is arylene or heteroarylene, wherein A2 is optionally substituted with halo;
X1 is —O—, —NH— or —N((C1-C4)alkyl)-;
R1a and R1b are independently H, (C1-C4)alkyl, (C2-C4)alkenyl or (C2-C4)alkynyl;
R2 is H, (C1-C4)alkyl, (C2-C4)alkenyl or (C2-C4)alkynyl;
R3a and R3b are independently H or (C1-C8)alkyl;
R4a and R4b are independently H, —OH, (C1-C4)alkoxy, halo(C1-C4)alkoxy or (C1-C8)alkyl;
R5 is H, (C1-C4)alkyl, (C2-C4)alkenyl or (C2-C4)alkynyl, or
R5 forms a cyclic moiety along with —N((C1-C4)alkyl)- of X1 or arylene of A2; and
R6 is H or (C1-C4)alkyl.

US Pat. No. 10,246,483

BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF

ENANTA PHARMACEUTICALS, I...

1. A compound represented by Formula I:
or a pharmaceutically acceptable salt, solvate or ester thereof,
wherein:
R1 is selected from the group consisting of:
1) Hydrogen;
2) Substituted or unsubstituted —C1-C8 alkyl;
3) Substituted or unsubstituted —C2-C8 alkenyl;
4) Substituted or unsubstituted —C2-C8 alkynyl;
5) Substituted or unsubstituted —C3-C8 cycloalkyl;
6) Substituted or unsubstituted aryl;
7) Substituted or unsubstituted arylalkyl;
8) Substituted or unsubstituted heterocycloalkyl;
9) Substituted or unsubstituted heteroaryl; and
10) Substituted or unsubstituted heteroarylalkyl;
Ra, Rb, and Rc are each independently selected from R1; or Ra and Rb, or Ra and Rc, or Rb and Rc are taken together with the two nitrogen atoms to which they are attached and the intervening carbon atom to form a heterocyclic, heteroaryl or heterocycloalkenyl ring;
R2 is selected from the group consisting of:
1) Hydrogen;
2) Halogen;
3) Substituted or unsubstituted —C1-C8 alkyl;
4) Substituted or unsubstituted —C2-C8 alkenyl;
5) Substituted or unsubstituted —C2-C8 alkynyl;
6) Substituted or unsubstituted arylalkyl; and
7) Substituted or unsubstituted aryl;
m is 0, 1, 2 or 3;
R3 is hydrogen, hydroxyl, —OSO3H, —OSO3?, —OAc, —PPO3H2 or —OPO32?;
R4 is hydrogen, halogen, CN, N3, hydroxyl, —OSO3H, —OSO3?, —OAc, —OPO3H2, —OPO32?, —SR2 or —NHR2, or R3 and R4 are taken together with the carbons to which they are attached to form —CH?CH—, a cycloalkyl ring or a heterocycloalkyl ring;
R5 and R6 are each independently hydrogen or hydroxyl protecting group; and
R7 is ethyl.

US Pat. No. 10,246,482

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Sage Therapeutics, Inc., ...

1. A compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein:R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, or heterocyclyl;
each of R2a and R2b is independently hydrogen, C1-C6 alkyl, halo, cyano, —ORA, or —NRBRC, or
R2a and R2b together with the carbon atom to which they are attached form a ring;
R3 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, or —C(O)NRBRC;
R4 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, or —ORA;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when the between —CR6 and —CR5aR5b is a double bond, then one of R5a or R5b is absent; and
when one of the is a double bond, R6 is absent;
each of R5a and R5b is independently absent, hydrogen, C1-C6 alkyl, or halo;
R6 is absent or hydrogen;
Z is —CR7aR7b—, wherein each of R7a and R7b is independently hydrogen or C1-C6 alkyl, or R7a and R7b, together with the carbon atom to which they are attached, form a ring;
RA is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;
each of RB and RC is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a ring.

US Pat. No. 10,246,481

BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE

CITY OF HOPE, Duarte, CA...

1. A method of synthesizing a compound having the following structure,
the method comprising,
(i) contacting a compound of formula (II)

 wherein R11 is R11A or R11B, with an oxidizing reagent to provide a compound of formula (III-A) or (III-B),

 or

(ii) when the product of step (i) has a structure according to formula (III-A), contacting the compound of formula (III-A) with an alcohol protecting agent to provide a compound of formula (III-B);
(iii) contacting a compound of formula (III-B) with an alkylating agent in the presence of a sterically hindered base to provide a compound of formula (IV),

(iv) optionally contacting the compound of formula (IV) with an alcohol deprotecting agent to provide a compound of formula (IV-A),

(v) treatment of the compound of formula (IV) or (IV-A) with a reducing agent to provide a compound of formula (I) or (I-A),

 or

 and
(vi) when the product of step (v) has a structure according to formula (I-A), contacting the compound of formula with an alcohol deprotecting agent to provide a compound of formula (I-A);
wherein,
L1 is —C(O)—, —C(O)O—, —C(O)NH—, or —CH2—;
R1 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR1A, —NHR1A, —COOH, —CONH2, —NO2, —SH, —SO2Cl, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or a carboxylate protecting group;
R2 is hydrogen or unsubstituted alkyl;
R3 is hydrogen, unsubstituted alkyl, or —OR3A;
R4 is hydrogen, unsubstituted alkyl, or —OR4A;
R5 is hydrogen, unsubstituted alkyl, or —OR5A;
R6 is hydrogen, unsubstituted alkyl, or —OR6A;
R7 is hydrogen, unsubstituted alkyl, or —OR7A;
R8 is hydrogen, unsubstituted alkyl, or —OR8A;
R9 is hydrogen, unsubstituted alkyl, or —OR9A;
R10 is hydrogen, unsubstituted alkyl, or —OR10A;
R11A is hydrogen;
R11B is an alcohol protecting group;
R12 is hydrogen, unsubstituted alkyl, or —OR12A;
R13 is unsubstituted alkyl;
R1A, R3A, R4A, R5A, R6A, R7A, R8A, R9A, R10A, R12A and R13A are independently hydrogen, unsubstituted alkyl, or an alcohol protecting group.

US Pat. No. 10,246,480

COMPOUNDS FOR THE TREATMENT OF CANCER

1. A compound of Formula (III):
or a pharmaceutically acceptable salt thereof, wherein
R1a is selected from the group consisting of —H, —OH, and —F;
R1b is selected from the group consisting of —H, —OH, and —F, wherein at least one of R1a and R1b is —H;
R4a is selected from the group consisting of —H, —OH, and —F;
R4b is selected from the group consisting of —H, —OH, and —F, wherein at least one of R4a and R4b is —H;
P1 and P2 each independently has an S or R stereochemical configuration;
Z is —O— or —NH—;
X1a and X2a are the same or different and are independently selected from ?O or ?S;
X1b and X2b are the same or different and are independently selected from —OR5 and —SR5;
wherein R5 is selected from the group consisting of —H, —C1-6alkyl, —C(O)C1-6alkyl, and —CH2OC(O)OC1-6alkyl;
L1 in formula (III) is four, five, or six carbons in length, and is

wherein indicates a singe bond, a double bond, or a triple bond and wherein (i) either 0 or 1 occurrence of in L1 indicates a triple bond; or (ii) 0, 1, or 2 occurrences of in L1 indicates a double bond, wherein geometry about each double bond is cis or trans; and (iii) wherein when 1 occurrence of in L1 indicates a triple bond, 0 occurrences of in L1 indicates a double bond; and (iv) wherein, when 2 occurrences of in L1 indicate a double bond, those double bonds are either adjacent bonds or alternating bonds;
wherein X10, X11, X12, X13, X14, and X15 are independently selected from a bond, —CH2—, or —CH—, wherein the —CH2— or —CH— is unsubstituted or substituted by (i) —OH, (ii) —F, (iii) —Cl, (iv) —NH2, or (v) -D, and when X10 or X15 is a bond, that bond is not a double bond or triple bond;
and wherein any two adjacent members of the group including X10, X11, X12, X13, X14, and X15 may optionally form, with additional atoms, a C3 cycloalkyl or a C3 heterocycloalkyl, said C3 heterocycloalkyl including an N or O atom;
wherein B1 and B2 are independently selected from:
where the bonds at points q and r on B1 and B2 are attached at points q and r on Formula (III).

US Pat. No. 10,246,479

METHOD OF PREPARATION OF NANOPORE AND USES THEREOF

THE TRUSTEES OF COLUMBIA ...

1. A tagged nucleotide, wherein the nucleotide comprises a tag capable of being cleaved in a nucleotide polymerization event and detected with the aid of a nanopore, wherein the tagged nucleotide has the structure:
wherein the tag comprises an oligonucleotide which comprises nucleotides having natural bases and (i) at least one abasic site or (ii) at least one nucleotide having a modified base;
wherein R1 is OH, wherein R2 is H or OH, wherein X is a linker and may comprise O, NH, S, or CH2, wherein Z is O, S, or BH3, wherein the base is adenine, guanine, cytosine, thymine, uracil, or a derivative of one of these bases, wherein n is 1, 2, 3, or 4.

US Pat. No. 10,246,478

POLYENE MACROLIDE DERIVATIVE

1. A compound represented by formula (I):wherein X is a group of formula (II):or —N(RF)—CO—X1,wherein in formula (II) Ring C is substituted or unsubstituted aromatic carbocycle, substituted or unsubstituted non-aromatic carbocycle, substituted or unsubstituted aromatic heterocycle or substituted or unsubstituted non-aromatic heterocycle;
wherein RF is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl; and
X1 is any one of following groups (III)-(VI):

wherein in formula (I) L, J1 and V1 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted amino or substituted or unsubstituted alkyloxy;
J2 and V2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl;or J1 and J2 and/or V1 and V2 may be taken together to form oxo;wherein in formula (III) or (IV) Ra1 and Rb1 are each independently, hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted amino, formyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, sulfo, cyano, substituted or unsubstituted ureido, guanidino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkyl ammonium, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted alkylphosphonyl, substituted or unsubstituted dialkynylphosphonyl, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkynylcarbonyloxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyloxy, substituted or unsubstituted non-aromatic carbocyclyloxy, substituted or unsubstituted aromatic heterocyclyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, substituted or unsubstituted non-aromatic heterocyclylcarbonyl, substituted or unsubstituted aromatic carbocyclylamino, substituted or unsubstituted non-aromatic carbocyclylamino, substituted or unsubstituted aromatic heterocyclylamino, substituted or unsubstituted non-aromatic heterocyclylamino, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl or substituted or unsubstituted non-aromatic heterocyclylsulfonyl;
Ra2 and Rb2 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkynylcarbonyloxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxyalkyl, substituted or unsubstituted non-aromatic heterocyclyloxyalkenyl or substituted or unsubstituted non-aromatic heterocyclyloxyalkynyl;
Ra3 and Rb3 are each independently, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxyalkyl, substituted or unsubstituted non-aromatic heterocyclyloxyalkenyl or substituted or unsubstituted non-aromatic heterocyclyloxyalkynyl;or Ra2 and Ra3 and/or Rb2 and Rb3 are each independently may be taken together to form oxo, substituted or unsubstituted imino or thioxo, or may be taken together with neighboring atoms to form substituted or unsubstituted non-aromatic carbocycle or substituted or unsubstituted non-aromatic heterocycle;Ra4, Rb4 and Rc4 are each independently, hydrogen, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl or substituted or unsubstituted non-aromatic carbocyclyl;
Rb5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl;
wherein in formula (V) or (VI) Ring A and Ring B are each independently, substituted or unsubstituted nitrogen-containing aromatic heterocycle or substituted or unsubstituted nitrogen-containing non-aromatic heterocycle;
wherein in formula (III) T is a bond, —N(Ra5)— or —O—;
wherein the Ra5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl or substituted or unsubstituted alkynylcarbonyl;
wherein in formula (III) or (IV) m and n are each independently an integer of 0 to 10;
wherein in formula (I) Y is any one of following groups:

wherein in formula (VII) RA is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl;
RB and RC are each independently hydrogen, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or substituted or unsubstituted alkynyl;or RB and RC may be taken together to form oxo, substituted or unsubstituted imino or thioxo, or may be taken together with neighboring atoms to form substituted or unsubstituted non-aromatic carbocycle or substituted or unsubstituted non-aromatic heterocycle;wherein in formula (VII) or (VIII) RD is hydrogen, hydroxy, carboxy, substituted or unsubstituted amino, substituted or unsubstituted carbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted guanidino, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl or substituted or unsubstituted non-aromatic heterocyclyl;
wherein in formula (VIII) RE is hydrogen, hydroxy or substituted or unsubstituted amino;
wherein in formula (VII) q is an integer of 0 to 10;provided that the following compounds are excluded:the compounds which X is either of following groups; and Y is —NH2;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,475

MULTIDENTATE DINUCLEAR CYCLOMETALLATED PLATINUM COMPLEXES CONTAINING N-(PYRIMIDIN-2-YL)-CARBAZOLE AND ITS ANALOGUES

ZHEJIANG UNIVERSITY OF TE...

1. A compound of Formula I:
wherein each of L1 and L2 is independently a six-membered carbocyclic, heterocyclic, heteroaryl ring;
wherein each of Y1, Y2, Y3 independently comprises N and C;
wherein V1, V2, V3, V4, V5, V6, V7 and V8 are coordinated with M1 or M2 and each independently comprises N and C; and at least two of V1, V2, V3 and V4 are N, at least two of V5, V6, V7 and V8 are N;
wherein each of A1 and A2 is independently selected from the group consisting O, S, CH2, CD2, CRaRb, C?O, SiRaRb, GeH2, GeRaRb, NH, NRc, PH, PRc, RcP?O, AsRc, RcAs?O, S?O, SO2, Se, Se?O, SeO2, BH, BRc, RcBi?O, BiH, or BiRc;
wherein each of X, X1 and X2 is independently selected from the group consisting N, B, CH, CD, CRa, SiH, SiD, SiRa, GeH, GeD, GeRd, P, P?O, As, As?O, Bi or Bi?O;
wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 may represent mono-, di, tri, tetra-substitutions, or no substitution, and R1, R2, R3, R4, R5, R6, R7, R8, R9, Ra, Rb, Rc and Rd are independently selected from the group consisting hydrogen, deuterium, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, halogen, hydroxyl, thiol, nitro, cyano, amino, a mono- or di-alkylamino, a mono- or diaryl amino, alkoxy, aryloxy, haloalkyl, aralkyl, ester, nitrile, isonitrile, heteroary, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, sulfinyl, ureido, phosphoramide, amercapto, sulfo, carboxyl, hydrzino, substituted silyl, or any conjugate or combination thereof; Two or more adjacent R1, R2, R3, R4, R5, R6, R7, R8 and R9 are optionally joined to form a fused ring;
wherein Ra, Rb, Rc and Rd may represent mono-, di, tri, tetra-substitutions, or no substitution, and Ra, Rb, Rc and Rd are independently selected from the group consisting hydrogen, deuterium, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, halogen, hydroxyl, thiol, nitro, cyano, amino, a mono- or di-alkylamino, a mono- or diaryl amino, alkoxy, aryloxy, haloalkyl, aralkyl, ester, nitrile, isonitrile, heteroary, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, sulfinyl, ureido, phosphorannide, annercapto, sulfo, carboxyl, hydrzino, substituted silyl, or any conjugate or combination thereof.

US Pat. No. 10,246,474

PREPARATION OF A HYDROXYALKYL PHOSPHONIC ACID

Rohm and Haas Company, P...

1. A process for converting a phosphonate to a hydroxyalkyl phosphonic acid comprising the step of contacting together water, the phosphonate, and a heterogeneous catalyst; wherein the heterogeneous catalyst is a sulfonated crosslinked macroreticular ion exchange resin; wherein the phosphonate is contacted with the sulfonated crosslinked ion-exchange resin at a temperature of from 80° C. to 120° C. for 1 to 24 hours to convert at least 70% of the phosphonate to the hydroxyalkyl phosphonic acid; wherein the phosphonate is characterized by the following formula:
where R is H or acetyl; and R1 is C1-C10-alkyl; and n is 2 to 10; and wherein methyl acetate and methanol are formed in addition to the hydroxyalkyl phosphonic acid.

US Pat. No. 10,246,472

GUANIDINE-FUNCTIONALIZED PARTICLES AND METHODS OF MAKING AND USING

3M Innovative Properties ...

1. A method of making a guanidine-functionalized particle, comprising:reacting O-methylisourea hemisulfate with a linker molecule comprising the formula
(RO)nRa3-nSi—Sm—X
where RO is an alkoxy group comprising one or two carbons, or is an acetoxy group,
where n is 1, 2 or 3,
where Ra is an unreactive group,
where S is a spacer group comprising a backbone with m atoms,
m is from 2-16, inclusive, and
where X is a primary amine that is capable of reacting with the O-methylisourea to form a guanidine group;
and,
reacting at least one of the RO groups of the linker molecule with a hydroxyl group of the particle to form a covalent bond between the linker molecule and the particle.

US Pat. No. 10,246,471

ETP DERIVATIVES

City of Hope, Duarte, CA...

1. A compound having formula:
wherein:
R1 is hydrogen, halogen, —CF3, —CN, —CHO, or substituted or unsubstituted alkyl;
R2 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33B, —NR34BR35B, —COOR33B, —CONR34BR35B, —NO2, —SR36B, —SOn2R34B, —SOn2OR34B, —SOn2NR34BR35B, —NHNR34BR35B, —ONR34BR35B, —NHC(O)NHNR34BR35B, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33C, —NR34CR35C, —COOR33C, —CONR34CR35C, —NO2, —SR36C, —SOn3R34C, —SOn3OR34C, —SOn3NR34CR35C, —NHNR34CR35C, —ONR34CR35C, —NHC(O)NHNR34CR35C, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33D, —NR34R35D, —COOR33D, —CONR34DR35D, —NO2, —SR36D, —SOn4R34D, —SOn4OR34D, SOn4NR34DR35D, —NHNR34DR35D, —ONR34DR35D, —NHC(O)NHNR34DR35D, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R5 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33E, —NR34ER35E, —COOR33E, —CONR34ER35E, —NO2, —SR36E, —SOn5R34E, —SOn5OR34E, —SOn5NR34ER35E, —NHNR34ER35E, —ONR34ER35E, —NHC(O)NHNR34ER35E, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R6 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33F, —NR34FR35F, —COOR33F, —CONR34FR35F, —NO2, —SR36F, —SOn6R34F, —SOn6OR34F, —SOn6NR34FR35F, —NHNR34FR35F, —ONR34FR35F, —NHC(O)NHNR34FR35F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R7 is hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33I, —NR34IR35I, —COOR33I, —CONR34IR35I, —NO2, —SR36I, —SOn9R34I, —SOn9OR34I, —SOn9NR34IR35I, —NHNR34IR35I, —ONR34IR35I, —NHC(O)NHNR34IR35I, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R10 and R11 are independently hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33L, —NR34LR35L, —COOR33L, —CONR34LR35L, —NO2, —SR36L, —SOn12R34L, —SOn12OR34L, —SOn12NR34LR35L, —NHNR34LR35L, —ONR34LR35L, —NHC(O)NHNR34LR35L, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or are optionally joined together to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
R12 and R13 are independently hydrogen, halogen, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OR33M, —NR34MR35M, —COOR33M, —CONR34MR35M, —NO2, —SR36M, —SOn13R34M, —SOn13OR34M, —SOn13NR34MR35M, —NHNR34MR35M, —ONR34MR35M, —NHC(O)NHNR34MR35M, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
R33A, R34A, R35A, R36A, R33B, R34B, R35B, R36B, R33C, R34C, R35C, R36C, R33D, R34D, R35D, R36D, R33E, R34E, R35E, R36E, R33F, R34F, R35F, R36F, R33I, R34I, R35I, R36I, R33L, R34L, R35L, R36L, R33M, R34M, R35M, and R36M are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
n1, n2, n3, n4, n5, n6, n9, n12, and n13 are independently 1 or 2.

US Pat. No. 10,246,469

BIARYL KINASE INHIBITORS

Bristol-Myers Squibb Comp...

1. A compound of formula (I)or a pharmaceutically acceptable salt thereof, wherein:A is selected from
wherein “” denotes the point of attachment to B;B is selected from
wherein “*” indicates the point of attachment to R5 and “**” indicates the point of attachment to ring A;R1 is selected from hydrogen, amino, —CO2H, cyclopropyl, difluoromethyl, ethyl, halo, hydroxymethyl, methoxy, methoxymethyl, methyl, —NHC(O)CH3, —NHCO2CH3, trifluoromethoxy, trifluoromethyl,
wherein Ra is selected from hydrogen, halo and methyl;R2 is selected from hydrogen, cyano, —CH2OH, halo, and methyl;
R3 is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, fluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, —CH2N(CH3)2, and a five-membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur;
R4 is selected from hydrogen, halo, and methyl;
R5 is selected from

R6 is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl;provided that when A isthen B isR1 is selected fromcyclopropyl, methoxymethyl,R5 is selected from

US Pat. No. 10,246,468

BACE1 INHIBITORS

Hoffmann-La Roche Inc., ...

1. A compound of formula I,
wherein
n is 1, 2 or 3;
R1 is selected from the group consisting of
i) C1-6-alkyl and
ii) halogen-C1-6-alkyl;
R2 is selected from the group consisting of
i) C1-6-alkyl, and
ii) halogen-C1-6-alkyl;
or R1 and R2 form together with the C-atom they are attached to, a C3-6-cycloalkyl-, wherein the C3-6-cycloalkyl- is optionally substituted by one or more substituents selected from the group consisting of halogen and hydroxyl;
R3 is each independently selected from the group consisting of
i) hydrogen,
ii) C1-6-alkyl, and
iii) halogen;
R4 is each independently selected from the group consisting of
i) hydrogen,
ii) C1-4-alkyl, and
iii) halogen;
or wherein R3 and R4 together are —(CH2)m—, wherein m is 2, 3, 4 or 5,
R5 is hydrogen;
R6 is selected from the group consisting of
i) C1-6-alkyl, and
ii) halogen-C1-6-alkyl;
R7 is selected from the group consisting of
i) hydrogen, and
ii) halogen;
R8 is selected from the group consisting of
i) aryl,
ii) aryl substituted by 1-4 substituents individually selected from amino, cyano, halogen, halogen-C1-6-alkyl, halogen-C1-6-alkoxy, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C2-6-alkynyl-C1-6-alkoxy, C2-6-alkynyl, C1-6-alkyl, COOR9, wherein R9 is H or C1-6-alkyl, CONR10R11, wherein R10 is H or C1-6-alkyl C3-6-cycloalkyl and R11 is H or C1-6-alkyl, C3-6-cycloalkyl that is optionally substituted by 1 to 4 substituents individually selected from the group consisting of halogen, cyano, C1-6-alkyl and C1-6-alkoxy, C3-6-cycloalkyl-C1-6-alkoxy and C3-4-cycloalkyl-C1-6-alkoxy, wherein the cycloalkyl unit is substituted by 1 to 4 substituents individually selected from the group consisting of halogen, cyano, C1-6-alkyl and C1-6-alkoxy;
iii) heteroaryl, and
iv) heteroaryl substituted by 1-4 substituents individually selected from amino, cyano, halogen, halogen-C1-6-alkyl, halogen-C1-6-alkoxy, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C2-6-alkynyl-C1-6-alkoxy, C2-6-alkynyl, C1-6-alkyl, COOR9, wherein R9 is H or C1-6-alkyl, CONR10R11, wherein R10 is H or C1-6-alkyl C3-6-cycloalkyl and R11 is H or C1-6-alkyl, C3-6-cycloalkyl that is optionally substituted by 1 to 4 substituents individually selected from the group consisting of halogen, cyano, C1-6-alkyl and C1-6-alkoxy, C3-6-cycloalkyl-C1-6-alkoxy and C3-6-cycloalkyl-C1-6-alkoxy, wherein the cycloalkyl unit is substituted by 1 to 4 substituents individually selected from the group consisting of halogen, cyano, C1-6-alkyl and C1-6-alkoxy;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,467

SPIRO[3H-INDOLE-3,2?-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS

Boehringer Ingelheim Inte...

1. A compound of formula (I)whereinR1 is a group, optionally substituted by one or more, identical or different Rb1 and/or Rc1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rb1 is independently selected from among —ORc1, —NRc1Rc1, halogen, —CN, —C(O)Rc1, —C(O)ORc1, —C(O)NRc1Rc1, —S(O)2Rc1, —S(O)2NRc1Rc1, —NHC(O)Rc1 and —N(C1-4alkyl)C(O)Rc1;
each Rc1 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd1 and/or Re1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd1 is independently selected from among, —ORe1, NRe1Re1 halogen, —CN,
C(O)Re1, —C(O)ORe1, —C(O)NRe1Re1, S(O)2Re1, —S(O)2NRe1Re1, —NHC(O)Re1 and —N(C1-4alkyl)C(O)Re1;
each Re1 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rf1 and/or Rg1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rf1 is independently selected from among —ORg1, —NRg1Rg1, halogen, —CN, —C(O)Rg1, —C(O)ORg1, —C(O)NRg1Rg1, —S(O)2Rg1, —S(O)2NRg1Rg1, —NHC(O)Rg1 and —N(C1-4alkyl)C(O)Rg1;
each Rg1 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
R2 and R3, each independently, is selected from among hydrogen, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, wherein this C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl is optionally substituted by one or more, identical or different Rb2 and/or Rc2;
each Rb2 is independently selected from among —ORc2, —NRc2Rc2, halogen, —CN, —C(O)Rc2, —C(O)ORc2, —C(O)NRc2Rc2, —S(O)2Rc2, —S(O)2NRc2Rc2, —NHC(O)Rc2 and —N(C1-4alkyl)C(O)Rc2;
each Rc2 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd2 and/or Re2, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd2 is independently selected from among —ORe2, —NRe2Re2, halogen, —CN, —C(O)Re2, —C(O)ORe2, —C(O)NRe2Re2, —S(O)2Re2, —S(O)2NRe2Re2, —NHC(O)Re2 and —N(C1-4alkyl)C(O)Re2;
each Re2 independently of one another denotes hydrogen or a group selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
A is selected from among phenyl and 5-6 membered heteroaryl;
each R4 is independently selected from among Ra4 and Rb4;
each Ra4 independently of one another is a group, optionally substituted by one or more, identical or different Rb4 and/or Rc4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rb4 is independently selected from among —ORc4, —NRc4Rc4, halogen, —CN, —C(O)Rc4, —C(O)ORc4, —C(O)NRc4Rc4, —C(O)NRg4ORc4, —S(O)2Rc4, —S(O)2NRc4Rc4, —NHSO2Rc4, —N(C1-4alkyl)SO2Rc4, —NHC(O)Rc4 and —N(C1-4alkyl)C(O)Rc4;
each Rc4 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd4 and/or Re4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd4 is independently selected from among —ORe4, —NRe4Re4, halogen, —CN, —C(O)Re4, —C(O)ORe4, —C(O)NRe4Re4, —C(O)NRg4ORe4, —S(O)2Re4, —S(O)2NRe4Re4, —NHC(O)Re4 and —N(C1-4alkyl)C(O)Re4;
each Re4 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rf4 and/or Rg4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rf4 is independently selected from among —ORg4, —NRg4Rg4, halogen, —CN, —C(O)Rg4, —C(O)ORg4, —C(O)NRg4Rg4, —C(O)NRg4ORg4, —S(O)2Rg4, —S(O)2NRg4Rg4, —NHC(O)Rg4 and —N(C1-4alkyl)C(O)Rg4;
each Rg4 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
r denotes the number 0, 1, 2 or 3
R5 and R6, each independently, is selected from among hydrogen, C1-4alkyl and C1-4haloalkyl;
n denotes the number 0;
each R7 is independently selected from among halogen, C1-4alkyl, —CN, C1-4haloalkyl, —OC1-4alkyl and —OC1-4haloalkyl;
q denotes the number 0, 1, 2 or 3;
W, X and Y is each independently selected from —N? and —CH?
with the proviso that the hydrogen in each —CH? may be replaced by a substituent R7 if present and that a maximum of two of W, X and Y can be —N?;
V is oxygen or sulfur;
or a salt thereof.

US Pat. No. 10,246,466

DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

TP Therapeutics, Inc., S...

1. A compound of the formulawhereineach L1 and L2 is independently —C(R1?)(R2?)—, —O—, —N(Rk?)—, —S—, —S(O)— or —S(O)2—;
each R1? and R2? is independently H, deuterium, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, mono- or bicyclic heteroaryl, —ORa?, —OC(O)Ra?, —OC(O)NRa?Rb?, —OS(O)Ra?, —OS(O)2Ra?, —SRa?, —S(O)Ra?, —S(O)2Ra?, —S(O)NRa?Rb?, —S(O)2NRa?Rb?, —OS(O)NRa?Rb?, —OS(O)2NRa?Rb?, —NRa?Rb?, —NRa?C(O)Rb?, —NRa?C(O)ORb?, —NRa?C(O)NRa?Rb?, —NRa?S(O)Rb?, —NRa?S(O)2Rb?, —NRa?S(O)NRa?Rb?, —NRa?S(O)2NRa?Rb?, —C(O)Ra?, —C(O)ORa?, —C(O)NRa?Rb?, —PRa?Rb?—P(O)Ra?Rb?, —P(O)2Ra?Rb?, —P(O)NRa?Rb?, —P(O)2NRa?Rb?, —P(O)ORa?, —P(O)2ORa?, —CN, or —NO2; or R1? and R2? taken together with the carbon or carbons to which they are attached form a C3-6cycloalkyl or a 4- to 6-membered heterocycloalkyl, wherein each hydrogen atom in C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, mono- or bicyclic heteroaryl, 4- to 6-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C1-6alkyl, C1-6haloalkyl, —ORe?, —OC(O)Re?, —OC(O)NRe?Rf?, —OS(O)Re?, —OS(O)2Re?, —OS(O)NRe?Rf?, —OS(O)2NRe?Rf?, —SRe?, —S(O)Re?, —S(O)2Re?, —S(O)NRe?Rf?, —S(O)2NRe?Rf?, —NRe?Rf?, —NRe?C(O)Re?, —NRe?C(O)ORf?, —NRe?C(O)NRe?Rf?, —NRe?S(O)Rf?, —NRe?S(O)2Rf?, —NRe?S(O)NRe?Rf?, —NRe?S(O)2NRe?Rf?, —C(O)Re?, —C(O)ORe?, —C(O)NRe?Rf?, —PRe?Rf?, —P(O)Re?Rf?, —P(O)2Re?Rf?, —P(O)NRe?Rf?, —P(O)2NRe?Rf?, —P(O)ORe?, —P(O)2ORe?, —CN, or —NO2;
each Rk? is independently H, deuterium, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by deuterium, halogen, C1-6alkyl, C1-6haloalkyl, —ORe?, —OC(O)Re?, —OC(O)NRe?Rf?, —OS(O)Re?, —OS(O)2Re?, —OS(O)NRe?Rf?, —OS(O)2NRe?Rf?, —SRe?, —S(O)Re?, —S(O)2Re?, —S(O)NRe?Rf?, —S(O)2NRe?Rf?, —NRe?Rf?, —NRe?C(O)Rf?, —NRe?C(O)ORf?, —NRe?C(O)NRe?Rf?, —NRe?S(O)Rf?, —NRe?S(O)2Rf?, —NRe?S(O)NRe?Rf?, —NRe?S(O)2NRe?Rf?, —C(O)Re?, —C(O)ORe?, —C(O)NRe?Rf?, —PRe?Rf?, —P(O)Re?Rf?, —P(O)2Re?Rf?, —P(O)NRe?Rf?, —P(O)2NRe?Rf?, —P(O)ORe?, —P(O)2ORe?, —CN, or —NO2;
each R3? and R4? is independently deuterium, halogen, —ORc?, —OC(O)Rc?, —OC(O)NRc?Rd?, —OC(?N)NRc?Rd?, —OS(O)Rc?, —OS(O)2Rc?, —OS(O)NRc?Rd?, —OS(O)2NRc?Rd?, —SRc?, —S(O)Rc?, —S(O)2Rc?, —S(O)NRc?Rd?, —S(O)2NRc?Rd?, —NRc?Rd?, —NRc?C(O)Rd?,—NRc?C(O)ORd?, —NRc?C(O)NRc?Rd?, —NRc?C(?N)NRc?Rd?, —NRc?S(O)Rd?, —NRc?S(O)2Rd?, —NRc?S(O)NRc?Rd?, —NRc?S(O)2NRc?Rd?, —C(O)Rc?, —C(O)ORc?, —C(O)NRc?Rd?, —C(?N)NRc?Rd?, —PRc?Rd?, —P(O)Rc?Rd?, —P(O)2Rc?Rd?, —P(O)NRc?Rd?, —P(O)2NRc?Rd?, —P(O)ORc?, —P(O)2ORc?, —CN, —NO2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, or mono- or bicyclic heteroaryl, or any two R3? groups or any two R4? groups taken together with the ring to which they are attached form a C5-8cycloalkyl or a 5- to 8-membered heterocycloalkyl, wherein each hydrogen atom in C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, mono- or bicyclic heteroaryl C5-8cycloalkyl or a 5- to 8-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C1-6alkyl, C1-6haloalkyl, —ORe?, —OC(O)Re?, —OC(O)NRe?Rf?, —OS(O)Re?, —OS(O)2Re?, —OS(O)NRe?Rf?, —OS(O)2NRe?Rf?, —SRe?, —S(O)Re?, —S(O)2Re?, —S(O)NRe?Rf?, —S(O)2NRe?Rf?, —NRe?Rf?, —NRe?C(O)Rf?, —NRe?C(O)ORf?, —NRe?C(O)NRe?Rf?, —NRe?S(O)Rf?, —NRe?S(O)2Rf?, —NRe?S(O)NRe?Rf?, —NRe?S(O)2NRe?Rf?, —C(O)Re?, —C(O)ORe?, —C(O)NRe?Rf?, —PRe?Rf?, —P(O)Re?Rf?, —P(O)2Re?Rf?, —P(O)NRe?Rf?, —P(O)2NRe?Rf?, —P(O)ORe?, —P(O)2ORe?, —CN, or —NO2;
R7? is H, deuterium, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by deuterium, halogen, —ORi?, —OC(O)Ri?, —OC(O)NRi?Rj?, —OS(O)Ri?, —OS(O)2Ri?, —OS(O)NRi?Rj?, —OS(O)2NRi?Rj?, —SRi?, —S(O)Ri?, —S(O)2Ri?, —S(O)NRi?Rj?, —S(O)2NRi?Rj?, —NRi?Rj?, —NRi?C(O)Rj?, —NRi?C(O)ORj?, —NRi?C(O)NRi?Rj?, —NRi?S(O)Rj?, —NRi?S(O)2Rj?, —NRi?S(O)NRi?Rj?, —NRi?S(O)2NRi?Rj?, —C(O)Ri?, —C(O)ORi?, —C(O)NRi?Rj?, —PRi?Rj?, —P(O)Ri?Rj?, —P(O)2Ri?Rj?, —P(O)NRi?Rj?, —P(O)2NRi?Rj?, —P(O)ORi?, —P(O)2ORi?, —CN, or —NO2;
each Ra?, Rb?, Rc?, Rd?, Re?, Rf?, Ri? and Rj? is independently selected from the group consisting of H, deuterium, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, and heteroaryl;
m? is 2, 3, 4, or 5;
n? is 2, 3, or 4;
p? is 0, 1, 2, 3, or 4; and
q? is 0, 1, 2, 3, or 4;or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,465

ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

LABORATORIOS DEL DR. ESTE...

1. A compound of Formula I
wherein
R1 is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C4-7 alkylcycloalkyl,
wherein the cycloalkyl in R1, if substituted, also in alkylcycloalkyl, is substituted with substituents selected from the group consisting of —R4??, halogen, —SR4??, —CN, haloalkyl, and —NR4??R4??,
wherein the alkyl, alkenyl and alkynyl in R1, if substituted, are substituted with substituents selected from the group consisting of halogen, —CN, and haloalkyl;
R2 is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl,
wherein the aryl or heterocyclyl in R2, if substituted, is substituted with substituents selected from the group consisting of —R4, —OR4, halogen, ?O, —OCH2CH2OH, —SR4, —S(O)R4, —S(O)2R4, —CN, haloalkyl, -haloalkoxy, —NR4R4??, —NO2, —NR4C(O)R4?, —NR4SO2R4?, —C(O)OR4, —C(O)NR4R4?, —NR4C(O)NR4?R4?, —S(O)2NR4R4?, and —NR4S(O)2NR4?R4?,
R3 is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C4-7 alkylcycloalkyl, substituted or unsubstituted C4-7 alkylaryl, substituted or unsubstituted C3-6 aryl, substituted or unsubstituted C3-6 heterocyclyl or substituted or unsubstituted C4-7 alkylheterocyclyl,
wherein the aryl, heterocyclyl or cycloalkyl in R3, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, is substituted with substituents selected from the group consisting of —R4, —OR4, halogen, ?O, —OCH2CH2OH, —SR4, —S(O)R4, —S(O)2R4, —CN, haloalkyl, -haloalkoxy, —NR4R4??, —NO2, —NR4C(O)R4?, —NR4S(O)2R4?, —C(O)OR4, —C(O)NR4R4?, —NR4C(O)NR4?R4??, —S(O)2NR4R4?, and —NR4S(O)2NR4?R4??
and wherein the alkyl, alkenyl and alkynyl as defined in R3, if substituted, are substituted with substituents selected from —OR4, halogen, —CN, and haloalkyl,
R3? is hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl or unsubstituted C2-6 alkynyl,
alternatively R3 and R3? taken together with the connecting C-atom form an substituted or unsubstituted C3-6 cycloalkyl,
wherein the cycloalkyl formed by R3 and R3? taken together with the connecting C-atom, if substituted, is substituted with substituents selected from the group consisting of —R4, —OR4, halogen, ?O, —OCH2CH2OH, —SR4, —S(O)R4, —S(O)2R4, —CN, haloalkyl, -haloalkoxy, —NR4R4??, —NO2, —NR4C(O)R4?, —NR4S(O)2R4?, —C(O)OR4, —C(O)NR4R4?, —NR4C(O)NR4?R4?, —S(O)2NR4R4?, and —NR4S(O)2NR4?R4?;
R4, R4? and R4? are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl or substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl,
wherein the cycloalkyl in R4, R4? or R4?, if substituted, is substituted with substituents selected from the group consisting of —R4??, halogen, —SR4??, —CN, haloalkyl, and —NR4??R4??,
wherein the alkyl, alkenyl and alkynyl in R4, R4? or R4?, if substituted, are substituted with substituents selected from the group consisting of halogen, —CN, and haloalkyl;
R4?? is hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl or -Boc;
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

US Pat. No. 10,246,464

THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

THE REGENTS OF THE UNIVER...

1. A compound represented by the structure of Formula (4):or a salt thereof, wherein:R1, R2, R4, R5, R8, and Ra are independently selected from hydrogen, halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl come together to form a C3-10 carbocycle or 3- to 10-membered heterocycle; and C3-10 carbocycle and 3- to 10-membered heterocycle; wherein any C3-10 carbocycle and 3- to 10-membered heterocycle of R1, R2, R4, R5, R8, and Ra is independently optionally substituted with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
R3 is selected from selected from hydrogen, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —S(O)2R20, —S(O)2N(R20)2, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl come together to form a C3-10 carbocycle or 3- to 10-membered heterocycle; and C3-10 carbocycle and 3- to 10-membered heterocycle; wherein any C3-10 carbocycle and 3- to 10-membered heterocycle of R3 is independently optionally substituted with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
R6 is independently selected at each occurrence from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl come together to form a C3-10 carbocycle or 3- to 10-membered heterocycle; and C3-10o carbocycle and 3- to 10-membered heterocycle; wherein any C3-10 carbocycle and 3- to 10-membered heterocycle of R6 is independently optionally substituted with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)22, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
R20 at each occurrence is independently selected from hydrogen; C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR30, —SR30, —N(R30)2, —N(R30)C(O)R30, —C(O)R30, —C(O)OR30, —C(O)N(R30)2, —OC(O)R30, —S(O)2R30, —S(O)2N(R30)2, —N(R30)S(O)2R30, —NO2, —P(O)(OR30)2, —P(O)(R30)2, —OP(O)(OR30)2, and —CN; and 3- to 10-membered heterocycle and C3-10 carbocycle;
R30 at each occurrence is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
Y is N or C(Ra);
L is absent or selected from alkylene and heteroalkylene;
s is selected from 0, 1, 2, 3, and 4;
R7a is -G-V-R9a:
G is selected from alkylene, heteroalkylene, C3-12 carbocycle, 3- to 12-membered heterocycle, and combinations thereof, wherein G is optionally substituted with one or more R32 groups;
V is selected from a C3-12 carbocycle, and 3- to 12-membered heterocycle;wherein V is optionally substituted with one or more R32 groups;R9a is selected from halogen, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)OR20, —OC(O)R20, —N(R20)S(O)2R20, —NO2, =S, =N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C3-10 carbocycle, and 3- to 10-membered heterocycle; C3-10 carbocycle and 3- to 10-membered heterocycle; or two R32 on the same carbon atom can come together to form a C3-10 carbocycle or 3- to 10-membered heterocycle, wherein each C3-10 carbocycle and 3- to 10-membered heterocycle of R32 is independently optionally substituted with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl; and
R32 at each occurrence is selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C3-10 carbocycle, and 3- to 10-membered heterocycle; C3-10 carbocycle and 3- to 10-membered heterocycle; or two R32 on the same carbon atom can come together to form a C3-10 carbocycle or 3- to 10-membered heterocycle, wherein each C3-10 carbocycle and 3- to 10-membered heterocycle of R32 is independently optionally substituted with one or more substituents selected from halogen, —OR20, —SR20, —N(R20)2, —N(R20)C(O)R20, —C(O)R20, —C(O)OR20, —C(O)N(R20)2, —OC(O)R20, —S(O)2R20, —S(O)2N(R20)2, —N(R20)S(O)2R20, —NO2, ?O, ?S, ?N(R20), —P(O)(OR20)2, —P(O)(R20)2, —OP(O)(OR20)2, —CN, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl.

US Pat. No. 10,246,463

HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITORS

The United States of Amer...

9. A pharmaceutical composition comprising:(i) at least one compound or pharmaceutically acceptable salt thereof, the compound having a chemical structure according to Formula I or a pharmaceutically acceptable salt thereof
wherein each bond depicted as “” is a single or double bond as needed to satisfy valence requirements,R1 is —ORa, aryl, heteroaryl, halo, aliphatic, heteroaliphatic, alicyclic, heteroalicyclic, —SRa, —COORa, or —N(Ra)2, and R2 is —ORa, —SRa, alicyclic, heteroalicyclic, aryl, or heteroaryl; or R1 and R2 together are ?O or ?S,
each R3 independently is aryl, heteroaryl, aliphatic, heteroaliphatic, —COORa, or —C(O)N(Ra)2,
m is 0, 1, or 2,
R4 and R5 together with the carbon atoms to which they are bound define a ring B where the ring B is aryl, heteroaryl, alicyclic, or heteroalicyclic, or R4 and R5 independently are hydrogen, aliphatic, heteroaliphatic, halo, —ORa, —SRa, oxygen, or sulfur, and
each Ra independently is hydrogen or alkyl; and
(ii) at least one pharmaceutically acceptable carrier.

US Pat. No. 10,246,462

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

FLX BIO, INC., South San...

1. A compound having structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is a substituted or unsubstituted heterocycloalkyl;
X1 is N;
X2 is N;
X3 is CR10;
X4 is C, CR11 or N;
z1 is an integer from 0 to 5;
z2 is an integer from 0 to 13;
z3 is an integer from 0 to 12;
z4 is an integer from 0 to 3;
is a single bond or double bond, wherein if is a single bond, then X4 is CR11 or N, and if is a double bond, then X4 is C;
L7 is a bond, —O—, —S—, —NR7B—, —C(O)—, —C(O)O—, —S(O)—, —S(O)2—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; wherein each substituted alkylene, substituted heteroalkylene, substituted cycoalkylene, substituted heterocycloalkylene, substituted arylene, or substituted heteroarylene is substituted with at least one substituent group;
R1 is hydrogen, halogen, —CX1.13, —CHX1.12, —CH2X1.1, —CN, —SOn1R1A, —SOv1NR1BR1C, —NHNR1BR1C, —ONR1BR1C, —NHC(O)NHNR1BR1C, —NHC(O)NR1BR1C, —N(O)m1, —NR1BR1C, —C(O)R1D, —C(O)OR1D, —C(O)NR1BR1C, —OR1A, —NR1BSO2R1A, —NR1BC(O)R1D, —NR1BC(O)OR1D, —NR1BOR1D, —OCX1.13, —OCHX1.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R2 is hydrogen, halogen, —CX2.13, —CHX2.12, —CH2X2.1, —CN, —SOn2R2A, —SOv2NR2BR2C, —NHNR2BR2C, —ONR2BR2C, —NHC(O)NHNR2BR2C, —NHC(O)NR2BR2C, —N(O)m2, —NR2BR2C, —C(O)R2D, —C(O)OR2D, —C(O)NR2BR2C, —OR2A, —NR2BSO2R2A, —NR2BC(O)R2D, —NR2BC(O)OR2D, —NR2BOR2D, —OCX2.13, —OCHX2.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R3 is independently hydrogen, halogen, —CX3.13, —CHX3.12, —CH2X3.1, —CN, —SOn3R3A, —SOv3NR3BR3C, —NHNR3BR3C, —ONR3BR3C, —NHC(O)NHNR3BR3C, —NHC(O)NR3BR3C, —N(O)m3, —NR3BR3C, —C(O)R3D, —C(O)OR3D, —C(O)NR3BR3C, —OR3A, —NR3BSO2R3A, —NR3BC(O)R3D, —NR3BC(O)OR3D, —NR3BOR3D, —OCX3.13, —OCHX3.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least on substituent group;
R4 is hydrogen, halogen, —CX4.13, —CHX4.12, —CH2X4.1, —CN, —SOn4R4A, —SOv4NR4BR4C, —NHNR4BR4C, —ONR4BR4C, —NHC(O)NHNR4BR4C, —NHC(O)NR4BR4C, —N(O)m4, —NR4BR4C, —C(O)R4D, —C(O)OR4D, —C(O)NR4BR4C, —OR4A, —NR4BSO2R4A, —NR4BC(O)R4D, —NR4BC(O)OR4D, —NR4BOR4D, —OCX4.13, —OCHX4.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R5 is independently hydrogen, halogen, oxo, —CX5.13, —CHX5.12, —CH2X5.1, —CN, —SOn5R5A, —SOv5NR5BR5C, —NHNR5BR5C, —ONR5BR5C, —NHC(O)NHNR5BR5C, —NHC(O)NR5BR5C, —N(O)m5, —NR5BR5C, —C(O)R5D, —C(O)OR5D, —C(O)NR5BR5C, —OR5A, —NR5BSO2R5A, —NR5BC(O)R5D, —NR5BC(O)OR5D, —NR5BOR5D, —OCX5.13, —OCHX5.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted hetercycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R6 is independently hydrogen, halogen, oxo, —CX6.13, —CHX6.12, —CH2X6.1, —CN, —SOn6R6A, —SOv6NR6BR6C, —NHNR6BR6C, —ONR6BR6C, —NHC(O)NHNR6BR6C, —NHC(O)NR6BR6C, —N(O)m6, —NR6BR6C, —C(O)R6D, —C(O)OR6D, —C(O)NR6BR6C, —OR6A, —NR6BSO2R6A, —NR6BC(O)R6D, —NR6BC(O)OR6D, —NR6BOR6D, —OCX6.13, —OCHX6.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R10 is hydrogen, halogen, —CX10.13, —CHX10.12, —CH2X10.1, —CN, —SOn10R10A, —SOv10NR10BR10C, —NHNR10BR10C, —ONR10BR10C, —NHC(O)NHNR10BR10C, —NHC(O)NR10BR10C, —N(O)m10, —NR10BR10C, —C(O)R10D, —C(O)OR10D, —C(O)NR10BR10C, —OR10A, —NR10BSO2R10A, —NR10BC(O)R10D, —NR10BC(O)OR10D, —NR10BOR10D, —OCX10.13, —OCHX10.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R11 is hydrogen, halogen, —CX11.13, —CHX11.12, —CH2X11.1, —CN, —SOn1R11A,
—SOv11NR11BR11C, —NHNR11BR11C, —ONR11BR11C, —NHC(O)NHNR11BR11C, —NHC(O)NR11BR11C, —N(O)m11, —NR11BR11C, —C(O)R11D, —C(O)OR11D, —C(O)NR11BR11C, —OR11A, —NR11BSO2R11A, —NR11BC(O)R11D, —NR11BC(O)OR11D, —NR11BOR11D, —OCX11.13, —OCHX11.12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R3A, R3B, R3C, R3D, R4A, R4B, R4C, R4D, R5A, R5B, R5C, R5D, R6A, R6B, R6C, R6D, R7B, R10A, R10B, R10C, R10D, R11A, R11B, R11C and R11D are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1B and R1C, R2B and R2C, R3B and R3C, R4B and R4C, R5B and R5C, R6B and R6C, R10B and R10C, R11B and R11C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; wherein each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl is substituted with at least one substituent group;
n1, n2, n3, n4, n5, n6, n10 and n11 are independently an integer from 0 to 4;
m1, m2, m3, m4, m5, m6, m10, m11, v1, v2, v3, v4, v5, v6, v10, and v11 are independently 1 or 2; and
X1.1, X2.1, X3.1, X4.1, X5.1, X6.1, X10.1, and X11.1 are independently —Cl, —Br, —I or —F.

US Pat. No. 10,246,461

DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE

Genentech, Inc., South S...

1. A tablet composition comprising:(i) from about 25 mg to about 300 mg of a free base of structure (I):

 and
(ii) fumaric acid, wherein the weight ratio of the free base of structure (I) to fumaric acid is from about 1:5 to about 3:1.

US Pat. No. 10,246,460

SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1-[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYTALLINE FORMS THEREOF

Hoffmann-La Roche Inc., ...

1. A process to synthesize compound formula I, comprising reacting compound formula III with compound formula VI

US Pat. No. 10,246,459

USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES

SYNGENTA PARTICIPATIONS A...

1. A method for reducing nematode damage to a plant comprising:i) applying a first composition with nematicidal properties to a seed prior to planting and/or to the soil surrounding a planted seed or plant;
ii) and applying a second composition comprising a systemic nematicidal compound to an aerial plant part of said previously treated plant or plant produced from said previously treated seed;wherein the systemic nematicidal compound is selected from a compound according to the following formula:whereinG is hydrogen or a latentiating group; and
A is hydrogen, C1-6alkyl, C1-6haloalkyl, or C1-6alkoxy;or an agrochemically acceptable salt or an N-oxide thereof.

US Pat. No. 10,246,458

ERGOLINE COMPOUNDS AND USES THEREOF

XOC PHARMACEUTICALS, INC....

1. A compound represented by structural Formula (VIII):or a salt thereof, wherein:R1 is cycloalkyl;
R3 is hydrogen or alkyl;
R4 and R5 are independently hydrogen, halo, —OR120, —OC(O)NR121R122, —OC(O)R123 or together with the atoms to which they are attached form a double bond;
R6 and R7 are independently hydrogen, alkyl or substituted alkyl;
R8 is alkyl;
R120 is hydrogen or alkyl;
R121, R122 are independently hydrogen or alkyl; and
R123 is alkyl.

US Pat. No. 10,246,457

INDAZOLE AND AZAINDAZOLE BTK INHIBITORS

1. A compound of Formula (I)wherein:X1 is N or C(H);
X2 is N or C(R6);
R1 is H, C1-3akyl, or —CH2—R1a, wherein R1a is phenyl or pyridyl;
R6 is H or C1-3alkyl;
R7 is:
(a.) a group of the formula —C(O)N(R7a)(R7b), wherein R7a and R7b are independently H or C1-3alkyl; or alternatively, R7a and R7b together with the N to which they are attached form a 5- to 6-membered heterocyclyl optionally containing 1 additional heteroatom selected from N or O;
(b.) Cy, wherein Cy is phenyl or a 5- or 6-membered heteroaryl containing 1 to 3 N ring atoms; wherein Cy is unsubstituted or substituted by 1 to 2 Rc substituents selected from:
(i.) C1-4alkyl,
(ii.) a group of the formula —C(R7d)2CO2H,
wherein R7d is H or C1-3alkyl;
(iii.) —CH2CH2OCH3; or
(iv.) tetrahydropyranyl;
or alternatively, two Rc substituents, together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl containing 1 N ring atom;
(c.) —C(O)OH;
(d.) H;
(e.) C1-3alkyl; or
(f.) C1-3fluoroalkyl;
R8 is H, C1-3alkyl or C1-3hydroxyalkyl;
R9 is:

 ora pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,455

HISTONE DEACETYLASE INHIBITORS

Taipei Medical University...

1. A compound of formula (I):whereinR1 is SO2Ra, in which Ra is phenyl substituted with

R2 is H;
R3 is H;
X is C;
A is unsubstituted pyridine; and
is a double bond,or a pharmaceutically acceptable salt or solvate thereof.

US Pat. No. 10,246,454

SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONES AS GAMMA SECRETASE MODULATORS

JANSSEN PHARMACEUTICA NV,...

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

US Pat. No. 10,246,453

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

Xenon Pharmaceuticals Inc...

1. A compound of formula (I):
wherein:
n is 1, 2, or 3;
m is 1, 2, 3 or 4;
X is a direct bond or —C(R9)R10—;
Y is a direct bond or —C(R11)R12—;
R1 is hydrogen, alkyl, —R17—OR14, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted N-heterocyclyl, an optionally substituted N-heteroaryl, an optionally substituted O-heteroaryl or an optionally substituted S-heteroaryl;
R2 is an optionally substituted 5-membered N-heteroaryl or an optionally substituted 6-membered N-heteroaryl;
R3 is —O — or —N(R13)—;
R4 and R5 are each independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;
or R4 and R1, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, an optionally substituted heterocyclyl or an optionally substituted aryl, and R5, if present, is hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;
each R6 is independently hydrogen, alkyl, alkenyl, halo, haloalkyl, cyano, —OR14 or optionally substituted cycloalkyl;
R7 is halo, haloalkyl, cyano or —OR14;
each R8 is independently hydrogen, alkyl, halo, haloalkyl or —OR14;
or two R8's, together with the carbon to which they are both attached, may form an optionally substituted cycloalkyl;
R9,R10, and R12 are each independently hydrogen, alkyl, haloalkyl or —OR14;
or R9 and R11 form an optionally substituted alkylene chain and R10 and R12 are as defined above; and
R13 is hydrogen, alkyl or haloalkyl;
each R14 are each independently hydrogen, alky, haloalkyl, optionally substituted aryl or optionally substituted aralkyl; and
R17 is a direct bond or an optionally substituted alkylene chain;
as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof;
or a pharmaceutically acceptable salt, solvate or prodrug thereof;
provided that when R3 is —O—, R2 is not optionally substituted thiadiazolyl.

US Pat. No. 10,246,452

MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO

Dow AgroSciences LLC, In...

1. A molecule having the following formula (“Formula One” and/or “Formula Two”)
wherein:
(A) Ar1 is selected from
(1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, or thienyl, or
(2) substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,
wherein said substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl, has one or more substituents independently selected from H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, OSO2—(C1-C8)alkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy,
wherein each alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, phenyl, and phenoxy substituent may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy;
(B) Het is a 5- or 6-membered, saturated or unsaturated, heterocyclic ring, containing one or more heteroatoms independently selected from nitrogen, sulfur, or oxygen, and where Ar1 and Ar2 are 1,3 for a 5-membered ring and 1,3 or 1,4 for a 6-membered ring, and where said heterocyclic ring may also be substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, oxo, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)2—(C1-C8)alkyl, OSO2—(C1-C8)alkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy,
wherein each alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, phenyl, and phenoxy substituent may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)—NRxRy, (C1-C8)alkyl-NR xRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy;
(C) Ar2 is selected from
(1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, or thienyl, or
(2) substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,
wherein said substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl, has one or more substituents independently selected from H, F, Cl, Br, I, CN, NO2, NRxRy, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, OSO2—(C1-C8)alkyl, C(O)—NRxRy, (C1-C8)alkyl-NR xRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy,
wherein each alkyl, haloalkyl, cycloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, phenyl, and phenoxy substituent may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)—NR xRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy;
(D) L is linker selected from
(1) a saturated or unsaturated, substituted linear (C1-C4)hydrocarbyl linker, and
(2) a saturated or unsaturated, substituted cyclic (C3-C8)hydrocarbyl group linker,
wherein each of said linkers connects Ar2 to NY and
wherein said substituted linear (C1-C4)hydrocarbyl linker and substituted cyclic (C3-C8)hydrocarbyl linker has one or more substituents independently selected from R8, R9, R10, R11, and R12, wherein each R8, R9, R10, R11, and R12, is selected from
—NRAC(O)—RB, —NRAC(O)O—RB, —C(O)—OH, or —C(O)O—RB,
where RA is H or (C1-C8)alkyl, and RB is (C1-C8)alkyl or (C1-C8)alkyl substituted with at least one phenyl;
(E) R1 is selected from the group consisting of H, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, C(O)—NR xRy, (C1-C8)alkyl-NRxRy, C(O)O—(C1-C8)alkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—(C1-C8)alkyl, (C1-C8)alkyl-S(O)2—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)O—(C1-C8)alkyl, (C1-C8)alkyl-C(O)O—(C1-C8)alkyl, C(O)alkyl, (C1-C8)alkyl-C(O)—(C1-C8)alkyl, (C1-C8)alkylphenyl, and (C1-C8)alkyl-O-phenyl,
wherein each alkyl, cycloalkyl, alkenyl, and alkynyl may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, oxo, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy;
(F) Q and Q1 are each independently selected from the group consisting of O and S;
(G) R2 is selected from the group consisting of (J), H, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, C(O)—(C1-C8)alkyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, (C1-C8)alkylphenyl, (C1-C8)alkyl-O—phenyl, C(O)—(Het-1), (Het-1), (C1-C8)alkyl-(Het-1), (C1-C8)alkyl-OC(O)—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—NR xRy, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-(Het-1), (C1-C8)alkyl-C(O)—(Het-1), (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl(NRxRy)—C(O)OH, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-NRxRy, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-N(Rx)—C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl(N(Rx)—(O)O—(C1-C8)alkyl)-C(O)OH, (C1-C8)alkyl-C(O)—(Het-1)—C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—(C3-C8)cycloalkyl, (C1-C8)alkyl-OC(O)-(Het-1), (C1-C8)alkyl-OC(O)—(C1-C8)alkyl-N(Rx)—C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-NRxRy, (C1-C8)alkyl-S(O)n—(Het-1), and (C1-C8)alkyl-O—(Het-1),
wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and (Het-1) may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NRxRy, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)H, C(O)OH, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl), phenyl, phenoxy, Si((C1-C8)alkyl)3, S(O)n—NRxRy, and (Het-1);
(H) R3 is selected from the group consisting of (C3-C8)cycloalkyl, phenyl, (C1-C8)alkylphenyl, (C1-C8)alkyl-O—phenyl, (C2-C8)alkenyl-O—phenyl, (Het-1), (C1-C8)alkyl-(Het-1), and (C1-C8)alkyl-O—(Het-1),
wherein each alkyl, cycloalkyl, alkenyl, phenyl, and (Het-1) may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NRxRy, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)H, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C1-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, O—(C1-C8)alkyl, S—(C1-C8)alkyl, (C1-C8)alkyl-O—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, phenoxy, and (Het-1),
(I) R4 is selected from the group consisting of (J), H, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, C(O)—(C1-C8)alkyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, (C1-C8)alkylphenyl, (C1-C8)alkyl-O—phenyl, C(O)—(Het-1), (Het-1), (C1-C8)alkyl-(Het-1), (C1-C8)alkyl-OC(O)—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—NR xRy, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-(Het-1), (C1-C8)alkyl-C(O)—(Het-1), (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl(NRxRy)—C(O)OH, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-NRxRy, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl-N(Rx)—C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-C(O)—N(Rx)(C1-C8)alkyl(N(Rx)—C(O)O—(C1-C8)alkyl)-C(O)OH, (C1-C8)alkyl-C(O)—(Het-1)-C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)O—(C1-C8)alkyl, (C1-C8)alkyl-OC(O)—(C1-C8)alkyl, (C1-C8)alkyl -OC(O)—(C3-C8)cycloalkyl, (C1-C8)alkyl-OC(O)—(Het-1), (C1-C8)alkyl-OC(O)—(C1-C8)alkyl-N(Rx)—C(O)O—(C1-C8)alkyl, (C1-C8)alkyl-NRxRy, (C1-C8)alkyl-S(O)n—(Het-1), and (C1-C8)alkyl-O—(Het-1),
wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and (Het-1) may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, NRxRy, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)H, C(O)OH, C(O)—NR xRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, phenoxy, Si((C1-C8)alkyl)3, S(O)n—NRxRy, and (Het-1);
(J) R2 and R4 together with Cx(Q1)(Nx), may form a 4- to 7-membered saturated or unsaturated, heterocyclic ring, which may further contain one or more heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen,
wherein each heterocyclic ring may be optionally substituted with one or more substituents independently selected from the group consisting of R5, R6, and R7,
wherein R5, R6, and R7 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, NO2, NRxRy, oxo, thioxo, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)H, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n-—C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and (Het-1);
(K) Rx and Ry are each independently selected from the group consisting of H, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, OSO2—(C1-C8)alkyl, C(O)H, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, , C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and (C1-C8)alkylphenyl,
wherein each alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, phenyl, and alkylphenyl may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)H, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and (Het-1);
(L) (Het-1) is a 5- or 6-membered, saturated or unsaturated, heterocyclic ring, containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen,
wherein said heterocyclic ring may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, oxo, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, OSO2—(C1-C8)alkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C3-Cs)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-Cs)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy,
wherein each alkyl, cycloalkyl, alkoxy, alkenyl, alkynyl, phenyl, and phenoxy substituent may be optionally substituted with one or more substituents independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, (C1-C8)haloalkoxy, (C2-C8)alkenyl, (C2-C8)alkynyl, S(O)n—(C1-C8)alkyl, S(O)n—(C1-C8)haloalkyl, OSO2—(C1-C8)alkyl, OSO2—(C1-C8)haloalkyl, C(O)—NRxRy, (C1-C8)alkyl-NRxRy, C(O)—(C1-C8)alkyl, C(O)O—(C1-C8)alkyl, C(O)—(C1-C8)haloalkyl, C(O)O—(C1-C8)haloalkyl, C(O)—(C3-C8)cycloalkyl, C(O)O—(C3-C8)cycloalkyl, C(O)—(C2-C8)alkenyl, C(O)O—(C2-C8)alkenyl, (C1-C8)alkyl-O—(C1-C8)alkyl, (C1-C8)alkyl-S(O)n—(C1-C8)alkyl, C(O)—(C1-C8)alkyl-C(O)O—(C1-C8)alkyl, phenyl, and phenoxy;
(M) n is each individually 0, 1, or 2; and
N-oxides, agriculturally acceptable acid addition salts, salts, solvates, esters, crystal polymorphs, isotopes, resolved stereoisomers, and/or tautomers thereof.

US Pat. No. 10,246,451

PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF

Aviara Pharmaceuticals, I...

1. A compound of formula I having a chemical structure of
wherein
R1 and R2 are independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, or arylalkyl;
R3 is hydroxyl or oxido paired with a pharmaceutically acceptable cation;
R4 is hydroxyl, C1-4 alkyoxy, or oxido paired with a pharmaceutically acceptable cation;
R5 is aryl, heteroaryl or arylalkyl which is substituted with one or more of C1-4 alkyl, alkoxy, aryloxy, halogen, haloalkoxy, —CF3, hydroxyl, —OCF3, aryl, —OCF2H, —OCF2CF2H, —O(C3-6 cycloalkyl), —OCH2CF3, thioalkoxy, dialkylamino, C3-6 cycloalkyl, haloalkyl;
X is CH2, O, or CF2;
R6 is C1-4 alkyl, aryl, heteroaryl which is substituted with one or more of C1-4 alkyl, alkoxy, aryloxy, halogen, haloalkoxy, —CF3, hydroxyl, —OCF3, aryl, —OCF2H, —OCF2CF2H, —O(C3-6 cycloalkyl), —OCH2CF3, thioalkoxy, dialkylamino, C3-6 cycloalkyl, haloalkyl; or
a pharmaceutically acceptable salt form or stereoisomer(s) thereof.

US Pat. No. 10,246,450

MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL

RHIZEN PHARMACEUTICALS SA...

1. A method of treating an autoimmune disorder comprising the step of administering to a subject in need thereof an effective amount of a compound of formulaor a pharmaceutically acceptable salt thereof, whereinRing Hy represents
optionally substituted with R??;R1 and R2 are the same or different and are independently selected from CH3, CH2F, CHF2, CF3, substituted or unsubstituted C(3-5)cycloalkyl, CH2—ORa, CH2—NRaRb, CN and COOH with the proviso that:
a) both R1 and R2 at the same time do not represent CF3,
b) both R1 and R2 at the same time do not represent CH3,
c) when R1 is CF3 then R2 is not CH3; and
d) when R1 is CH3 then R2 is not CF3;
Ring Ar represents:

L1 and L2 together represent NH—C(?O)—;
A is absent;
R?? is selected from hydrogen, hydroxy, cyano, halogen, —ORa, —COORa, —S(?O)q—Ra, —NRaRb, C(?X)—Ra, substituted or unsubstituted C(1-6) alkyl group, substituted or unsubstituted C(1-6) alkenyl, substituted or unsubstituted C(1-6) alkynyl, and substituted or unsubstituted C(3-5)cycloalkyl;
each occurrence of X is independently selected from O, S and —NRa;
Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, monocyclic substituted or unsubstituted aryl; and substituted or unsubstituted pyridyl;
each occurrence of Ra and Rb are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —ORc, —S(?O)q—Rc, —NRcRd, —C(?Y)—Rc, —CRcRd—C(?Y)—Rc, —CRcRd—Y—CRcRd—, —C(?Y)—NRcRd—, —NRRd—C(?Y)—NRcRd—, —S(?O)q—NRcRd—, —NRcRd—S(?O)q—NRcRd—, —NRcRd—NRcRd—, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when Ra and Rb are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NRc and S;
each occurrence of Rc and Rd may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two Rc and/or Rd substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;
each occurrence of Y is selected from O, S and —NRa; and
each occurrence of q independently represents 0, 1 or 2;
wherein the autoimmune disorder is chronic obstructive pulmonary disease, inflammatory bowel disease, allergic rhinitis, multiple sclerosis, psoriasis, Crohn's disease, colitis, ulcerative colitis, arthritis, bone diseases associated with increased bone resorption, or chronic obstructive airway disease.

US Pat. No. 10,246,449

1,2,3 TRIAZOLE-THIAZOLE COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF

1. A 1,2,3 triazole-thiazole compound of formula (I);
wherein;
R is independently selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl and alkoxyalkyl;
n is 1, 2 or 3; and
X is a halogen;
or pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,448

4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS

1. A compound of formula (I):
whereinR1 is an unsubstituted or substituted 5, 6 or 7-membered, aliphatic or aromatic heterocycle group having 1, 2, 3 or 4 heteroatoms selected from the group consisting of N, O and S; andR2 is selected from the group consisting of hydrogen, C1-C2 alkyl, F, Cl and OH;or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,447

3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS

GlaxoSmithKline Intellect...

1. A compound of Formula (I):
wherein:
R1 is heteroaryl optionally substituted by methyl, ethyl, or halo; and
R2 is H, methyl or ethyl;
wherein:
heteroaryl as defined for R1 is selected from the group consisting of oxazolyl, pyridinyl, pyrimidinyl, pyridazinyl and imidazolyl,
wherein:
the oxazolyl, pyridinyl, pyrimidinyl, and pyridazinyl, respectively, is optionally substituted by methyl, ethyl, chloro or fluoro; or
a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,446

BLOCKERS OF THE GROWTH HORMONE RECEPTOR IN DISEASE PREVENTION AND TREATMENT

University of Southern Ca...

1. A compound having formula I:
or a pharmaceutically acceptable salt thereof;wherein:R1 is NO2, SO3H, NH2, or halogen, and
R2 is hydrogen, NO2, SO3H, NH2, or C1-8 alkyl, or halogen.

US Pat. No. 10,246,445

METHOD FOR PRODUCING BENZOXAZOLE COMPOUND

SUMITOMO CHEMICAL COMPANY...

1. A method for preparing a compound represented by formula (3):
wherein n is 1, 2, 3, or 4,
which comprises mixing a compound represented by formula (2)

tri(C1-C3 alkyl)silyl(C1-C4 perfluoroalkane), and a fluoride.

US Pat. No. 10,246,444

1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS

SABILA BIOSCIENCES LLC, ...

1. A compound having formula (I):
including enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, wherein:
A is selected from the group consisting of
with the proviso that when A isthen Y cannot be N and X2 cannot be H when Y is N;Z1 is selected from the group consisting of S, SO, and SO2;
Z2 is selected from the group consisting of S, SO, and SO2;
Z3 is selected from the group consisting of SH, SCOR1, SO2R2, and SO3H;
Z4 is selected from the group consisting of SH, SCOR1, SO2R2, and SO3H;
n=0, 1, 2, 3, 4;
W is selected from the group consisting of CO and SO2;
X1 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, and, optionally substituted C1-6 alkoxy;
X2 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, OR3,
and the C2-6 sugar alcohols such as ethylene glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, galacitol frucitol, iditol, inositol, and sorbitol;Y is selected from the group consisting of N and C—CN;
R is at each occurrence independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, halogen, C1-6 haloalkyl, C3-7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, alkoxyheteroarylalkyl,

R1a is at each occurrence independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, and C1-6 alkoxy;
R1 is at each occurrence independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, and optionally substituted C1-6 alkoxy;
R2 is at each occurrence independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, and optionally substituted C1-6 alkoxy;
R3 is an optionally substituted C1-6 alkyl;
R4 is at each occurrence independently selected from the group consisting of hydrogen, OH, and OR5;
q=0, 1, 2, 3, 4, or 5;
R5 is at each occurrence an optionally substituted C1-6 alkyl;
two R5 substituents can be joined together with the atoms to which they are bound to form a 5 to 6 membered ring.

US Pat. No. 10,246,443

CYANOQUINOLINE DERIVATIVES

TIANJIN HEMAY ONCOLOGY PH...

1. A method for treating tumor in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula I, a stereoisomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected from the group consisting of substituted or unsubstituted alkenylacylamino and substituted or unsubstituted alkynylacylamino;
R2 and R3 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; wherein R2 and R3 are not both hydrogen;
or R2 and R3 together with nitrogen atom to which they are attached form substituted or unsubstituted heterocyclyl; and
R4 is substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl;
wherein the tumor is selected from the group consisting of sarcoma; sinus tumor; urogenital system cancer; esophageal cancer; liver cancer; kidney cancer; endocrine cancer; skin cancer; melanoma; and brain or central nervous system cancer.

US Pat. No. 10,246,442

4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS

JANSSEN PHARMACEUTICA NV,...

1. A compound of the formula (I):wherein:n is 1 or 2;
each R1 is a member independently selected from the group consisting of bromo, fluoro, cyclohexyl, cyclohexyloxy, phenyl, 2-methylphenyl, benzyl, phenoxy, 4-chlorophenoxy, 2,6-dimethyl-phenoxy, piperidinyl, and (2,6-dimethylbenzyl)amino;
R2 is a member selected from the group consisting of —H, cyclopropyl, 2,6-dimethylbenzyl, and —C1-4alkyl;
R3 is a member selected from the group consisting of —H, —C1-4alkyl optionally substituted with —OCH3 or —N(C1-4alkyl)2, cyano, —SO2CH3, tetrahydropyran, —(CH2)mC3-8cycloalkyl, and —(CH2)mphenyl optionally substituted with one or more halo; or —C1-4alkyl; wherein
m is 0-1; or
R2 and R3 can be taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine, 4-methyl-1,4-diazepane, thiomorpholine, 4-hydroxypiperidine, morpholine, 4-acetamidopiperidine, 4-cyanopiperidine, 4-fluoropiperidine, azepane, or 4-isopropylpiperidine;
or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,441

AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT

IDEMITSU KOSAN CO., LTD.,...

1. An organic electroluminescence device, comprising:a cathode:
an anode; and
an organic thin-film layer interposed between the cathode and the anode, wherein the organic thin-film layer comprises a light emitting layer and at least one selected from the group consisting of a hole transporting layer and a hole injecting layer, and
wherein at least one selected from the group consisting of the hole transporting layer and the hole injecting layer comprises an aromatic amine derivative represented by formula (9):

wherein:
at least one of Ar3 to Ar5 represents the substituent A and at least one of Ar3 to Ar5 represents the substituent B;
a group out of Ar3 to Ar5 except the substituent A and the substituent B represents a substituted or unsubstituted aryl group having 6 to 25 ring carbon atoms or a substituted or unsubstituted heteroaryl group having 5 to 25 ring carbon atoms, wherein an optional substituent of the aryl group and the heteroaryl group is a linear or branched alkyl group having 1 to 15 carbon atoms, a cycloalkyl group having 3 to 15 ring carbon atoms, a trialkylsilyl group having linear or branched alkyl groups each having 1 to 15 carbon atoms, a triarylsilyl group having aryl groups each having 6 to 25 ring carbon atoms, an alkylarylsilyl group having a linear or branched alkyl group having 1 to 15 carbon atoms and an aryl group having 6 to 25 ring carbon atoms, an aryl group having 6 to 25 ring carbon atoms, a halogen atom, or a cyano group:
the substituent A is represented by formula (1);
the substituent B is represented by formula (2);

wherein:
L1 and L2 each represent a substituted or unsubstituted arylene group having 6 to 25 ring carbon atoms, and a substituent which L1 and L2 may have is a linear or branched alkyl group having 1 to 15 carbon atoms, a cycloalkyl group having 3 to 15 ring carbon atoms, a trialkylsilyl group having linear or branched alkyl groups each having 1 to 15 carbon atoms, a triarylsilyl group having aryl groups each having 6 to 25 ring carbon atoms, an alkylarylsilyl group having a linear or branched alkyl group having 1 to 15 carbon atoms and an aryl group having 6 to 25 ring carbon atoms, an aryl group having 6 to 25 ring carbon atoms, a halogen atom, or a cyano group;
Ar1 represents a substituted or unsubstituted aryl group having 6 to 25 ring carbon atoms, and a substituent which Ar1 may have is selected from the group consisting of a linear or branched alkyl group having 1 to 15 carbon atoms, a cycloalkyl group having 3 to 15 ring carbon atoms, a trialkylsilyl group having linear or branched alkyl groups each having 1 to 15 carbon atoms, a triarylsilyl group having aryl groups each having 6 to 25 ring carbon atoms, an alkylarylsilyl group having a linear or branched alkyl group having 1 to 15 carbon atoms and an aryl group having 6 to 25 ring carbon atoms, an aryl group having 6 to 25 ring carbon atoms, a halogen atom, and a cyano group;
a represents an integer of 0 to 3, and b, c, and d each independently represent an integer of 0 to 4; and
R1 to R4 each independently represent a linear or branched alkyl group having 1 to 15 carbon atoms, a cycloalkyl group having 3 to 15 ring carbon atoms, a trialkylsilyl group having linear or branched alkyl groups each having 1 to 15 carbon atoms, a triarylsilyl group having aryl groups each having 6 to 25 ring carbon atoms, an alkylarylsilyl group having a linear or branched alkyl group having 1 to 15 carbon atoms and an aryl group having 6 to 25 ring carbon atoms, an aryl group having 6 to 25 ring carbon atoms, a halogen atom, or a cyano group, and a plurality of R1's to R4's adjacent to each other may be bonded to each other to form a saturated or unsaturated, divalent group that forms a ring.

US Pat. No. 10,246,440

INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR ? (T))

1. A method of treating acne, atopic dermatitis and/or psoriasis comprising administering a pharmaceutical composition comprising at least one compound of formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof and/or a solvate thereof:
wherein in formula (I):
L represents a single bond or a methylene group CH2,
X represents a cyclic radical chosen from the radicals X1 and X2 below:

one or two of the elements Y1, Y2, Y3, Y4 and Y5 represent(s) a nitrogen atom and the other elements correspond to a group —CR2, or each of the elements Y1, Y2, Y3, Y4 and Y5 corresponds to a group —CR2,
each of the elements Q1, Q2 and Q3 corresponds to an identical or different —CR2a group,
R1 represents a linear or branched C3-C5 alkyl radical, optionally substituted with a hydroxyl group and/or a halogen atom, a C3-C5 cycloalkyl radical, a linear or branched C2-C5 alkenyl radical, a —CH2—(C3-C5)cycloalkyl radical, a C4-C5 heterocycloalkyl radical, a —CH2—(C4-C5)heterocycloalkyl radical,
R2 represents a hydrogen atom or a halogen atom, a linear or branched C1-C5 alkyl radical, a linear or branched C2-C4 alkenyl radical, a C1-C4 alkoxy radical, a cyano group —CN, a radical —C(?O)R?2 with R?2 denoting a C1-C3 alkoxy radical, a —CF3 radical; said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms,
R2a represents a hydrogen atom or a halogen atom, a linear or branched C1-C5 alkyl radical, a linear or branched C2-C4 alkenyl radical, a C1-C4 alkoxy radical, a —CN group, a hydroxyl group —OH, a group —CH(R3a)OH, a carboxylic group —COOH, a carbamoyl group —CONR2cR2d, an amido group —NR2cCOR2d, a group —SO2R2c, a group —SOR2c, a group —S(?O)(?NH—R2c), said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms,
R2c and R2d, which are identical or different, represent a hydrogen atom or a linear or branched C1-C5 alkyl radical;
R3a represents a hydrogen atom or a linear or branched C1-C5 alkyl radical,
R3 represents a hydrogen atom, a halogen atom, a group (CHR6)n—(Z)o—(CHR?6)p—R7 or a group CH?R7,
n, o and p, which are identical or different, represent zero or a natural integer ranging from 1 to 3,
Z represents a divalent group selected from the group consisting of a methylene group —CH2—, an amino group —NH— and an oxygen atom —O—,
R6 and R?6, which are identical or different, represent a hydrogen atom, a methyl group —CH3, a group —OH, a hydroxymethyl group, or a carboxylic function-COOH,
R7 represents:
a hydrogen or a halogen atom,
a group COOR?7 with R?7 denoting (C1)alkyl(C6)heterocycle,
a heterocycloalkyl radical, wherein the heterocycloalkyl radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups, one or more —OH groups, one or more carbonyl functions, one or more linear or branched C1-C4 hydroxyalkyl groups, one or more amino groups, one or more groups —C(?O)R7a, one or more groups S(?O)2R7a; R7a representing a linear or branched C1-C3 alkyl radical, a linear or branched C1-C3 alkoxy radical, or an amino radical N(R8a)(R8b),
a C3-C6 cycloalkyl radical, wherein the cycloalkyl radical is optionally substituted with one or more methyl radicals, one or more halogen atoms, a cyano group —CN or one or more groups —COR13; R13 denoting a linear or branched C1-C3 alkoxy radical, or a hydroxyl group,
an aromatic radical, wherein the aromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups optionally substituted with one or more halogen atoms, one or more C1-C3 alkoxy groups, one or more amino groups —NR11R12, one or more groups —COR11, one or more groups —COOR11, one or more amido groups —CONR11R12, one or more groups —SOR11, one or more groups —SO2R11, one or more groups —NHCOR11, one or more groups —NHCOOR11, one or more groups —SO2NR11R12 or one or more —CN groups; R11 and R12, which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms;
a heteroaromatic radical, wherein the heteroaromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C1-C3 alkyl groups optionally substituted with one or more halogen atoms, one or more C1-C3 alkoxy groups, one or more amino groups —NR11R12, one or more groups —COR11, one or more groups —COOR11, one or more amido groups —CONR11R12, one or more groups —SOR11, one or more groups —SO2R11, one or more groups —NHCOR11, one or more groups —NHCOOR11, one or more groups —SO2NR11R12 or one or more —CN groups; R11 and R12, which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms;
R5 represents a hydrogen atom or a halogen atom, a linear or branched C1-C3 alkyl radical optionally substituted with one or more halogen atoms; an amino radical —NH2, a C4-C5 heterocyclic radical, an OCH2—(C4-C5) heterocyclic radical, a radical CH2R?7a with R?7a denoting a methoxy radical, a hydroxyl group —OH, a —CH2COOH group, a group —CH(R5b)OH, a carboxylic group —COOH, a —CN group, a thioxo function,
R5b represents a hydrogen atom, a linear or branched C1-C3 alkyl radical optionally substituted with one or more carboxylic functions; a cyclopropyl radical,
R8a and R8b, which are identical or different, denote a hydrogen atom, a linear or branched C1-C3 alkyl radical or a cyclopropyl radical; and
wherein the compound of formula (I) inhibit activity of a ROR?t receptor.

US Pat. No. 10,246,439

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF

ENANTA PHARMACEUTICALS, I...

1. A compound represented by Formula I, or a pharmaceutically acceptable salt thereof:wherein;X1 and X2 are independently C(R8) or N;
X3 is C(R9) or N, in which R9 is selected from the group consisting of hydrogen, optionally substituted —C1-C8 alkyl, optionally substituted —C1-C8 alkoxy or halo;
X4 is S, O, or N(R10);
R1 is selected from

wherein R4 is selected from the group consisting of:
1) Hydrogen;
2) Substituted or unsubstituted —C1-C8 alkyl;
3) Substituted or unsubstituted —C2-C8 alkenyl;
4) Substituted or unsubstituted —C2-C8 alkynyl;
5) Substituted or unsubstituted —C3-C8 cycloalkyl;
6) Substituted or unsubstituted aryl;
7) Substituted or unsubstituted arylalkyl;
8) Substituted or unsubstituted 3- to 8-membered heterocycloalkyl;
9) Substituted or unsubstituted heteroaryl; and
10) Substituted or unsubstituted heteroarylalkyl;
R2, R3, R5 and R8 are each independently selected from the group consisting of:
1) Hydrogen;
2) Halogen;
3) —NO2;
4) Cyano;
5) Substituted or unsubstituted —C1-C8 alkyl;
6) Substituted or unsubstituted —C2-C8 alkenyl;
7) Substituted or unsubstituted —C2-C8 alkynyl;
8) Substituted or unsubstituted —C3-C8 cycloalkyl;
9) Substituted or unsubstituted aryl;
10) Substituted or unsubstituted arylalkyl;
11) Substituted or unsubstituted 3- to 8-membered heterocycloalkyl;
12) Substituted or unsubstituted 3- to 8-membered heterocycloalkyl-alkyl;
13) Substituted or unsubstituted heteroaryl;
14) Substituted or unsubstituted heteroarylalkyl;
15) —N(R6)(R7);
16) —S(O)2N(R6)(R7);
17) —N(R6) C(O)R7;
18) —N(R6) S(O)2R6; and
9) —OR6;
R6 and R7 are independently selected from the group consisting of hydrogen, —C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein each —C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with 1-3 substituents independently selected from halo, alkyl, cycloalkyl, alkylamino, dialkylamino, alkylC(O)NH—, arylC(O)NH—, heteroarylC(O)NH—, —CN, alkoxy, —CF3, aryl, and heteroaryl; alternatively, R6 and R7 are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocycloalkyl group; and
R10 is selected from the group consisting of hydrogen, —C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein each —C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with 1-3 substituents independently selected from halo, alkyl, cycloalkyl, alkylamino, dialkylamino, alkylC(O)NH—, arylC(O)NH—, heteroarylC(O)NH—, —CN, alkoxy, —CF3, aryl, and heteroaryl.

US Pat. No. 10,246,438

NON-SELECTIVE KINASE INHIBITORS

PULMOKINE, INC, Renssela...

1. A method of reducing phosphorylation of an extracellular signal-regulated kinase (ERK), the method comprising administering to a subject a therapeutically-effective amount of a compound of the formula:or a pharmaceutically-acceptable salt thereof.

US Pat. No. 10,246,437

CRYSTAL FORM OF NERATINIB MALEATE AND PREPARATION METHOD THEREFOR

Crystal Pharmatech Co., L...

1. A maleate crystalline Form C of the compound of Formula (I), wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 10.9±0.2°, 15.2°±0.2° and 23.5°±0.2°

US Pat. No. 10,246,436

6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME

TREVENA, INC., King of P...

1. A compound having the formula of:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,246,435

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

FORMA Therapeutics, Inc.,...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X1 is C, S, or S(O);
Y1 is N or CH;
Y2 is N or CR5;
Y3 is N or CR6;
Y4 is N or CR7;
R1 is —OH;
R2 is (C1-C6) alkyl, or (C6-C14) aryl, wherein the alkyl or aryl are optionally substituted with one to three R8;
R4 and R4? are independently H;
R5 is H;
R6 is H, (C1-C6) alkyl, (C1-C6) alkoxy, halogen, —NH2, —NHC(O)(C1-C6) alkyl, (C6-C14) aryl, wherein the alkyl or aryl are optionally substituted with one to three R13;
R7 is H, (C1-C6) alkyl, (C6-C14) aryl, or —O—(C6-C14) aryl, wherein the alkyl or aryl are optionally substituted with one to three R14;
each R8 is independently (C1-C6) alkyl, halogen, or (C0-C4)-alkylene-(C6-C14) aryl, wherein the alkyl or aryl are optionally substituted with one to three R9;
or two R8 together when on adjacent atoms form a (C3-C8) cycloalkyl optionally substituted with one to three R9;
each R9 is independently (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —(C0-C3)-alkylene-(C6-C14) aryl, wherein alkyl or aryl are optionally substituted with one to three R19;
each R13 is independently (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, CN, —OH, —NH2, (C1-C6) alkylamino, di(C1-C6) alkylamino, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl and heterocycloalkyl are optionally substituted with one to three R15;
each R14 is independently (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, CN, —OH, —NH2, —C(O)(C1-C6) alkyl, —S(O)q(C1-C6) alkyl, (C1-C6) alkylamino, or di(C1-C6) alkylamino;
each R15 is independently (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —C(O)(C1-C6) alkyl, —S(O)q(C1-C6) alkyl, —NH2, (C1-C6) alkylamino, di(C1-C6) alkylamino, —OH, or CN;
each R19 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, or CN;
m is 0;
n is 1;
q is independently at each occurrence 0, 1, or 2; and
provided that
(a) when R2 is optionally substituted (C1-C6) alkyl, R5 is H; and R7 is H; then R6 is not chloro;
(b) R5, R6, and R7 are not all simultaneously H; and
(c) the compound is further characterized by any one or more of the following:
i. at least one of Y1, Y2, Y3, or Y4 is N;
ii. at least one of R6 or R7 is an optionally substituted (C6-C14) aryl;
iii. R6 is (C1-C6) alkyl, —NHC(O)(C1-C6) alkyl, (C6-C14) aryl, wherein the alkyl or aryl of R6 is substituted with a R13 that is (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, CN, —OH, —NH2, (C1-C6) alkylamino, or di(C1-C6) alkylamino;
iv. R6 is (C1-C6) alkyl, —NHC(O)(C1-C6) alkyl, (C6-C14) aryl, wherein the alkyl or aryl of R6 is substituted with a R13 that is (C1-C6) alkyl or a 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the heterocycloalkyl is substituted with one to three R15; or
v. R7 is H, (C1-C6) alkyl, (C6-C14) aryl, or —O—(C6-C14) aryl, wherein the alkyl or aryl of R7 is substituted with a R14 that is (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, CN, —OH, —NH2—, —C(O)(C1-C6) alkyl, —S(O)q(C1-C6) alkyl, (C1-C6) alkylamino, or di(C1-C6) alkylamino.

US Pat. No. 10,246,434

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

FORMA Therapeutics, Inc.,...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein
X1 is C;
Y1 is N or CH;
Y2 iS N or CR5;
Y3 is N or CR6;
Y4 is CR7;
R1 is —OH;
R2 is (C1-C6) alkyl, (C6-C14) aryl, (C3-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R8;
R4 and R4? are H;
R5 is H;
R6 is H;
R7 is (C1-C6) alkyl or (C6-C14) aryl, wherein the alkyl and aryl are optionally substituted with one or more R14;
each R8 is independently (C1-C6) alkyl, halogen, —(C0-C4)-alkylene-aryl, —(C0-C4)-alkylene-heteroaryl, —(C0-C4)-alkylene-O-heteroaryl, or —C(O)R21, wherein the alkyl, alkylene, aryl, and heteroaryl are optionally substituted with one or more R9;
each R9 is independently (C1-C6) alkyl, halogen, or —NR23S(O)qR24;
each R14 is independently halogen, (C6-C14) aryl, or —O—(C3-C8)cycloalkyl, wherein in the aryl and cycloalkyl are optionally substituted with one or more R16;
each R16 is halogen;
each R21 is (C2-C6) alkenyl;
each R23 and R24 is independently H or (C2-C6) alkenyl;
m is 0;
n is 1; and
q is 2.

US Pat. No. 10,246,433

ARYL AND HETEROARYL FUSED LACTAMS

Pfizer Inc., New York, N...

1. A compound of formula (II-A):
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is C1-C4 alkyl or halo;
R2 is 5-12 membered heteroaryl, where said 5-12 membered heteroaryl is optionally substituted by 1 to 3 R32 groups;
R3 is H;
R4 is H or halo;
m is 0;
R5 is absent;
each R32 is independently selected from the group consisting of —Cl, —F, —OH, —CH3, —CH2CH3, —CF3, —CH2OH, —CH2OCH3, —OCH3, —OC2H5, —OCF3, —CN, —C(O)NH2, —C(O)NHCH3, —C(O)N(CH3)2, —NHC(O)CH3, —NH2, —NHCH3, —N(CH3)2, cyclopropyl, 4-6 membered heterocyclyl, phenyl and 5-6 membered heteroaryl, where said 4-6 membered heterocyclyl, phenyl or 5-6 membered heteroaryl are optionally substituted by 1 to 3 halo, C1-C4 alkyl or C1-C4 alkoxy, which are independently selected;
X and Z are independently C1-C4 alkyl; and
Y is H.

US Pat. No. 10,246,432

4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS

Heptares Therapeutics Lim...

1. A method for the treatment of a disorder, comprising administering an effective amount of a compound to a subject in need thereof, wherein the compound is selected from the group consisting of the compounds represented by the following formulae:
or a pharmaceutically acceptable salt thereof, wherein
R1 is halogen, optionally substituted C1-C3 alkyl, cyclopropyl, optionally substituted C1-C3 alkoxy, cyano, hydroxyl, nitro or NH2;
R2 is H or F;
R3 is H, halogen, optionally substituted C1-C3 alkyl, optionally substituted C1-C3 alkoxy or cyano;
R4 is H, halogen, optionally substituted C1-C3 alkyl, optionally substituted C1-C3 alkoxy, or cyano; and
n is 0-3,
wherein the disorder is migraine, dystonia, depression, anxiety or amyotrophic lateral sclerosis (ALS).

US Pat. No. 10,246,430

METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES

Lung Biotechnology PBC, ...

1. A method of preparing a compound represented by the structural Formula (I):
and salts thereof; comprising:
(a) reacting a substituted halophenol with 6-oxabicyclo[3.1.0]hex-2-ene in presence of a palladium catalyst to form an ether compound represented by structural Formula (III):

(b) acetylating the ether compound of Formula (III) to form a compound of Formula (IV)

(c) allylating the compound of Formula (IV) with allyltributylstannane in presence of AIBN to form the allylation product (V)

(d) subjecting the terminal alkene compound of Formula (V) to intermolecular allylic acetoxylation to form a compound of Formula (VI)

(e) subjecting the compound of Formula (VI) to dihydroxylation to form a compound of Formula (VII)

(f) subjecting the dihydroxy compound (VII) to oxidation to form an aldehyde compound of Formula (VIII)

(g) reducing the aldehyde compound of Formula (VIII) and removing the acetyl group to provide the diol compound of Formula (IX); and

(h) converting the diol of Formula (IX) to a protected aldehyde of Formula (VIIIA); and

(i) reacting the protected aldehyde of Formula (VIIIA) with a phosphonate of Formula (X) to obtain a compound of Formula (I)
wherein:X is F, Cl, Br or I;
R1 is an alkyl, cycloalkyl or TBDMS;
R2 is independently H or an alcohol protecting group;
R3 is a straight or branched alkyl group having 1-4 carbon atoms; and
R6 is an alcohol protecting group.

US Pat. No. 10,246,429

VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

AMGEN INC., Thousand Oak...

1. A compound of Formula Ior a stereoisomer, tautomer, hydrate, solvate or a pharmaceutically acceptable salt thereof, whereinA4 is CR4 or N;
A5 is CR5 or N;
A6 is CR6 or N;
A7 is CR7 or N, provided that no more than two of A4, A5, A6, and A7 are N;
each of Ra and Rb, independently, is H, F, Cl, C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, CN, —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl or —C(O)C1-6-alkyl, wherein each of the C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, and C1-6-alkyl portion of —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl, and —C(O)C1-6-alkyl are optionally substituted with 1-4 substituents independently selected from F, oxo, or OH;
R1 is H, F, Cl, C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, CN, —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl, —C(O)NH2, —CH?CHC(O)NH2, —CH?CHC(O)NHC1-6-alkyl, —CH?CHC(O)N(C1-6-alkyl)2, —CH?CHC(O)NHC1-6-alkyl-OC1-6-alkyl, —CH?CHC(O)-heterocyclyl, —CH?C(CH3)C(O)-heterocyclyl, —CH?CHC(O)2H, —CH?CHC(O)OC1-6-alkyl, —CH?CHCH2OH, C1-6-alkyl-C(O)NHC1-6-alkyl, C1-6-alkyl-C(O)N(C1-6-alkyl)2, —C(O)C1-6-alkyl, —C(O)C2-6-alkenyl, —C(O)OH, —C(O)OC1-6-alkyl, —C(O)NHC1-6-alkyl, —C(O)N(C1-6-alkyl)2, —C(O)NHC3-6-cycloalkyl, —C(O)NH-aryl, —C(O)NH-heterocyclyl, —C(O)NHOC1-6-alkyl, —C(O)N(C1-6-alkyl)OC1-6-alkyl, —C(O)-heterocyclyl, —CH2-heteroaryl, or heteroaryl, wherein the heterocyclyl groups of the —CH?CHC(O)-heterocyclyl, —CH?C(CH3)C(O)-heterocyclyl, —C(O)— heterocyclyl, and —C(O)NH-heterocyclyl groups are fully or partially saturated 3-, 4-, 5-, or 7-membered monocyclic rings or 6-, 7-, 8-, 9-, or 10-membered bicyclic rings that include 1 heteroatom selected from N, O, or S if the ring is a 3-membered ring, that include 1 or 2 heteroatoms independently selected from N, O, or S if the ring is a 4- or 5-membered ring, and include 1, 2, or 3 heteroatoms independently selected from N, O, or S if the ring is a 6-, 7-, 8-, 9-, or 10-membered ring, wherein the heteroaryl groups of the —CH2-heteroaryl and heteroaryl groups is a 5- or 6-membered ring that includes 1, 2, 3, or 4 heteroatoms independently selected from N, O, or S, wherein the aryl group of the —C(O)NH-aryl group is a phenyl or naphthyl group, wherein each of the C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, and C1-6-alkyl and C2-6-alkenyl portions of —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl, C(O)C1-6-alkyl, —C(O)C2-6-alkenyl, —CH?CHC(O)NHC1-6-alkyl, —C(O)NHC1-6-alkyl, —C(O)N(C1-6-alkyl)2, and C1-6-alkyl-C(O)NHC1-6-alkyl groups is optionally substituted with 1-4 substituents independently selected from F, CN, oxo, or OH, and further wherein each of the heterocyclyl groups of the —CH?CHC(O)-heterocyclyl, —CH?C(CH3)C(O)-heterocyclyl, —C(O)heterocyclyl, and —C(O)NH-heterocyclyl groups is optionally substituted with 1-4 substituents independently selected from methyl, F, OH, oxo, —CN, OCH3, —CH2OC1-6-alkyl, —C(O)C1-6-alkyl, —C(O)OC1-6-alkyl, —CH2OH, —NH2, —NHC1-6-alkyl, —N(C1-6-alkyl)2, —CF3, phenyl, or —CH2—C3-6-cycloalkyl and further wherein each of the heteroaryl groups of the —CH2-heteroaryl and heteroaryl groups and the aryl group of the —C(O)NH-aryl group is optionally substituted with 1-3 substituents independently selected from halo, methyl, or OH;
R2 is H, F, Cl, C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, CN, —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl, —C(O)NH2, —CH?CHC(O)NHC1-6-alkyl, —CH?CHC(O)2H, —CH?CHCH2OH, C1-6-alkyl-C(O)NHC1-6-alkyl, —C(O)C1-6-alkyl, or —C(O)C2-6-alkenyl, wherein each of the C1-6-alkyl, C2-4-alkenyl, C2-4-alkynyl, and C1-6-alkyl and C2-6-alkenyl portion of —CH2OC1-6-alkyl, —OC1-6-alkyl, —S(O)oC1-6-alkyl, —NHC1-6-alkyl, C(O)C1-6-alkyl, —C(O)C2-6-alkenyl, —CH?CHC(O)NHC1-6-alkyl, and C1-6-alkyl-C(O)NHC1-6-alkyl, is optionally substituted with 1-4 substituents independently selected from F, CN, oxo, or OH;
R3 is C1-4-alkyl, CH2OC1-4-alkyl, CH2OH, C1-4haloalkyl or cyclopropyl, wherein each of the C1-4-alkyl, CH2OC1-4-alkyl, C1-4-haloalkyl, and cyclopropyl is optionally substituted with 1-4 F atoms;
each of R4, R5, R6 and R7, independently, is H, halo, haloalkyl, haloalkoxyl, C1-4-alkyl, CN, OH, OC1-4-alkyl, S(O)oC1-4-alkyl, NHC1-4-alkyl, C(O)C1-4-alkyl, C(O)OC1-4-alkyl, or CH2OH;
R8 is selected from H, F, Cl, or C1-3-alkyl;
one of R9 and R10 is selected from F or H and the other of R9 and R10 is a fully or partially unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, or 10-membered bicyclic ring formed of carbon atoms, said ring optionally including 1-4 heteroatoms if monocyclic or 1-5 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, wherein the ring is optionally substituted, independently, with 1-5 substituents of R11;
each R11, independently, is H, halo, haloalkyl, CN, OH, NO2, NH2, SF5, acetyl, —C(O)NHC1-6-alkyl, —OCH2C(O)NHC1-6-alkyl, —OCH2C(O)N(C1-6-alkyl)2, —OCH2CH2-pyrrolidinonyl, oxo, cyclopropylmethoxy, 2-propynyloxy, 2-butynyloxy, 2-pentyloxy, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, C1-6-alkylamino-, C1-6-dialkylamino-, C1-6-alkoxyl, C1-6-thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolyl, pyrrolidinyl, piperazinyl, oxetan-3-yl, imidazo-pyridinyl, dioxolyl, or —OCH2-heteroaryl, wherein the heteroaryl group of the —OCH2-heteroaryl group is a 5- or 6-membered ring that includes 1, 2, 3, or 4 heteroatoms selected from N, O, or S, and further wherein each of the cyclopropylmethoxy, 2-propynyloxy, 2-butynyloxy, 2-pentyloxy, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, C1-6-alkylamino-, C1-6-dialkylamino-, C1-6-alkoxyl, C1-6-thioalkoxyl, morpholinyl, pyrazolyl, isoxazolyl, dihydropyranyl, pyrrolidinyl, oxetan-3-yl, dioxolyl, or —OCH2-heteroaryl is optionally substituted independently with 1-5 substituents of F, Cl, Br, CN, NO2, NH2, OH, oxo, CF3, CHF2, CH2F, methyl, methoxy, ethyl, ethoxy, CH2CF3, CH2CHF2, propyl, propoxy, isopropyl, isopropoxy, cyclopropyl, butyl, butoxyl, cyclobutyl, isobutoxy, tert-butoxy, isobutyl, sec-butyl, tert-butyl, trimethylsilyl, cyclopentyl, cyclohexyl, C1-3alkylamino-, C1-3dialkylamino, C1-3thioalkoxyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, thienyl, furyl, pyrrolyl, tetrahydropyranyl, pyrrolidinyl, or oxetan-3yl; and
the subscript o is selected from 0, 1, or 2.

US Pat. No. 10,246,426

TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS

IDORSIA PHARMACEUTICALS L...

1. A compound of formula (I)
wherein
X represents a ring carbon or a ring nitrogen atom;
R1 represents
(C2-6)alkyl;
(C2-4)alkyl mono-substituted with cyano, or (C1-3)alkoxy;
(C1-4)fluoroalkyl;
(C1-3)fluoroalkoxy;
pentafluoro-sulfanyl;
(C3-6)cycloalkyl-L1- wherein
said (C3-6)cycloalkyl optionally contains one ring oxygen atom; wherein said (C3-6)cycloalkyl is unsubstituted; or mono-substituted with fluoro, (C1-3)alkyl, (C1-3)alkoxy, hydroxy, cyano, or (C1-3)fluoroalkyl; or di-substituted with fluoro, or tri-substituted with two fluoro substituents and a (C1-3)alkyl substituent; and
the linker L1 represents a direct bond, (C1-2)alkylene, oxygen, or (C1-2)alkylene-oxy;
5- or 6-membered heteroaryl, independently optionally mono-substituted with (C1-3)alkyl;
—NR11R12, wherein
R11 and R12 independently represent hydrogen, (C1-3)alkyl, (C2-3)fluoroalkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl mono- or di-substituted with fluoro, (C3-6)cycloalkyl-(C1-3)alkyl, (C1-3)alkoxy-(C2-3)alkyl;
or R11 and R12, together with the nitrogen atom to which they are attached to, form a 4- to -6 membered ring which is optionally mono- or di-substituted with fluoro; a 2-oxo-pyrrolidinyl group; or a morpholinyl group;
and (R4)n represents one or two optional substituents independently selected from (C1-4)alkyl, (C1-4)alkoxy, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, halogen, and cyano;
or R1 together with (R4)n forms a non-aromatic 5- or 6-membered ring which is fused to the phenyl/pyridine ring; wherein said 5- or 6-membered ring optionally contains one or two heteroatoms independently selected from oxygen and nitrogen; wherein said fused 5- or 6-membered non-aromatic ring independently is optionally further mono-substituted with oxo; or di-, tri-, or tetra-substituted wherein one substituent is oxo and the remaining are (C1-3)alkyl;
or R1 together with (R4)n forms an aromatic 5- or 6-membered ring which is fused to the phenyl/pyridine ring; wherein said 5- or 6-membered ring optionally contains one or two nitrogen atoms, wherein said fused 5- or 6-membered aromatic ring independently is optionally further mono- or di-substituted wherein the substituents are independently selected from (C1-4)alkyl, (C3-6)cycloalkyl, (C1)fluoroalkyl, or cyano;
Y represents a ring carbon or a ring nitrogen atom; and
R2 represents (C1-4)alkyl; (C3-6)cycloalkyl; (C1-4)alkoxy; (C3-6)cycloalkyl-oxy; (C1-3)fluoroalkyl; (C1-3)fluoroalkoxy; (C1-3)alkoxy-(C2-3)alkoxy; halogen; cyano; or —NR21R22, wherein R21 and R22 independently represent hydrogen, or (C1-3)alkyl, or R21 and R22, together with the nitrogen atom to which they are attached to, form a 4- to -6 membered ring optionally mono- or di-substituted with fluoro, or a morpholinyl group;
and
(R5)m represents one or two optional substituents independently selected from (C1-4)alkyl; (C3-6)cycloalkyl; (C1-4)alkoxy; halogen; cyano; (C1-3)fluoroalkyl; and (C1-3)fluoroalkoxy;
or a salt of such a compound.

US Pat. No. 10,246,425

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE COMPOUNDS

Parion Sciences, Inc., D...

1. A method for blocking sodium channels in a subject or a cell comprising administering to the subject or cell a compound of the formula:or a pharmaceutically acceptable salt thereof, wherein:Ar is a moiety selected from the group of:

X is selected from —CH2—, —O—, and —S—;
R1 and R2 are independently selected from H and C1-C6 alkyl; or R1 and R2 together with the nitrogen atom to which they are bound form a 5-membered or 6-membered heterocyclic ring optionally containing one additional ring heteroatom selected from N and O;
R3 is an alkyl group having from 3 to 8 carbon atoms or a polyhydroxylated alkyl group having from 3 to 8 carbon atoms;
R4 is a polyhydroxylated alkyl group having from 3 to 8 carbon atoms; and
R5 is selected from H and C1-C3 alkyl.

US Pat. No. 10,246,424

SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Araxes Pharma LLC, San D...

1. A compound having the following structure (I):or a pharmaceutically acceptable salt or stereoisomer or thereof, wherein:A is N;
G1 and G2 are each independently N or CH;
L1 is a bond or NR7;
L2 is a bond or alkylene;
R1 is aryl or heteroaryl;
R2a, R2b and R2c are each independently H, amino, cyano, halo, hydroxyl, C1-C6 alkyl, C1-C6 alkylaminyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy; C3-C8 cycloalkyl, heterocyclylalkyl, C2-C6 alkynyl, C2-C6 alkenyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, aminylcarbonyl, heteroaryl or aryl;
R3a and R3b are, at each occurrence, independently H, —OH, —NH2, —CO2H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C8 cycloalkyl, heterocyclylalkyl, C2-C6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R3a and R3b join to form oxo, a carbocyclic or heterocyclic ring; or R3a is H, —OH, —NH2, —CO2H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C8 cycloalkyl, heterocyclylalkyl, C2-C6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R3b joins with R4b to form a carbocyclic or heterocyclic ring;
R4a and R4b are, at each occurrence, independently H, —OH, —NH2, —CO2H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C8 cycloalkyl, heterocyclylalkyl, C2-C6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R4a and R4b join to form oxo, a carbocyclic or heterocyclic ring; or R4a is H, —OH, —NH2, —CO2H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C8 cycloalkyl, heterocyclylalkyl, C2-C6 alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R4b joins with R3b to form a carbocyclic or heterocyclic ring;
R5a and R5b are, at each occurrence, independently H, hydroxyl, halo or C1-C6 alkyl, or R5a and R5b join to form oxo;
R6 is amino, cyano, substituted alkyl or substituted or unsubstituted: haloalkyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, C1-C6 alkylphosphoryl, C1-C6 alkylphosphorylaminyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, heteroarylalkyloxy or heteroarylalkylaminyl when R1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R6 is methyl when R1 is substituted aryl or substituted or unsubstituted heteroaryl;
R7 is, at each occurrence, independently H, C1-C6 alkyl, C3-C8 cycloalkyl or heterocyclyl;
m1 and m2 are each independently 1, 2 or 3;
n is an integer from 0 to 6;
X is a bond, —O—, —NR7— or —S—; and
E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a KRAS, HRAS or NRAS G12C mutant protein,
wherein each occurrence of alkyl, alkylene, aryl, heteroaryl, heterocyclyl, alkenyl, alkynyl, hydroxylalkly, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, alkylphosphoryl, alkylphosphorylaminyl, aminylcarbonyl, alkylaminyl, haloalkyl, alkoxy, haloalkoxy; cycloalkyl, heterocyclylalkyl, heteroarylalkyloxy, heteroarylalkylaminyl and carbocyclic and heterocyclic rings is optionally substituted with one or more substituents unless otherwise specified, the optional substituents being selected from the group consisting of aminyl, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, aminylsulfonyl, aminylcarbonyl, C1-C12 alkyl, C1-C6 alkylaminylcarbonyl, aminylcarbonylC1-C6 alkyl, C1-C12 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkoxyalkyl, C1-C6 haloalkoxyalkyl, cyanoC1-C6 alkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C2-C6 alkynyl, C1-C6 alkylaminyl, C1-C6 alkylcarbonylaminyl, C1-C6 hydroxyalkyl, C2-C6 alkenylcarbonylaminyl, C1-C6 thioalkyl, aryl, aralkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylalkyl, aminylcarbonylC3-C8 cycloalkyl, C3-C8 cycloalkylaminylcarbonyl, C3-C8 fused cycloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl, and
wherein: i) each aryl comprises a 6- to 18-membered carbocyclic aromatic ring radical; ii) each heterocyclyl comprises a 3- to 18-membered non-aromatic ring radical having one to twelve ring carbon atoms and from one to six ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and iii) each heteroaryl comprises a 5- to 14-membered ring radical comprising hydrogen atoms, one to thirteen ring carbon atoms, one to six ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.

US Pat. No. 10,246,423

PROCESS FOR PREPARING STATIN PRECURSOR

Centrient Pharmaceuticals...

1. A process for preparing the compound of formula (IV), the process comprising the steps of:(a) providing a starting mixture comprising the compound of formula (II) and toluene

(b) a first reaction step, wherein the starting mixture is contacted with an organic sulfonyl halide and the resulting first reaction mixture is kept at a first temperature of below 110° C., thereby forming an intermediate mixture comprising the compound of formula (III)

wherein R is an organic group having from 1 to 15 carbons; and
(c) a second reaction step, wherein the intermediate mixture is contacted with N-methylmethane sulfonamide and the resulting second reaction mixture is kept at a second temperature, thereby forming a second mixture comprising the compound of formula (IV)

US Pat. No. 10,246,422

HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

1. A heterocyclic compound of formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof,
wherein,
Y is —CH2, —C(O), —C(CH3)2, or a spirocyclopropyl;
R1 is

R2, R3, and R6, which may be identical or different, are a hydrogen atom, F, or —CH3;
R4 is a hydrogen atom, an alkyl, an alkene, an alkyne, a cycloalkyl, a cycloalkene, an aralkyl, a heteroaralkyl, or one of the following:

R5 is a halogen; an alkyl; a cycloalkyl optionally substituted with R13, R14, and/or R15; an alkene; a cycloalkene; an alkyne; an ether; or one of the following:

with Het representing 1 to 3 nitrogen atoms among the 6 atoms of the aromatic ring, and these nitrogen atoms may, independently of one another, be substituted with an oxygen atom to form an N-oxide group;
R7 is

with n=0 or 1;
R8 and R9, which may be identical or different, are a hydrogen atom, F, or —CH3;
R10 is hydrogen atom, —OR11, —SR11, —NR11R12, —S(O)R11, —SO2R11, —OC(O)R11, —CO2R11, a halogen, —NO2, —CN, —C(O)NR11R12, —CF3, or —OCF3;
R11 and R12, which may be identical or different, are a hydrogen atom, a C1-C6 alkyl, CF3, or an ether;
R13, R14, and R15, which may be identical or different, are a hydrogen atom, a C1-C6 alkyl, a cycloalkyl, —OR16, —NR16R17, a halogen, —OCF3, —CF3, —CN, —CO2R16, —CONR16R17, —NO2, —OCH2OR16, —SR16, —S(O)R16, —SO2R16, or an ether;
A, B, and D, which may be identical or different, are a C, N, O, or S atom;
R16 and R17, which may be identical or different, are a hydrogen atom, a C1-C6 alkyl, or —C(O)R18;
Z is —CH2, O, or —NR18; and
R18 is a hydrogen atom or a C1-C3 alkyl.

US Pat. No. 10,246,421

INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES

Esanex, Inc., Indianapol...

1. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein
bond “” is a single or a double bond;
R3 is hydrogen, halogen, cyano, —C(O)OH, —C(O)—O(C1-C6 alkyl), —N(RN)2, C1-C6 alkyl,
C1-C6 alkoxy, C1-C6 haloalkyl, C3-C7 cycloalkyl, aryl, or heteroaryl, wherein;
each alkyl, cycloalkyl, aryl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, mono- or di-(C1-C6) alkylamino, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, or carboxamide; and each RN is independently hydrogen or —C1-C6 alkyl-;
R4 and R5 are independently hydrogen or halogen;
R6 is halogen or —Z1RZ1, and wherein
Z1 is —O—, —NH—, —S(O)p—, or —S(O)2NH—, wherein p is 0, 1 or 2; and
RZ1 is a C1-C14 alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R22, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO2, and SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent to each other, and
R22 is heteroaryl, aryl, saturated or unsaturated C3-C10 cycloalkyl, or saturated or unsaturated C2-C10 heterocycloalkyl, wherein each aryl, heteroaryl, saturated or unsaturated cycloalkyl, or saturated or unsaturated heterocycloalkyl, independently, is optionally substituted with at least one group, which independently is hydroxy, halo, amino, cyano, carboxy, carboxamido, nitro, oxo, —S—(C1-C6)alkyl, —SO2-(C1-C6)alkyl, —SO2-aryl, —SO—(C1-C6)alkyl, —SO-aryl, —SO2NH2, —SO2NH—(C1-C6)alkyl, —SO2NH-aryl, (C1-C6)alkoxy, or mono- or di-(C1-C10)alkylamino; and wherein each is optionally fused to a C6-C10 aryl group, C5-C8 saturated cyclic group, or a C5-C10 heterocycloalkyl group;
and wherein RZ1 optionally substituted at any available position independently with C1-C10 alkyl, C1-C10 haloalkyl, C2-C10 alkenyl, C2-C10 alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C1-C6)alkyl, —SO2-(C1-C6)alkyl, —SO2NH2, —SO2NH—(C1-C6)alkyl, —SO2NH-aryl, —SO2-aryl, —SO—(C1-C6)alkyl, —SO-aryl, C1-C6 alkoxy, C2-C10 alkenyloxy, C2-C10 alkynyloxy, mono- or di-(C1-C10)alkylamino, —OC1-C10 alkyl-Z, or R23, wherein
Z is OR31 or —N(R30)2, wherein
each R30 is independently hydrogen or C1-C6 alkyl, or N(R30)2 represents pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,3- or 1,4-diazepanyl, or morpholinyl, each of which is optionally substituted with hydroxy, amino, aminoalkyl, C1-C6 alkyl, mono- or di(C1-C6)alkylamino, C1-C6 alkoxy, or halogen;
R31 is hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, heteroaryl, or C1-C6 acyl;
R23 is heteroaryl, aryl, saturated or unsaturated C5-C10 cycloalkyl, or saturated or unsaturated C5-C10 heterocycloalkyl, and each is optionally substituted with at least one group which is independently hydroxy, oxo, halo, amino, cyano, nitro, —SH, —S—(C1-C6)alkyl, —SO2-(C1-C6)alkyl, —SO2-aryl, —SO—(C1-C6)alkyl, —SO-aryl, —SO2NH2, —SO2NH—(C1-C6)alkyl, —SO2NH-aryl, C1-C6 alkoxy, or mono- or di-(C1-C10)alkylamino;
R9 and R10 are independently hydrogen or C1-C8 alkyl; or R9 and R10 taken together with the carbon atom to which they are attached form C3-C8 cycloalkyl;
R1 is hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 alkoxy, mono- or di-(C1-C10)alkylamino, C1-C10 alkoxy(C1-C10)alkyl, hydroxy(C1-C10) alkoxy, or amino(C1-C10)alkoxy-;
R41 is a group of the formula

 wherein
R1 and R2 are independently H, hydroxy, C2-C6 alkenyl, C2-C6 alkynyl, heteroaryl, aryl, C3-C8 cycloalkyl, heterocycloalkyl, wherein
each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, mono- or di-(C1-C6) alkylamino, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, or carboxamide;
X4 is oxygen;
X is N or CRC; and
Y is N or CRC;
each RC is independently is hydrogen, halogen, cyano, nitro, —C(O)RC1, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C3-C7 cycloalkyl, C3-C7 cycloalkyl(C1-C10)alkyl, heterocycloalkyl, aryl, or heteroaryl, wherein
each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, mono- or di-(C1-C6) alkylamino, cyano, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, carboxamide, heterocycloalkyl, aryl, or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted with from 1-4 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, mono- or di-(C1-C6) alkylamino, halo(C1-C6)alkyl, or carboxamide;
RC1 is —C1-C6 alkyl, —ORC2, or —N(RCN)2, wherein
RC2 is —H, C1-C10 alkyl, C1-C10 haloalkyl, C3-C7 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
each RCN is independently —H, C1-C10 alkyl, C1-C10 haloalkyl, C3-C7 cycloalkyl, heterocycloalkyl, C1-C6 acyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, amino, mono- or di-(C1-C6) alkylamino, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, or carboxamide.

US Pat. No. 10,246,420

PYRAZOLE DERIVATIVES

BAYER CROPSCIENCE AKTIENG...

1. A compound of formula (I)
and/or one or more tautomers and/or salts thereof, wherein
R1 is H, CH3, F, Cl, Br, or C1-C4 alkoxy,
R2 is methyl or ethyl,
X is a structure element selected from the group consisting of NH, N(CH3), O, S, CH2, CH(OH), and CH(CH3),
Q1 is a 5- to 7-membered carbocyclic ring, optionally substituted with up to 5 independently selected substituents RQ1;
or a 5- to 7-membered heterocyclic ring containing ring members selected from the group consisting of C, N, O and S, and containing up to 3 heteroatom ring members independently selected from the group O, S, and N, wherein the heterocyclic ring contains as heteroatom ring members up to 1 O atom, up to 1 S atom, and up to 3 N atoms,
wherein optionally up to 3 carbon ring members are independently selected from C(?O) and C(?S), and, if present, the sulfur atom ring members are independently selected from S, S(O), or S(O)2,
wherein the heterocyclic ring is optionally substituted with up to 5 substituents RQ1 on carbon atom heterocyclic ring members and optionally substituted with substituents RN on nitrogen atom heterocyclic ring members, if present, each RQ1 is independently selected from the group consisting of halogen, cyano, nitro, amino, hydroxy, formyl, C1-C6 alkyl, C1-C6haloalkyl, C3-C6 cycloalkyl, C3-C7 halocycloalkyl, C3-C6 heterocyclyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, C3-C7 alkenylalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyl, C3-C7 alkynylalkoxy, C3-C7 alkynyloxy, C3-C7 cycloalkoxy, C3-C6 halocycloalkoxy, C3-C6 heterocyclyloxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3haloalkylsulfinyl, C1-C3 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C1-C2 alkylsulfonyloxy, C1-C2 haloalkylsulfonyloxy, C4-C7 alkylcycloalkyl, C4-C6 cycloalkylalkyl, C2-C3 alkylcarbonyl, C2-C3 alkylcarbonyloxy, C1-C4 alkanoylamino, C2-C3 alkylcarbonylamino, (C1-C6 alkoxy)iminocarbonyl, tri(C1-C4-alkyl)silyl, SCF3, SF5, SCN, isonitrile, CRC?NO—C1-C4 alkyl, —NR1NR2N and optionally substituted phenyl,
Q2 is a 5- or 6-membered carbocyclic ring, [optionally] substituted with 1 [up] to 5 substituents RQ2;
or a 5- to 7-membered heterocyclic ring containing ring members selected from the group consisting of C, N, O and S, and containing up to 3 heteroatom ring members independently selected from the group O, S, and N, wherein the heterocyclic ring contains as heteroatom ring members up to 1 O atom, up to 1 S atom, and up to 3 N atoms, wherein optionally up to 3 carbon ring members are independently selected from C(?O) and C(?S), and, if present, the sulfur atom ring members are independently selected from S, S(O), or S(O)2,
wherein the heterocyclic ring is [optionally] substituted with [up] 1 to 5 substituents RQ2 on carbon atom heterocyclic ring members and optionally substituted with substituents RN on nitrogen atom heterocyclic ring members, if present,
each RQ2 is independently selected from the group consisting of halogen, cyano, nitro, amino, hydroxy, formyl, C1-C6 alkyl, C1-C6haloalkyl, C3-C6 cycloalkyl, C3-C7 halocycloalkyl, C3-C6 heterocyclyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, C3-C7 alkenylalkoxy, C2-C6 alkenyloxy, C2-C6 alkynyl, C3-C7 alkynylalkoxy, C3-C7 alkynyloxy, C3-C7 cycloalkoxy, C3-C6 halocycloalkoxy, C3-C6 heterocyclyloxy, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3haloalkylsulfinyl, C1-C3 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C1-C2 alkylsulfonyloxy, C1-C2 haloalkylsulfonyloxy, C4-C7 alkylcycloalkyl, C4-C6 cycloalkylalkyl, C2-C3 alkylcarbonyl, C2-C3 alkylcarbonyloxy, C1-C4 alkanoylamino, C2-C3 alkylcarbonylamino, (C1-C6 alkoxy)iminocarbonyl, tri(C1-C4-alkyl)silyl, SCF3, SF5, SCN, isonitrile, CRC?NO—C1-C4 alkyl, —NR1NR2N and optionally substituted phenyl,
wherein each RN is independently selected from the group consisting of cyano, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C1-C6alkoxy, C2-C6 alkoxyalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylaminoalkyl and C3-C6 dialkylaminoalkyl, C1-C6 aminoalkyl, benzyl, and SO2RS,
wherein each RC is independently selected from the group consisting of H and C1-C4 alkyl,
wherein R1N and R2N each are independently selected from C1-C4 alkyl and C3-C6 cycloalkyl,
wherein each RS is independently selected from C1-C4 alkyl, C1-C4 haloalkyl, and C3-C6 cycloalkyl,
wherein each optionally substituted phenyl is independently selected from phenyl substituted with up to 5 radicals selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, (C1-C4)-alkoxy-(C1-C4)-alkoxy, (C1-C4) alkylthio and nitro,
provided that at least one substituent RQ2 that is present is C3-C7 alkenylalkoxy or C3-C7 alkynylalkoxy.

US Pat. No. 10,246,419

LIVER X RECEPTOR (LXR) MODULATORS

RALEXAR THERAPEUTICS, INC...

1. A method of treating a disease, disorder, or condition in a mammal that would benefit from LXR modulation comprising administering to the mammal a compound of Formula (IA):
or a pharmaceutically acceptable salt thereof, wherein:
L1 is a bond;
R1 is —OR9, —N(R9)2, C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C2-C9heterocycloalkyl, —C(?O)R8, or —C(?O)N(R9)2;
R2 is C1-C6alkyl, C2-C6alkenyl, C3-C8cycloalkyl, or —C1-C6alkyl-C3-C8cycloalkyl;
R3 is hydrogen or halogen;
R4 is aryl; wherein aryl is substituted with at least one R11;
each R5 is independently halogen, C1-C6alkyl, or C1-C6haloalkyl;
R8 is C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, —C1-C6alkyl-aryl, aryl, or heteroaryl;
each R9 is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl;
each R10 is independently hydrogen or C1-C6alkyl;
each R11 is independently halogen, nitro, —OR10, —N(R10)2, —CN, —C(?O)R10, —C(?O)OR10, —C(?O)N(R10)2, —NR10C(?O)R10, —NR10SO2R10, —SOR10, —SO2R10, —SO2N(R10)2, —C(?O)OCH2SCH3, optionally substituted C1-C6alkyl, or optionally substituted C1-C6haloalkyl;
wherein at least one R11 is —NR10SO2R10, —SOR10, —SO2R10, or —SO2N(R10)2; and
n is 0.

US Pat. No. 10,246,418

CRYSTAL FORM OF LENVATINIB METHANESULFONATE SALT AND PREPARATION METHOD THEREOF

Crystal Pharmatech Co., L...

1. A crystalline Form M of compound (I) mesylate, wherein the X-ray powder diffraction pattern shows at least three characteristic peaks at 2theta values of 11.4°±0.2°, 6.1°±0.2°, 15.1°±0.2°, 12.5°±0.2°, 23.8°±0.2°, 21.8°±0.2°, 7.9°±0.2° and 20.2±0.2°.

US Pat. No. 10,246,417

PICOLINAMIDES AS FUNGICIDES

Dow AgroSciences LLC, In...

1. A composition for the control of a fungal pathogen including mixtures of at least one of the compounds of Formula I
wherein:
Q is

X is hydrogen or C(O)R5;
Y is hydrogen or C(O)R5;
Z is N or N+?O? and W is O or S;
R1 is hydrogen or alkyl, substituted with 0, 1 or multiple R8;
R2 is methyl;
R3 and R3? are independently chosen from C2-C6 alkyl, C3-C6 cycloalkyl, aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R8; Alternatively, R3 and R3? may be taken together to form a 3-6 membered saturated or partially saturated carbocycle or heterocycle, optionally substituted with 0, 1 or multiple R8;
R4 is chosen from aryl or heteroaryl, each optionally substituted with 0, 1 or multiple R8;
R5 is chosen from alkoxy or benzyloxy, each optionally substituted with 0, 1, or multiple R8;
R6 is chosen from hydrogen, alkoxy, or halo, each optionally substituted with 0, 1, or multiple R8;
R7 is chosen from hydrogen, —C(O)R9, or —CH2OC(O)R9;
R8 is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkynyl, alkoxy, cyano, or heterocyclyl, each optionally substituted with 0, 1, or multiple R10;
R9 is chosen from alkyl, alkoxy, or aryl, each optionally substituted with 0, 1, or multiple R8;
R10 is chosen from hydrogen, alkyl, aryl, acyl, halo, alkenyl, alkoxy, or heterocyclyl;
R11 is chosen from hydrogen or alkyl, each substituted with 0, 1 or multiple R8; and
a phytologically acceptable carrier material.

US Pat. No. 10,246,416

PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO] ALKANOIC ACIDS, ESTERS AND AMIDES

Akebia Therapeutics, Inc....

1. A compound having the formula:
or a pharmaceutically acceptable salt thereof,
wherein A is a ring selected from:
2,3-difluorophenyl, 3,4-difluoro-phenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3-bromophenyl, 3,5-dichlorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichloro-phenyl, 2,4,6-trichlorophenyl, 2-chloro-3-methylphenyl, 2-chloro-4-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-6-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4-methylphenyl, 3-chloro-5-methylphenyl, 3-chloro-6-methyl-phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methylphenyl, 2-fluoro-5-methylphenyl, 2-fluoro-6-methylphenyl, 3-fluoro-2-methylphenyl, 3-fluoro-4-methylphenyl, 3-fluoro-5-methylphenyl, and 3-fluoro-6-methylphenyl;
Z is independently chloro or bromo; and
R10 is absent.

US Pat. No. 10,246,415

PROCESS FOR PREPARING CARBAZOLES

Dow Global Technologies L...

1. A process for preparing a carbazole comprising:(a) contacting a compound represented by formula (1) below
wherein Cl is a chlorine atom; X is selected from the group consisting of bromo, iodo, triflate (trifluoromethanesulfonate), mesylate (methanesulfonate), arenesulfonates; R1-R4 are selected from the group consisting of hydrogen, alkyls, fluoroalkyls, aryls, heteroaryls, alkoxys, tertiary amines, fluoro, nitrile (CN), nitro (NO2), and trialkyl(aryl)silyl; and R1-R4 are never the same as X with diboron reagents in the presence of PdCl2(dppf) to form a dichlorobiaryl represented by formula (2);
and (b) contacting the 2,2?-dichlorobiaryl represented by formula (2) with a H2N—Y compound, wherein Y is selected from the group consisting of H, —COOR, —C(O)R, SiR3, SiAr3, CH2Ar, Na, Li, and 2-pyrimidyl, wherein Ar is a phenyl group and R is selected from the group consisting of alkyls, aryls, heteroaryls, and alkoxys in the presence of palladium containing catalytic components;
thereby forming the carbazole represented by formula (3) below

US Pat. No. 10,246,414

ALLOSTERIC MODULATORS OF CB1 CANNABINOID RECEPTORS

Northeastern University, ...

1. A pharmaceutical composition for treatment of Huntington's disease, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
and a pharmaceutically-acceptable carrier or diluent.

US Pat. No. 10,246,413

SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS

1. A compound of the general formula (I):
wherein:
X represents —CH2CH2;
Y represents —O—;
Z represents a covalent bond;
R* represents —R**, —CH2—R**, —CH2—CH?CH2, -cyclo-C6H11, or -cyclo-C5H9;
R** represents

R? and R? represent independently of each other —CH3, —C2H5, —CH(CH3)2, —CH2CH?CH2, -cyclo-C3H5, or —C(CH3)3;
RA represents:

RB represents: —R26,

RC represents: —R27,

RD represents: —R28,

R1-R22, R18?-R22?, R26-R39 represent independently of each other —H, —OH, —OCH3, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —OCH2—COOH, —OPh, —OCH2-Ph, —OCPh3, —CH2—OH, —C2H4—OH, —C3H6—OH, —CH(OH)—CH2—OH, —CH2—OCH3, —C2H4—OCH3, —C4H8—OCH3, —C3H6—OCH3, —CH2—OC2H5, —C2H4—OC2H5, —C3H6—OC2H5, —C4H8—OC2H5, —CH2—OC3H7, —C2H4—OC3H7, —C3H6—OC3H7, —CH2—O-cyclo-C3H5, —C2H4—O-cyclo-C3H5, —C3H6—O-cyclo-C3H5, —C4H8—O-cyclo-C3H5, —CH2—OCH(CH3)2, —C2H4—OCH(CH3)2, —C3H6—OCH(CH3)2, —C4H8—OCH(CH3)2, —CH2—OC(CH3)3, —C2H4—OC(CH3)3, —C3H6—OC(CH3)3, —C4H8—OC(CH3)3, —CH2—OC4H9, —C2H4—OC4H9, —C3H6—OC4H9, —C4H8—OC4H9, —CH2—OPh, —C2H4—OPh, —C3H6—OPh, —C4H8—OPh, —CH2—OCH2-Ph, —C2H4—OCH2-Ph, —C3H6—OCH2-Ph, —C4H8—OCH2-Ph, —SH, —SCH3, —SC2H5, —SC3H7, —S-cyclo-C3H5, —SCH(CH3)2, —SC(CH3)3, —NO2, —F, —Cl, —Br, —I, —P(O)(OH)2, —P(O)(OCH3)2, —P(O)(OC2H5)2, —P(O)(OCH(CH3)2)2, —C(OH)[P(O)(OH)2]2, —Si(CH3)2(C(CH3)3), —Si(C2H5)3, —Si(CH3)3, —N3, —CN, —OCN, —NCO, —SCN, —NCS, —CHO, —COCH3, —COC2H5, —COC3H7, —CO-cyclo-C3H5, —COCH(CH3)2, —COC(CH3)3, —COOH, —COCN, —COOCH3, —COOC2H5, —COOC3H7, —COO-cyclo-C3H5, —COOCH(CH3)2, —COOC(CH3)3, —OOC—CH3, —OOC—C2H5, —OOC—C3H7, —OOC-cyclo-C3H5, —OOC—CH(CH3)2, —OOC—C(CH3)3, —CONH2, —CH2—CONH2, —CONHCH3, —CONHC2H5, —CONHC3H7, —CONH-cyclo-C3H5, —CONH[CH(CH3)2], —CONH[C(CH3)3], —CON(CH3)2, —CON(C2H5)2, —CON(C3H7)2, —CON(cyclo-C3H5)2, —CON[CH(CH3)2]2, —CON[C(CH3)3]2, —NHCOCH3, —NHCOC2H5, —NHCOC3H7, —NHCO-cyclo-C3H5, —NHCO—CH(CH3)2, —NHCO—C(CH3)3, —NHCO—OCH3, —NHCO—OC2H5, —NHCO—OC3H7, —NHCO—O-cyclo-C3H5, —NHCO—OCH(CH3)2, —NHCO—OC(CH3)3, —NH2, —NHCH3, —NHC2H5, —NHC3H7, —NH-cyclo-C3H5, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N(cyclo-C3H5)2, —N[CH(CH3)2]2, —N[C(CH3)3]2, —SOCH3, —SOC2H5, —SOC3H7, —SO-cyclo-C3H5, —SOCH(CH3)2, —SOC(CH3)3, —SO2CH3, —SO2C2H5, —SO2C3H7, —SO2-cyclo-C3H5, —SO2CH(CH3)2, —SO2C(CH3)3, —SO3H, —SO3CH3, —SO3C2H5, —SO3C3H7, —SO3-cyclo-C3H5, —SO3CH(CH3)2, —SO3C(CH3)3, —SO2NH2, —SO2NHCH3, —SO2NHC2H5, —SO2NHC3H7, —SO2NH-cyclo-C3H5, —SO2NHCH(CH3)2, —SO2NHC(CH3)3, —SO2N(CH3)2, —SO2N(C2H5)2, —SO2N(C3H7)2, —SO2N(cyclo-C3H5)2, —SO2N[CH(CH3)2]2, —SO2N[C(CH3)3]2, —O—S(?O)CH3, —O—S(?O)C2H5, —O—S(?O)C3H7, —O—S(?O)-cyclo-C3H5, —O—S(?O)CH(CH3)2, —O—S(?O)C(CH3)3, —S(?O)(?NH)CH3, —S(?O)(?NH)C2H5, —S(?O)(?NH)C3H7, —S(?O)(?NH)-cyclo-C3H5, —S(?O)(?NH)CH(CH3)2, —S(?O)(?NH)C(CH3)3, —NH—SO2—CH3, —NH—SO2—C2H5, —NH—SO2—C3H7, —NH—SO2-cyclo-C3H5, —NH—SO2—CH(CH3)2, —NH—SO2—C(CH3)3, —O—SO2—CH3, —O—SO2—C2H5, —O—SO2—C3H7, —O—SO2-cyclo-C3H5, —O—SO2—CH(CH3)2, —O—SO2—C(CH3)3, —OCF3, —CH2—OCF3, —C2H4—OCF3, —C3H6—OCF3, —OC2F5, —CH2—OC2F5, —C2H4—OC2F5, —C3H6—OC2F5, —O—COOCH3, —O—COOC2H5, —O—COOC3H7, —O—COO-cyclo-C3H5, —O—COOCH(CH3)2, —O—COOC(CH3)3, —NH—CO—NH2, —NH—CO—NHCH3, —NH—CO—NHC2H5, —NH—CS—N(C3H7)2, —NH—CO—NHC3H7, —NH—CO—N(C3H7)2, —NH—CO—NH[CH(CH3)2], —NH—CO—NH[C(CH3)3], —NH—CO—N(CH3)2, —NH—CO—N(C2H5)2, —NH—CO—NH-cyclo-C3H5, —NH—CO—N(cyclo-C3H5)2, —NH—CO—N[CH(CH3)2]2, —NH—CS—N(C2H5)2, —NH—CO—N[C(CH3)3]2, —NH—CS—NH2, —NH—CS—NHCH3, —NH—CS—N(CH3)2, —NH—CS—NHC2H5, —NH—CS—NHC3H7, —NH—CS—NH-cyclo-C3H5, —NH—CS—NH[CH(CH3)2], —NH—CS—NH[C(CH3)3], —NH—CS—N(cyclo-C3H5)2, —NH—CS—N[CH(CH3)2]2, —NH—CS—N[C(CH3)3]2, —NH—C(?NH)—NH2, —NH—C(?NH)—NHCH3, —NH—C(?NH)—NHC2H5, —NH—C(?NH)—NHC3H7, —O—CO—NH-cyclo-C3H5, —NH—C(?NH)—NH-cyclo-C3H5, —NH—C(?NH)—NH[CH(CH3)2]—O—CO—NH[CH(CH3)2], —NH—C(?NH)—NH[C(CH3)3], —NH—C(?NH)—N(CH3)2, —NH—C(?NH)—N(C2H5)2, —NH—C(?NH)—N(C3H7)2, —NH—C(?NH)—N(cyclo-C3H5)2, —O—CO—NHC3H7, —NH—C(?NH)—N[CH(CH3)2]2, —NH—C(?NH)—N[C(CH3)3]2, —O—CO—NH2, —O—CO—NHCH3, —O—CO—NHC2H5, —O—CO—NH[C(CH3)3], —O—CO—N(CH3)2, —O—CO—N(C2H5)2, —O—CO—N(C3H7)2, —O—CO—N(cyclo-C3H5)2, —O—CO—N[CH(CH3)2]2, —O—CO—N[C(CH3)3]2, —O—CO—OCH3, —O—CO—OC2H5, —O—CO—OC3H7, —O—CO—O-cyclo-C3H5, —O—CO—OCH(CH3)2, —O—CO—OC(CH3)3, —CH2F, —CHF2, —CF3, —CH2C1, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2C1, —CH2—CH2Br, —CH2—CH2I, -cyclo-C5H9, -cyclo-C6H11, —CH2-cyclo-C6H11, —CH2—CH2-cyclo-C6H11, -cyclo-C7H13, -cyclo-C8H15, -Ph, —CH2-Ph, —CH2—CH2-Ph, —CH?CH-Ph, —CPh3, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C7H15, —C8H17, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH?CH2, —CH2—CH?CH2, —C(CH3)?CH2, —CH?CH—CH3, —C2H4—CH?CH2, —CH2—CH?CH—CH3, —CH?CH—C2H5, —CH2—C(CH3)?CH2, —CH(CH3)—CH?CH, —CH?C(CH3)2, —C(CH3)?CH—CH3, —CH?CH—CH?CH2, —C3H6—CH?CH2, —C2H4—CH?CH—CH3, —CH2—CH?CH—C2H5, —CH?CH—C3H7, —CH2—CH?CH—CH?CH2, —CH?CH—CH?CH—CH3, —CH?CH—CH2—CH?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C2H4—C(CH3)?CH2, —CH2—CH(CH3)—CH?CH2, —CH(CH3)—CH2—CH?CH2, —CH2—CH?C(CH3)2, —CH2—C(CH3)?CH—CH3, —CH(CH3)—CH?CH—CH3, —C(CH3)?C(CH3)2, —C(CH3)2—CH?CH2, —CH(CH3)—C(CH3)?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C4H8—CH?CH2, —C3H6—CH?CH—CH3, —C2H4—CH?CH—C2H5, —CH2—CH?CH—C3H7, —CH?CH—C4H9, —C3H6—C(CH3)?CH2, —C2H4—CH(CH3)—CH?CH2, —CH2—CH(CH3)—CH2—CH?CH2, —C2H4—CH?C(CH3)2, —CH(CH3)—C2H4—CH?CH2, —C2H4—C(CH3)?CH—CH3, —CH2—CH(CH3)—CH?CH—CH3, —CH(CH3)—CH2—CH?CH—CH3, —CH2—CH?CH—CH(CH3)2, —CH2—CH?C(CH3)—C2H5, —CH2—C(CH3)?CH—C2H5, —CH(CH3)—CH?CH—C2H5, —CH?CH—CH2—CH(CH3)2, —CH?CH—CH(CH3)—C2H5, —CH?C(CH3)—C3H7, —C(CH3)?CH—C3H7, —CH2—CH(CH3)—C(CH3)?CH2, —C[C(CH3)3]?CH2, —CH(CH3)—CH2—C(CH3)?CH2, —CH(CH3)—CH(CH3)—CH?CH2, —CH?CH—C2H4—CH?CH2, —CH2—C(CH3)2—CH?CH2, —C(CH3)2—CH2—CH?CH2, —CH2—C(CH3)?C(CH3)2, —CH(CH3)—CH?C(CH3)2, —C(CH3)2—CH?CH—CH3, —CH?CH—CH2—CH?CH—CH3, —CH(CH3)—C(CH3)?CH—CH3, —CH?C(CH3)—CH(CH3)2, —C(CH3)?CH—CH(CH3)2, —C(CH3)?C(CH3)—C2H5, —CH?CH—C(CH3)3, —C(CH3)2—C(CH3)?CH2, —CH(C2H5)—C(CH3)?CH2, —C(CH3)(C2H5)—CH?CH2, —CH(CH3)—C(C2H5)?CH2, —CH2—C(C3H7)?CH2, —CH2—C(C2H5)?CH—CH3, —CH(C2H5)—CH?CH—CH3, —C(C4H9)?CH2, —C(C3H7)?CH—CH3, —C(C2H5)?CH—C2H5, —C(C2H5)?C(CH3)2, —C[CH(CH3)(C2H5)]?CH2, —C[CH2—CH(CH3)2]?CH2, —C2H4—CH?CH—CH?CH2, —CH2—CH?CH—CH2—CH?CH2, —C3H6—C?C—CH3, —CH2—CH?CH—CH?CH—CH3, —CH?CH—CH?CH—C2H5, —CH2—CH?CH—C(CH3)?CH2, —CH2—CH?C(CH3)—CH?CH2, —CH2—C(CH3)?CH—CH?CH2, —CH(CH3)—CH2—C?CH, —CH(CH3)—CH?CH—CH?CH2, —CH?CH—CH2—C(CH3)?CH2, —CH(CH3)—C?C—CH3, —CH?CH—CH(CH3)—CH?CH2, —CH?C(CH3)—CH2—CH?CH2, —C2H4—CH(CH3)—C?CH, —C(CH3)?CH—CH2—CH?CH2, —CH?CH—CH?C(CH3)2, —CH2—CH(CH3)—CH2—C?CH, —CH?CH—C(CH3)?CH—CH3, —CH?C(CH3)—CH?CH—CH3, —CH2—CH(CH3)—C?CH, —C(CH3)?CH—CH?CH—CH3, —CH?C(CH3)—C(CH3)?CH2, —C(CH3)?CH—C(CH3)?CH2, —C(CH3)?C(CH3)—CH?CH2, —CH?CH—CH?CH—CH?CH2, —C?CH, —C?C—CH3, —CH2—C?CH, —C2H4—C?CH, —CH2—C?C—CH3, —C?C—C2H5, —C3H6—C?CH, —C2H4—C?C—CH3, —CH2—C?C—C2H5, —C?C—C3H7, —CH(CH3)—C?CH, —C4H8—C?CH, —C2H4—C?C—C2H5, —CH2—C?C—C3H7, —C?C—C4H9, —C?C—C(CH3)3, —CH(CH3)—C2H4—C?CH, —CH2—CH(CH3)—C?C—CH3, —CH(CH3)—CH2—C?C—CH3, —CH(CH3)—C?C—C2H5, —CH2—C?C—CH(CH3)2, —C?C—CH(CH3)—C2H5, —C?C—CH2—CH(CH3)2, —CH(C2H5)—C?C—CH3, —C(CH3)2—C?C—CH3, —CH(C2H5)—CH2—C?CH, —CH2—CH(C2H5)—C?CH, —C(CH3)2—CH2—C?CH, —CH2—C(CH3)2—C?CH, —CH(CH3)—CH(CH3)—C?CH, —CH(C3H7)—C?CH, —C(CH3)(C2H5)—C?CH, —CH2—CH(C?CH)2, —C?C—C?CH, —CH2—C?C—C?CH, —C?C—C?C—CH3, —CH(C?CH)2, —C2H4—C?C—C?CH, —CH2—C?C—CH2—C?CH, —C?C—C2H4—C?CH, —CH2—C?C—C?C—CH3, —C?C—CH2—C?C—CH3, —C?C—C?C—C2H5, —C(C?CH)2—CH3, —C?C—CH(CH3)—C?CH, —CH(CH3)—C?C—C?CH, —CH(C?CH)—CH2—C?CH, —CH(C?CH)—C?C—CH3,

R18 and R18? or R19 and R19? or R20 and R20? or R21 and R21? or R22 and R22? form together ?O,
or ?CR23?R24?, wherein R23? and R24? represent independently of each other —H, —CH3, —C2H5, —CF3, —CH2CF3, or —C2F5;R23-R25 represent independently of each other —H, —CH2—OCH3, —C2H4—OCH3, —C3H6—OCH3, —CH2—OC2H5, —C2H4—OC2H5, —C3H6—OC2H5, —CH2—OC3H7, —C2H4—OC3H7, —C3H6—OC3H7, —CH2—O-cyclo-C3H5, —C2H4—O-cyclo-C3H5, —C3H6—O-cyclo-C3H5, —CH2—OCH(CH3)2, —C2H4—OCH(CH3)2, —C3H6—OCH(CH3)2, —CH2—OC(CH3)3, —C2H4—OC(CH3)3, —C3H6—OC(CH3)3, —CH2—OC4H9, —C2H4—OC4H9, —C3H6—OC4H9, —CH2—OPh, —C2H4—OPh, —C3H6—OPh, —CH2—OCH2-Ph, —C2H4—OCH2-Ph, —C3H6—OCH2-Ph, —CH2F, —CHF2, —CF3, —CH2Cl, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2Cl, —CH2—CH2Br, —CH2—CH2I, -cyclo-C8H15, -Ph, —CH2-Ph, —CH2—CH2-Ph, —CH?CH-Ph, —CPh3, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C7H15, —C8H17, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH?CH2, —CH2—CH?CH2, —C(CH3)?CH2, —CH?CH—CH3, —C2H4—CH?CH2, —CH2—CH?CH—CH3, —CH?CH—C2H5, —CH2—C(CH3)?CH2, —CH(CH3)—CH?CH, —CH?C(CH3)2, —C(CH3)?CH—CH3, —CH?CH—CH?CH2, —C3H6—CH?CH2, —C2H4—CH?CH—CH3, —CH2—CH?CH—C2H5, —CH?CH—C3H7, —CH2—CH?CH—CH?CH2, —CH?CH—CH?CH—CH3, —CH?CH—CH2—CH?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C2H4—C(CH3)?CH2, —CH2—CH(CH3)—CH?CH2, —CH(CH3)—CH2—CH?CH2, —CH2—CH?C(CH3)2, —CH2—C(CH3)?CH—CH3, —CH(CH3)—CH?CH—CH3, —CH?CH—CH(CH3)2, —CH?C(CH3)—C2H5, —C(CH3)?CH—C2H5, —C(CH3)?C(CH3)2, —C(CH3)2—CH?CH2, —CH(CH3)—C(CH3)?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C4H8—CH?CH2, —C3H6—CH?CH—CH3, —C2H4—CH?CH—C2H5, —CH2—CH?CH—C3H7, —CH?CH—C4H9, —C3H6—C(CH3)?CH2, —C2H4—CH(CH3)—CH?CH2, —CH2—CH(CH3)—CH2—CH?CH2, —C2H4—CH?C(CH3)2, —CH(CH3)—C2H4—CH?CH2, —C2H4—C(CH3)?CH—CH3, —CH2—CH(CH3)—CH?CH—CH3, —CH(CH3)—CH2—CH?CH—CH3, —CH2—CH?CH—CH(CH3)2, —CH2—CH?C(CH3)—C2H5, —CH2—C(CH3)?CH—C2H5, —CH(CH3)—CH?CH—C2H5, —CH?CH—CH2—CH(CH3)2, —CH?CH—CH(CH3)—C2H5, —CH?C(CH3)—C3H7, —C(CH3)?CH—C3H7, —CH2—CH(CH3)—C(CH3)?CH2, —C[C(CH3)3]?CH2, —CH(CH3)—CH2—C(CH3)?CH2, —CH(CH3)—CH(CH3)—CH?CH2, —CH?CH—C2H4—CH?CH2, —CH2—C(CH3)2—CH?CH2, —C(CH3)2—CH2—CH?CH2, —CH2—C(CH3)?C(CH3)2, —CH(CH3)—CH?C(CH3)2, —C(CH3)2—CH?CH—CH3, —CH?CH—CH2—CH?CH—CH3, —CH(CH3)—C(CH3)?CH—CH3, —CH?C(CH3)—CH(CH3)2, —C(CH3)?CH—CH(CH3)2, —C(CH3)?C(CH3)—C2H5, —CH?CH—C(CH3)3, —C(CH3)2—C(CH3)?CH2, —CH(C2H5)—C(CH3)?CH2, —C(CH3)(C2H5)—CH?CH2, —CH(CH3)—C(C2H5)?CH2, —CH2—C(C3H7)?CH2, —CH2—C(C2H5)?CH—CH3, —CH(C2H5)—CH?CH—CH3, —C(C4H9)?CH2, —C(C3H7)?CH—CH3, —C(C2H5)?CH—C2H5, —C(C2H5)?C(CH3)2, —C[CH(CH3)(C2H5)]?CH2, —C[CH2—CH(CH3)2]?CH2, —CH2—CH?CH—CH?CH—CH3, —CH?CH—CH?CH—C2H5, —CH2—CH?CH—C(CH3)?CH2, —CH2—CH?C(CH3)—CH?CH2, —CH2—C(CH3)?CH—CH?CH2, —CH(CH3)—CH2—C?CH, —CH(CH3)—CH?CH—CH?CH2, —CH?CH—CH2—C(CH3)?CH2, —CH(CH3)—C?C—CH3, —CH?CH—CH(CH3)—CH?CH2, —CH?C(CH3)—CH2—CH?CH2, —C2H4—CH(CH3)—C?CH, —C(CH3)?CH—CH2—CH?CH2, —CH?CH—CH?C(CH3)2, —CH2—CH(CH3)—CH2—C?CH, —CH?CH—C(CH3)?CH—CH3, —CH?C(CH3)—CH?CH—CH3, —CH2—CH(CH3)—C?CH, —C(CH3)?CH—CH?CH—CH3, —CH?C(CH3)—C(CH3)?CH2, —C(CH3)?CH—C(CH3)?CH2, —C(CH3)?C(CH3)—CH?CH2, —CH?CH—CH?CH—CH?CH2, —C?CH, —C?C—CH3, —CH2—C?CH, —C2H4—C?CH, —CH2—C?C—CH3, —C?C—C2H5, —C3H6—C?CH, —C2H4—C?C—CH3, —CH2—C?C—C2H5, —C?C—C3H7, —CH(CH3)—C?CH, —C4H8—C?CH, —C2H4—C?C—C2H5, —CH2—C?C—C3H7, —C?C—C4H9, —C?C—C(CH3)3, —CH(CH3)—C2H4—C?CH, —CH2—CH(CH3)—C?C—CH3, —CH(CH3)—CH2—C?C—CH3, —CH(CH3)—C?C—C2H5, —CH2—C?C—CH(CH3)2, —C?C—CH(CH3)—C2H5, —C?C—CH2—CH(CH3)2, —CH(C2H5)—C?C—CH3, —C(CH3)2—C?C—CH3, —CH(C2H5)—CH2—C?CH, —CH2—CH(C2H5)—C?CH, —C(CH3)2—CH2—C?CH, —CH2—C(CH3)2—C?CH, —CH(CH3)—CH(CH3)—C?CH, —CH(C3H7)—C?CH, —C(CH3)(C2H5)—C?CH, —CH2—CH(C?CH)2, —C?C—C?CH, —CH2—C?C—C?CH, —C?C—C?C—CH3, —CH(C?CH)2, —C2H4—C?C—C?CH, —CH2—C?C—CH2—C?CH, —C?C—C2H4—C?CH, —CH2—C?C—C?C—CH3, —C?C—CH2—C?C—CH3, —C?C—C?C—C2H5, —C(C?CH)2—CH3, —C?C—CH(CH3)—C?CH, —CH(CH3)—C?C—C?CH, —CH(C?CH)—CH2—C?CH, or —CH(C?CH)—C?C—CH3;
RN represents —H, —CH2—OCH3, —C2H4—OCH3, —C3H6—OCH3, —CH2—OC2H5, —C2H4—OC2H5, —C3H6—OC2H5, —CH2—OC3H7, —C2H4—OC3H7, —C3H6—OC3H7, —CH2—O-cyclo-C3H5, —C2H4—O-cyclo-C3H5, —C3H6—O-cyclo-C3H5, —CH2—OCH(CH3)2, —C2H4—OCH(CH3)2, —C3H6—OCH(CH3)2, —CH2—OC(CH3)3, —C2H4—OC(CH3)3, —C3H6—OC(CH3)3, —CH2—OC4H9, —C2H4—OC4H9, —C3H6—OC4H9, —CH2—OPh, —C2H4—OPh, —C3H6—OPh, —CH2—OCH2-Ph, —C2H4—OCH2-Ph, —C3H6—OCH2-Ph, —CHO, —COCH3, —COC2H5, —COC3H7, —CO-cyclo-C3H5, —COCH(CH3)2, —COC(CH3)3, —COCN, —COOCH3, —COOC2H5, —COOC3H7, —COO-cyclo-C3H5, —COOCH(CH3)2, —COOC(CH3)3, —CONH2, —CONHCH3, —CONHC2H5, —CONHC3H7, —CONH-cyclo-C3H5, —CONH[CH(CH3)2], —CONH[C(CH3)3], —CON(CH3)2, —CON(C2H5)2, —CON(C3H7)2, —CON(cyclo-C3H5)2, —CON[CH(CH3)2]2, —CON[C(CH3)3]2, —SO2CH3, —SO2C2H5, —SO2C3H7, —SO2-cyclo-C3H5, —SO2CH(CH3)2, —SO2C(CH3)3, —CH2—OCF3, —C2H4—OCF3, —C3H6—OCF3, —OC2F5, —CH2—OC2F5, —C2H4—OC2F5, —C3H6—OC2F5, —CH2F, —CHF2, —CF3, —CH2Cl, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2Cl, —CH2—CH2Br, —CH2—CH2I, -cyclo-C8H15, -Ph, —CH2-Ph, —CH2—CH2-Ph, —CH?CH-Ph, —CPh3, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C7H15, —C8H17, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH?CH2, —CH2—CH?CH2, —C(CH3)?CH2, —CH?CH—CH3, —C2H4—CH?CH2, —CH2—CH?CH—CH3, —CH?CH—C2H5, —CH2—C(CH3)?CH2, —CH(CH3)—CH?CH, —CH?C(CH3)2, —C(CH3)?CH—CH3, —CH?CH—CH?CH2, —C3H6—CH?CH2, —C2H4—CH?CH—CH3, —CH2—CH?CH—C2H5, —CH?CH—C3H7, —CH2—CH?CH—CH?CH2, —CH?CH—CH?CH—CH3, —CH?CH—CH2—CH?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C2H4—C(CH3)?CH2, —CH2—CH(CH3)—CH?CH2, —CH(CH3)—CH2—CH?CH2, —CH2—CH?C(CH3)2, —CH2—C(CH3)?CH—CH3, —CH(CH3)—CH?CH—CH3, —CH?CH—CH(CH3)2, —CH?C(CH3)—C2H5, —C(CH3)?CH—C2H5, —C(CH3)?C(CH3)2, —C(CH3)2—CH?CH2, —CH(CH3)—C(CH3)?CH2, —C(CH3)?CH—CH?CH2, —CH?C(CH3)—CH?CH2, —CH?CH—C(CH3)?CH2, —C4H8—CH?CH2, —C3H6—CH?CH—CH3, —C2H4—CH?CH—C2H5, —CH2—CH?CH—C3H7, —CH?CH—C4H9, —C3H6—C(CH3)?CH2, —C2H4—CH(CH3)—CH?CH2, —CH2—CH(CH3)—CH2—CH?CH2, —C2H4—CH?C(CH3)2, —CH(CH3)—C2H4—CH?CH2, —C2H4—C(CH3)?CH—CH3, —CH2—CH(CH3)—CH?CH—CH3, —CH(CH3)—CH2—CH?CH—CH3, —CH2—CH?CH—CH(CH3)2, —CH2—CH?C(CH3)—C2H5, —CH2—C(CH3)?CH—C2H5, —CH(CH3)—CH?CH—C2H5, —CH?CH—CH2—CH(CH3)2, —CH?CH—CH(CH3)—C2H5, —CH?C(CH3)—C3H7, —C(CH3)?CH—C3H7, —CH2—CH(CH3)—C(CH3)?CH2, —C[C(CH3)3]?CH2, —CH(CH3)—CH2—C(CH3)?CH2, —CH(CH3)—CH(CH3)—CH?CH2, —CH?CH—C2H4—CH?CH2, —CH2—C(CH3)2—CH?CH2, —C(CH3)2—CH2—CH?CH2, —CH2—C(CH3)?C(CH3)2, —CH(CH3)—CH?C(CH3)2, —C(CH3)2—CH?CH—CH3, —CH?CH—CH2—CH?CH—CH3, —CH(CH3)—C(CH3)?CH—CH3, —CH?C(CH3)—CH(CH3)2, —C(CH3)?CH—CH(CH3)2, —C(CH3)?C(CH3)—C2H5, —CH?CH—C(CH3)3, —C(CH3)2—C(CH3)?CH2, —CH(C2H5)—C(CH3)?CH2, —C(CH3)(C2H5)—CH?CH2, —CH(CH3)—C(C2H5)?CH2, —CH2—C(C3H7)?CH2, —CH2—C(C2H5)?CH—CH3, —CH(C2H5)—CH?CH—CH3, —C(C4H9)?CH2, —C(C3H7)?CH—CH3, —C(C2H5)?CH—C2H5, —C(C2H5)?C(CH3)2, —C[CH(CH3)(C2H5)]?CH2, —C[CH2—CH(CH3)2]?CH2, —C2H4—CH?CH—CH?CH2, —CH2—CH?CH—CH2—CH?CH2, —C3H6—C?C—CH3, —CH2—CH?CH—CH?CH—CH3, —CH?CH—CH?CH—C2H5, —CH2—CH?CH—C(CH3)?CH2, —CH2—CH?C(CH3)—CH?CH2, —CH2—C(CH3)?CH—CH?CH2, —CH(CH3)—CH2—C?CH, —CH(CH3)—CH?CH—CH?CH2, —CH?CH—CH2—C(CH3)?CH2, —CH(CH3)—C?C—CH3, —CH?CH—CH(CH3)—CH?CH2, —CH?C(CH3)—CH2—CH?CH2, —C2H4—CH(CH3)—C?CH, —C(CH3)?CH—CH2—CH?CH2, —CH?CH—CH?C(CH3)2, —CH2—CH(CH3)—CH2—C?CH, —CH?CH—C(CH3)?CH—CH3, —CH?C(CH3)—CH?CH—CH3, —CH2—CH(CH3)—C?CH, —C(CH3)?CH—CH?CH—CH3, —CH?C(CH3)—C(CH3)?CH2, —C(CH3)?CH—C(CH3)?CH2, —C(CH3)?C(CH3)—CH?CH2, —CH?CH—CH?CH—CH?CH2, —C?CH, —C?C—CH3, —CH2—C?CH, —C2H4—C?CH, —CH2—C?C—CH3, —C?C—C2H5, —C3H6—C?CH, —C2H4—C?C—H3, —CH2—C?C—C2H5, —C?C—C3H7, —CH(CH3)—C?CH, —C4H8—C?CH, —C2H4—C?C?—C2H5, —CH2—C?C—C3H7, —C?C—C4H9, —C?C—C(CH3)3, —CH(CH3)—C2H4—C?CH, —CH2—CH(CH3)—C?C—CH3, —CH(CH3)—CH2—C?C—CH3, —CH(CH3)—C?C—C2H5, —CH2—C?C—CH(CH3)2, —C?C—CH(CH3)—C2H5, —C?C—CH2—CH(CH3)2, —CH(C2H5)—C?C—CH3, —C(CH3)2—C?C—CH3, —CH(C2H5)—CH2—C?CH, —CH2—CH(C2H5)—C?CH, —C(CH3)2—CH2—C?CH, —CH2—C(CH3)2—C?CH, —CH(CH3)—CH(CH3)—C?CH, —CH(C3H7)—C?CH, —C(CH3)(C2H5)—C?CH, —CH2—CH(C?CH)2, —C?C—C?CH, —CH2—C?C—C?CH, —C?C—C?C—CH3, —CH(C?CH)2, —C2H4—C?C—C?CH, —CH2—C?C—CH2—C?CH, —C?C—C2H4—C?CH, —CH2—C?C—C?C—CH3, —C?C—CH2—C?C—CH3, —C?C—C?C—C2H5, —C(C?CH)2—CH3, —C?C—CH(CH3)—C?CH, —CH(CH3)—C?C—C?CH, —CH(C?CH)—CH2—C?CH, or —CH(C?CH)—C?C—CH3;
L1, represents: —CH2—, —C2H4—, —C3H6—, —C4H8—, —C5H10—, —C6H12—C7H14—, —C8H16—, —C9H18—, —C10H20—, —CH2CH2O—, —CH(CH3)—, —C[(CH3)2]—, —CH(C3H7)—, —CH2—CH(CH3)—, —CH(CH3)—CH2—, —CH(CH3)—C2H4—, —CH2—CH(CH3)—CH2—, —C2H4—CH(CH3)—, —CH2—C[(CH3)2]—, —C[(CH3)2]—CH2—, —CH(CH3)—CH(CH3)—, —C[(C2H5)(CH3)]—, —(CH2—CH2—O)n—CH2—CH2—, —C(CH3)?CH—C(CH3)?CH—, —C2H4—CH?CH—CH?CH—, —CH2—CH?CH—CH2—CH?CH—, —C3H6—C?C—CH2—, —CH2—CH?CH—CH?CH—CH2—, —CH(CH3)—C?C—CH2—, —CH?CH—CH?CH—C2H4—, —CH2—CH?CH—C(CH3)?CH—, —CH2—CH?C(CH3)—CH?CH—, —CH2—C(CH3)?CH—CH?CH—, —CH(CH3)—CH?CH—CH?CH—, —CH?CH—CH2—C(CH3)?CH—, —CONH—, —NHCO—, —CH2—CONH—, —CONH—CH2—, —NHCO—CH2—, or —CH2—NHCO—;
L2 and L3 represent independently of each other:
a bond, —CH2—, —C2H4—, —C3H6—, —C4H8—, —C5H10—, —C6H12—, —C7H14—, —C8H16—, —C9H18—, —C10H20—, —CH2CH2O—, —CH(CH3)—, —C[(CH3)2]—, —CH(C3H7)—, —CH2—CH(CH3)—, —CH(CH3)—CH2—, —CH(CH3)—C2H4—, —CH2—CH(CH3)—CH2—, —C2H4—CH(CH3)—, —CH2—C[(CH3)2]—, —C[(CH3)2]—CH2—, —CH(CH3)—CH(CH3)—, —C[(C2H5)(CH3)]—, —(CH2—CH2—O)n—CH2—CH2—, —C(CH3)?CH—C(CH3)?CH—, —C2H4—CH?CH—CH?CH—, —CH2—CH?CH—CH2—CH?CH—, —C3H6—C?C—CH2—, —CH2—CH?CH—CH?CH—CH2—, —CH(CH3)—C?C—CH2—, —CH?CH—CH?CH—C2H4—, —CH2—CH?CH—C(CH3)?CH—, —CH2—CH?C(CH3)—CH?CH—, —CH2—C(CH3)?CH—CH?CH—, —CH(CH3)—CH?CH—CH?CH—, —CH?CH—CH2—C(CH3)?CH—, —CONH—, —NHCO—, —CH2—CONH—, —CONH—CH2—, —NHCO—CH2—, or —CH2—NHCO—; and
wherein each n is an integer from 1 to 10; or
L1-RB and L2-RC or L1-RB and L3-RD or L2-RC and L3-RD form together a cyclic ring selected from the group consisting of:
or enantiomers, stereoisomeric forms, mixtures of enantiomers, anomers, deoxy-forms, diastereomers, mixtures of diastereomers, prodrugs, tautomers, hydrates, solvates or racemates thereof or pharmaceutically acceptable salts thereof.

US Pat. No. 10,246,412

CHEMICAL FILM ON SUBSTRATE AND METHOD OF FORMING THE SAME, METHOD OF FORMING PARACYCLOPHANE CONTAINING FUNCTIONAL GROUND WITH DISULFIDE BOND

MAY-HWA ENTERPRISE CORPOR...

1. A method of forming a chemical film comprising:providing a substrate;
performing a chemical vapor deposition (CVD) process to form a chemical film on the substrate, wherein the chemical film comprises poly-p-xylylene with disulfide functional group, wherein monomer of the poly-p-xylylene is formed by adding 3,3?-dithiodipropionic acid and N-ethyl-N?-(3-(dimethylamino)propyl)carbodiimide into 4-aminomethyl [2,2] paracyclophane, thereby obtaining a paracyclophane comprising a disulfide functional group.

US Pat. No. 10,246,411

(Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS

1. A (Z)-3,4,5-trimethoxystyryl benzenesulfonamide of general formula A
wherein, X?H, F, OCH3, NH2, or OH; and R?H, Cl, F, OCH3, NH2, NO2, OH, trifluoromethyl, trifluoromethoxy, methyl, or tert-butyl.

US Pat. No. 10,246,410

HYDRAZINYL AND AMINOOXY COMPOUNDS AND THEIR METHODS OF USE

Life Technologies Corpora...

1. A compound selected from the group consisting of:or a salt thereof.

US Pat. No. 10,246,409

METHOD FOR PREPARATION OF BIS(FLUOROSULFONYL)-IMIDE

Lonza Ltd, Visp (CH)

1. A method for the preparation of a compound of formula (I);
the method comprises a step STEP1;
STEP1 comprises a reaction REAC1-1;
in REAC1-1 a mixture MIXTURE-TRIPLE is reacted with HF at a temperature TEMP1-1, TEMP1-1 is at least 80° C.;
MIXTURE-TRIPLE comprises three components, a compound of formula (II), a compound of formula (III) and a compound of formula (IV);

X is identical with X1 or with X2;
X1 and X2 are identical or different and independently from each other selected from the group consisting of F, Cl, Br, I, RESF, and tolyl;
wherein RESF is a fluorinated C1-9 alkyl, which is unsubstituted or substituted by a substituent OCF3;
Rn+ is selected from the group consisting of H+, Li+, Na+, K+, Mg2+, Ca2+, Zn2+, Cu2+, Al3+, Ti3+, Fe2+, Fe3+, B3+,
[N(R20)(R21)(R22)R23]+, and [P(R20)(R21)(R22)R23]+;R20, R21, R22 and R23 are identical or different and independently from each other selected from the group consisting of H, C1-8 alkyl, C5-6 cycloalkyl, phenyl, benzyl, vinyl and allyl;
n is 1, 2 or 3;
wherein
the total content of the three components in MIXTURE-TRIPLE is of from 50 to 100%, the % being % by weight based on the total weight of MIXTURE-TRIPLE;
wherein
the relative ratio of the three components in MIXTURE-TRIPLE is of from
2 to 98% of the compound of formula (II),
49 to 1% of the compound of formula (III), and
49 to 1% of the compound of formula (IV);
the % are % by weight and are based on the combined weight of the three components in MIXTURE-TRIPLE; the relative ratios of the three components add up to 100%.

US Pat. No. 10,246,408

PROCESS FOR PREPARING BIPHENYLAMINES FROM ANILIDES BY RUTHENIUM CATALYSIS

BAYER CROPSCIENCE AKTIENG...

1. A process for preparing one or more biphenylamides of formula (Ia)
in which
R1 is hydrogen, hydroxyl, fluorine, chlorine, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio or C1-C4-haloalkyl,
R2 is C1-C4-alkyl, C6-C10-aryl or C6-C10-aryl-CH2—, and
X1 is hydrogen, C1-C3-alkyl, C1-C4-alkoxy, fluorine or chlorine,
X2 is hydrogen, C1-C3-alkyl, C1-C4-alkoxy, fluorine or chlorine,
X3 is hydrogen, C1-C3-alkyl, C1-C4-alkoxy, fluorine or chlorine,
comprising reacting one or more
anilides of formula (II)

in which
R1 and R2 are each as defined above,
with an organoboron compound of formula (III)

in which
X1, X2 and X3 are each as defined above,and which is selected from one of the following groups consisting of:(I) boronic acids of formula (III) in whichQ is a hydroxyl group,
m is 2,
p is 1,
or the anhydrides, dimers or trimers of these boronic acids;(II) boronic acid derivatives of formula (III) in whichQ is F, Cl, Br, I, C1-C4-alkyl, C6-C10-aryl, C1-C4-alkoxy or C6-C10-aryloxy,
m is 2,
p is 1;(III) borinic acids of formula (III) in whichQ is OH, F, Cl, Br, I, C1-C4-alkyl, C6-C10-aryl, C1-C4-alkoxy or C6-C10-aryloxy,
m is 1,
p is 2;(IV) cyclic boronic esters of formula (III) in whichQ is a C2-C3-alkyldioxy radical which, together with the boron atom to which it is bonded, forms a 5- or 6-membered ring optionally substituted by one or more C1-C4-alkyl radicals,
m is 1,
p is 1;(V) boronates of formula (III) in whichQ is OH, F, Cl, Br, I, C1-C4-alkyl, C6-C10-aryl, C1-C4-alkoxy or C6-C10-aryloxy,
m is 3,
p is 1
and the negative charge of the boronate anion is compensated for by a cation,(VI) triarylboranes of formula (III) in whichm is 0,
p is 3; and(VII) tetraarylborates of formula (III) in whichm is 0,
p is 4
and the negative charge of the tetraarylborate anion is compensated for by a cation,
in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal sulphate.